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ABSTRACT 
Marc Potempa: Mechanisms Regulating HIV-1 Protease Activity 
(Under the direction of Ronald Swanstrom) 
 
 The Human Immunodeficiency Virus Type 1 (HIV-1) Protease (PR) has no direct 
involvement in the early steps of HIV-1 replication. Nonetheless, it is the timely and ordered 
processing of the viral structural proteins by the HIV-1 PR during virion maturation that 
facilitates the successful completion of virus entry, reverse transcription, and integration. Though 
a considerable amount of research has been devoted to deciphering how the enzyme prepares a 
virus particle for infection, the mechanisms regulating its activities continue to remain 
incompletely defined.  
 RNA serves as one putative regulatory factor, since efficient processing of the maturation 
intermediate p15NC requires RNA in vitro. Though previously believed relevant to only p15NC 
cleavage, I demonstrate that RNA enhances HIV-1 proteolysis reactions in a substrate-
independent manner. The increased catalytic activity of the HIV-1 PR results from a direct 
interaction between RNA and the enzyme, with the magnitude of the effect dependent upon the 
size of the RNA molecule. Large (>400 base) RNAs accelerated proteolytic processing by over 
100-fold under near-physiological conditions. This considerable change stemmed from both 
improved substrate recognition (Km) and turnover rate (kcat). 
 Variability in amino acid sequence also guides HIV-1 PR activity. However, the absence 
of any overt patterns across HIV-1 cleavage sites has complicated the delineation of why these
 iv 
differences result in diverse processing efficiencies. To address this question, I generated the 
largest-to-date dataset of globular proteins cleaved by the HIV-1 PR in near-physiological 
conditions. From these data, I unravel a number of site-specific processing requirements, and 
identify potentially important relationships shared between multiple cleavage sites. These results 
additionally enabled the formation of a preliminary conceptual model for explaining processing 
site amino acid composition.
 
 v 
Though the mind has a habit of blinding itself with all that is amiss, that which we need to 
appreciate does not always go overlooked. And now, as I complete this arduous-yet-worthwhile 
experience, I want to mention what I have come to appreciate above all else: the people 
surrounding me. So it is to you, my family, friends, colleagues, and mentors, that I dedicate this 
work and my success. Without you, my dreams are just wishes.  
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CHAPTER I 
THE ROLE OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE IN 
VIRAL REPLICATION 
 
A. Classification of the human immunodeficiency virus 
 Since its discovery in 1983 (1), the World Health Organization estimates more than 70 
million people have been infected with the Human Immunodeficiency Virus (HIV) (2). HIV is 
an enveloped, positive-sense RNA virus belonging to the family Retroviridae. The hallmark of 
retroviruses is their ability to reverse transcribe their genome into DNA and then insert that DNA 
into the host cell’s genome. Once embedded in a chromosome, the virus becomes a permanent 
part of that cell. While most retroviruses require an actively replicating cell for infection, HIV 
can productively infect resting cells (3, 4) giving it, and other retroviruses like it, the further 
classification of Lentivirus. HIV itself is subdivided into HIV-1 and HIV-2, and then also several 
different groups and subtypes. Group M of HIV-1 is the most common worldwide (5). 
 While Lentiviruses also encode a number of accessory proteins (6), a trio of open-reading 
frames (ORF) are common to all retroviruses: gag, pro-pol, and env (Figure 1.1). The gag ORF 
codes for the Gag polyprotein, the main structural unit of immature virus particles. The surface 
glycoprotein Envelope (Env), which mediates the attachment and fusion of virus particles to 
target cells, results from the transcription and translation of the env ORF. The remaining ORF, 
pro-pol, encodes the viral protease (PR), reverse transcriptase (RT), and integrase (IN) enzymes. 
The activities of RT and IN have already been prefaced. The former converts an RNA molecule 
into a double-stranded DNA copy, and the latter implants the viral DNA into the host cell’s
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genome. As for the PR, its activities take place during the maturation step of the virus lifecycle. 
Maturation converts an immature, non-infectious virus particle that has just been created into one 
primed to complete the fusion, reverse transcription, and integration steps necessary for infection 
of a new cell. 
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Figure 1.1: Organization of the HIV-1 genome. In blue, red, and purple are the three principal 
ORFs common to all retroviruses, gag, pro-pol, and env, respectively. The dashed line within 
pro-pol separates the polymerase (RT) and RNase H (RTH) domains of the RT coding region; 
the dashed line in env separates the gp120 and gp41 regions (labels not otherwise provided). In 
gray are the domains of the HIV-1 accessory proteins, while the uncolored regions are non-
protein coding regions.
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______________________________ 
1This section of Chapter I previously appeared as an article in Current Topics in Microbiology and Immunology. The original 
citation is as follows: Potempa et al. “The Triple Threat of HIV-1 Protease Inhibitors”. Current Topics in Microbiology and 
Immunology. 2015, 389: 203-241. 
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B. The triple threat of HIV-1 protease inhibitors1  
1.  Introduction 
The HIV-1 PR is an indispensable enzyme, responsible for initiating the maturation of 
newly produced virus particles during the late stages of the HIV-1 replication cycle. The 
principal substrates for the PR are two HIV-1 polyproteins, Gag and Gag-Pro-Pol, with Gag 
representing most of the structural proteins of the virion and the Gag-Pro-Pol polyprotein 
including the viral enzymes used in replication. These proteins are translated from the same viral 
mRNA, and consequently share the same first 432 amino acids. This shared region contains the 
structural proteins Matrix (MA), Capsid (CA), and Nucleocapsid (NC), along with a 14-amino 
acid spacer peptide (SP1) set between CA and NC. While Gag is the predominant translation 
product, about 5-10% of the time a –1 ribosomal frameshifting event takes place to produce Gag-
Pro-Pol instead of just Gag (7). So, while the C terminus of Gag includes a second 16-amino acid 
spacer peptide (SP2) and a functional domain involved in virus budding called p6, Gag-Pro-Pol 
instead contains the transframe (TF) region, and monomers of the PR, RT, and IN enzymes.  
Gag and Gag-Pro-Pol drive the assembly of new virions through the reorganization of 
cholesterol-rich lipid raft microdomains on the plasma membrane (8, 9). Gag and Gag-Pro-Pol 
are targeted to the membrane via a myristate moiety postranslationally attached to their N termini 
(10-12). Dimers of genomic HIV-1 RNA, which are transported to the plasma membrane 
through interactions with Gag in the cytoplasm (12, 13), act as scaffolds to facilitate the higher-
order multimerization interactions necessary for particle formation (14, 15). Multimerization
initiates the budding process, but for efficient completion the host cellular Endosomal Sorting 
Complex Required for Transport (ESCRT) machinery is co-opted (reviewed in:(16-18)).   
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Ultimately, released virions contain approximately 2400 Gag (19) and 120-240 Gag-Pro-Pol 
molecules (7). Immediately after or concomitant with virus budding (20), the HIV-1 PR activates 
as a result of Gag-Pro-Pol dimerization, and PR functions to convert newly formed virus 
particles into mature, infectious virions (reviewed in: (18, 21)). This maturation process entails a 
series of ordered, highly regulated cleavage events that liberate the functional domains from 
within the Gag and Gag-Pro-Pol polyproteins.
Though maturation is conventionally thought of as the last stage of the HIV-1 lifecycle, 
these depictions use the host cell as a frame of reference rather than the virus. Consequently, the 
multifaceted impact the HIV-1 PR exerts on the ability of a virus to successfully complete the so-
called early steps in the HIV-1 lifecycle can go underappreciated. Antagonizing the HIV-1 PR 
can disrupt a number of early events including fusion (22-25), reverse transcription (25-30), and 
post-reverse transcription steps (25), i.e. nuclear import and/or integration. In this chapter, we 
review the triple threat of protease inhibitors (PIs): the intermolecular cooperativity that forms 
the basis of their cooperative dose-response in inhibition; the pleiotropic effects of HIV-1 PR 
inhibition on the early events of the replication cycle; and the potency associated with being a 
transition state analog and the considerable degree of improvement PIs can still undergo. 
Although many of the discoveries described within originally derived from work with other 
retroviruses, our review will focus on HIV-1. Accordingly, the provided references have been 
selected to highlight research performed with HIV-1. 
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2. Molecular mechanisms behind the antiviral activity of PIs  
2.1  The HIV-1 PR, the most effective drug target among HIV-1 inhibitors  
The HIV-1 PR is a member of the aspartyl proteinase family of enzymes. These enzymes 
are found as pseudodimers in eukaryotes, (due to an ancient gene duplication/fusion event), but 
are encoded as a monomer in the retroviral genome. For its activation, two PR monomers must 
interact to create the catalytic site at their dimerization interface (31-33). The active site formed 
by this interaction consists of a pair of aspartic acid residues, one from each monomer, and a 
water molecule to mediate the hydrolysis of peptide bonds (reviewed in: (18)). The initial 
activation of the HIV-1 PR occurs in the context of Gag-Pro-Pol. This embedded PR dimer is 
extremely unstable (34), and exhibits much lower enzymatic activity than fully released dimers 
(35, 36a). It appears that Gag-Pro-Pol active sites adopt the same conformation as the mature PR 
only a small fraction (3-5%) of the time (34), thereby limiting the embedded PR to 
intramolecular cleavage events. The first three cleavage events are all intramolecular, first at 
SP1/NC, then an internal TF site, and lastly the TF/PR site, and succeed in liberating the N 
termini of the PR monomers (36a, 37-39). These free ends fold into a four-stranded beta-sheet 
with other amino acids at the C terminus of the PR domain, conferring the stability and catalytic 
activity necessary for intermolecular cleavage events(40b). The subsequent proteolytic events 
that completely separate the enzyme monomers are intermolecular, and are performed by the 
mature PR (41, 42). 
Since the N-terminally tethered PR does not function intermolecularly (39), processing of 
Gag polyproteins occurs subsequent to PR dimer maturation. Just like Gag-Pro-Pol, Gag 
cleavage follows a specific order of events (Figure 1.2). For simplicity, the five hydrolyzed 
peptide bonds may be separated into three groups based on their rate of cleavage: fast, medium, 
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and slow. The SP1/NC site is the only member of the fast group. Cleavage at the MA/CA and 
SP2/p6 sites belong to the medium group (43-45), and these events happen ~10-fold more slowly 
than the fast cleavage event in an in vitro system using full-length Gag substrates (44). Lastly, 
the slow cleavages, CA/SP1 and NC/SP2, occur at rates ~400-fold slower than the fast site (43, 
45, 46). The mechanisms that guide the PR through the proper sequence of intermolecular 
cleavage events are still not fully understood. There is only weak amino acid sequence similarity 
among the different cleavage sites (47), making complex interactions with the amino acid 
sequence a critical determinant (48, 49). Current models suggest the enzyme recognizes a 
conserved shape, called the substrate envelope, rather than particular amino acid sequences (48). 
Nonetheless, contextual cues also appear critical as exemplified by an ~12-fold increase in 
cleavage rate of the CA/SP1 site when placed into the MA/CA context (50). In any case, even 
partial disruption of HIV-1 PR activity results in disproportionately large effects on infectivity 
(26, 28-30, 51). 
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Figure 1.2: A model representation of the step-wise processing of HIV-1 Gag by the HIV-1 
Protease. Gag, comprising MA (blue), CA (green), SP1 (light green), NC (red), SP2 (tan), and 
p6 (gray), is extended in a radial orientation from the membrane (gold), as is Gag-Pro-Pol, which 
contains the viral enzymes PR (brown), RT (blue-gray), and IN (purple). In the first of three 
stages, the SP1/NC site is cleaved to remove the NCp15 region comprised of NC/SP2/p6. The 
genomic RNA dimer increases in stability, but does not yet condense. In the second stage, two 
cleavage events occur at approximately the same rate. Proteolytic processing of the SP2/p6 
releases the p6 domain from NCp9 and induces condensation of the RNA. Cleavage at the 
MA/CA site releases the CA/SP1 protein from the membrane, dissolving the immature CA 
lattice. In the final stage, spacer peptides are removed from NC and CA. After SP1 removal, CA 
forms a fullerene cone-shaped shell that surrounds the ribonucleoprotein core. The precise 
mechanism by which the CA cone forms (i.e. stochastic or nucleated) is still under investigation. 
This completed structure constitutes the pre-reverse transcription complex.
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The vital role the HIV-1 PR plays in the replication cycle made it an extremely attractive 
drug target. After the first potent and bioavailable PI was introduced into triple drug regimens, it 
became apparent that it was possible to fully suppress viral replication and that this led to 
significant reductions in morbidity and mortality associated with HIV-1 infection (52, 53). These 
beneficial results further demonstrated the inherent dependency of HIV-1 on PR activity. The 
plethora of HIV-1 PR crystal structures (reviewed in: (54)) has facilitated the development of 
several extremely potent PIs by employing “structure-based drug design” (reviewed in: [55]). 
Currently, nine PIs are used in the treatment of HIV-1 infection. All of these, except for 
Tipranavir [56] are transition-state analogs that mimic a PR cleavage site, but replace the 
hydrolysable P1-P1′ amide bond (Schechter and Berger nomenclature (55)) with a variety of 
non-hydrolyzable transition-state isosteres (56). PIs bind the wild-type PR enzyme with binding 
affinities in the nM to pM range (57-61). Comparatively, the binding affinity of the HIV-1 PR 
for its conventional substrates is in the µM to mM range (62), making PIs several orders of 
magnitude better interacting partners for the PR active site than their natural substrate. The tight 
binding of PIs and the need for multiple PR enzyme molecules in each virion to complete 
maturation (see below) give this class of enzymes distinctive properties among all classes of 
inhibitors of viral replication. 
 
2.2 HIV-1 PIs display cooperative inhibition of their target enzyme  
Once the intravirion space has been sealed off from the host cell cytoplasm, the virus 
particle must subsist on a limited set of packaged resources until after entry into the next target 
cell. Based on the estimated number of Gag-Pro-Pol molecules included during virion assembly, 
and because each enzyme functions as a multimer, the virus must complete maturation, reverse 
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transcription, and integration with a maximum of 125 PR homodimers, 125 RT heterodimers, 
and 62 IN tetramers, respectively. Results from phenotypic mixing experiments have shown that 
both the PR (29, 63) and RT (64) enzymes are packaged into virions in excess, because viruses 
can tolerate some level of catalytically inactivated enzymes without substantial losses in 
infectivity. However, complete loss of infectivity occurs prior to inactivating 100% of the 
enzymes, which suggests that multiple copies of these enzymes are required to perform their 
associated life cycle step. Siliciano and colleagues confirmed this latter conclusion by 
demonstrating that PI and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) dose 
response curves for inhibition of infectivity display characteristics typical of cooperative binding 
reactions (65).  
Conventionally, cooperative binding refers to the attachment of ligands to a multivalent 
receptor, where the attachment of a ligand to the receptor increases the affinity of the receptor for 
its ligands at other sites. However, although each PR and RT enzyme contains only a single 
binding site for their respective inhibitors, Shen et al. still found evidence of cooperativity (65). 
This can be explained by the microenvironment that is formed when a virus particle separates 
from the host cell. As mentioned above, each particle contains a specific number of enzymes that 
collectively can complete >100% of the enzymatic activities required for its associated step. If, 
for example, each PR enzyme contributes 5% to that total ability, and their abilities are, for 
example’s sake, additive, then this theoretical virus would require at least 20 functional PR 
enzymes to complete maturation. Such enzymes can be thought of as intermolecularly 
cooperative. Thus, in support of the conclusion from the phenotypic mixing experiments, 
intermolecular cooperative action requires that multiple enzymes work together to complete a 
single activity as though they are one enzyme. This concept forms the basis of the “critical subset
___________________________ 
2Although NNRTI dose-response curves show RT functions as a cooperative enzyme, the other class of reverse transcriptase 
inhibitors, the Nucleoside Reverse Transcriptase Inhibitors (NRTIs), seemingly contradicts this finding (68). This discrepancy 
has been explained by considering the different targets for these inhibitor classes. NNRTIs seek out and interact specifically with 
the enzyme RT, whereas NRTIs actually target the elongating viral DNA molecule. Thus, just as integration requires only one 
enzyme tetramer to catalyze insertion of proviral DNA into the target cell genome, and is thus non-cooperative, only a single 
NRTI molecule needs to be incorporated into a growing DNA chain to terminate DNA elongation. Therefore, the effectiveness of 
NRTIs is independent of the number of RT molecules present. One exception does exist: AZT. When AZT is incorporated, it 
remains in the nucleotide-binding site because the large azido group sterically blocks its transfer to the primer site on RT (340). 
As a result, RT can excise AZT from its position in the nucleotide binding site using ATP (340, 341). It is this excision activity 
that appears to be dependent upon the concentration of RT (27, 68), and therefore AZT-mediated inhibition displays some degree 
of cooperativity. 
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model” (66). In contrast, integration appears to be non-cooperative, likely requiring only a single 
catalytically active IN tetramer bound to the ends of the newly synthesized viral DNA to 
complete the integration step (65-67).  
The importance of cooperativity becomes evident when considering the potency of 
antiretroviral drugs. Whenever the total number or functionality of an enzyme is reduced, the 
enzymes theoretically become more sensitive to inhibition. Each lost enzyme decreases the total 
catalytic potential present in the virion, moving the sum closer to falling below the critical 
threshold required for infectivity (66). Disrupting an infection would therefore require inhibiting 
one fewer enzyme, and a lower drug concentration, i.e. IC50. Such a prediction has been 
experimentally proven several times. Henderson et al. found that reducing the amount of 
functional HIV-1 PR in virions by phenotypic mixing or mutation-induced fitness losses 
generated an increased sensitivity to PIs (68). Similarly, lowering the amounts of RT by 
phenotypic mixing (69) or because of PR fitness losses (27, 68) increases RT sensitivity to 
NNRTIs (68, 69) and zidovudine2 (AZT) (27, 68).  
Unlike non-cooperative enzymes, when the content or the catalytic activity of cooperative 
enzymes is reduced, the critical threshold is approached more rapidly. In other words, slightly 
raising the concentration or effectiveness of a drug will result in disproportionately large 
increases in inhibition. The converse, that minor reductions in drug concentration or 
effectiveness will have nonlinear decreases in inhibition, would also be true. It was the latter 
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prediction Sampah et al. demonstrated to support the model (67). When drug resistance 
mutations were introduced into viruses, and then challenged by the associated antiretroviral drug, 
differences were observed in the IC50 values for non-cooperative and cooperative enzymatic 
reactions alike. However, only cooperative enzymes showed changes to the slope of their dose-
response curve, which is the mathematical descriptor for cooperativity. This change in slope 
reflected a much more severe reduction in inhibitory ability. 
Siliciano and coworkers determined the theoretical slope value for most of the PIs 
currently in use, and found that the predicted values (66) had underestimated the actual values 
(65). The exceptionally high experimentally determined values underscore the superiority of PIs 
relative to other drugs at inhibiting HIV-1 replication (65, 70). But intriguingly, the slope for 
each PI varied considerably from the other drugs of the same class. Furthermore, the magnitudes 
of those differences are accentuated when compared to the intra-class fluctuation in other classes 
(65). In simplest terms, this result established that there are inherent differences in the maximum 
level of effectiveness each current HIV-1 PI can attain, and helps explain why certain PIs have 
been somewhat successful at monotherapy (71), whereas others fail more readily (72). But this 
PI-to-PI variability only encompasses one noteworthy detail about PI slopes. In addition, the 
slope values for PIs do not remain constant; as drug concentrations increase, so too do the slopes 
(70). In contrast, non-cooperative drugs such as NRTIs or IN inhibitors maintain a constant slope 
as their concentrations increase. 
 
3. The pleiotropic effects of HIV-1 PIs 
The implications of the constantly metamorphosing slope were not fully appreciated until 
the effects of PIs on individual stages of the lifecycle were determined. The changing slope 
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results from the additive effect of interfering with multiple, distinct stages of the lifecycle (25). 
Considerable evidence exists to support this conclusion: disrupting maturation impairs fusion 
(22-25), reverse transcription (25, 27, 29, 30, 68), and post-reverse transcription steps (25). In 
other words, the considerable inhibitory capabilities offered by PIs results, in part, from its 
ability to perform like multiple drugs at once. Below, we discuss the various stages of the virus 
lifecycle PIs disturb, briefly reviewing the evidence and commenting on the potential 
mechanistic basis of the effect. 
 
3.1  PIs antagonize fusion between the viral envelope and target cell membrane 
3.1.1  The HIV-1 Env protein mediates fusion of the viral envelope and cellular membrane 
The HIV-1 Env protein is translated as a polyprotein precursor, gp160, in the rough 
endoplasmic reticulum, where it is co-translationally glycosylated (reviewed in: (73)). Following 
translation, gp160 traffics to the trans-Golgi network, and is cleaved by cellular furin or furin-
like proteases into the heterodimer gp120/gp41 (74). These proteins remain non-covalently 
attached, assemble into trimers of heterodimers with other gp120/gp41 molecules (75), and 
migrate to the plasma membrane. gp120 is entirely surface-expressed, and contains the CD4 and 
coreceptor binding sites. The cellular chemokine receptor CCR5 serves as the dominant 
coreceptor, enabling fusion with CD4+ T cells and macrophages. Later on in infection, Env 
evolves the ability to utilize the chemokine receptor CXCR4 as an alternative (reviewed in: 
(76)). gp41 has three distinct domains: the ectodomain that includes the fusion peptide (77), a 
single-pass transmembrane domain that keeps the Env assemblies tethered to the membrane, and 
an ~150 amino acid cytoplasmic tail (CT) that is present on the inner face of the viral envelope 
(78). Despite considerable clustering of Env around Gag assembly sites (79, 80), only about 10-
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15 Env trimers get incorporated into each HIV-1 virion (81-83). Nonetheless, these low numbers 
are sufficient to mediate fusion between the HIV-1 viral membrane envelope and the target cell 
membrane. 
 Fusion requires a series of conformational changes and rearrangements in both the Env 
protein and in the lipid membrane (reviewed in: (84)). Once Env binds CD4, structural changes 
in gp120 expose the coreceptor binding site in tandem with changes in gp41 that results in the 
formation of the Pre-Hairpin Complex (85, 86). Presumably, these conformational changes 
position the gp41 fusion peptide within the target cell membrane (reviewed in: (84, 87)). As a 
result, a pore forms between the intravirion space and the target cell cytoplasm, although the size 
of the pore is too small for larger virus assemblies to cross the membrane. The secondary 
interactions between the Env-CD4 complex and CCR5 or CXCR4 lead to additional structural 
changes that cause gp120 to dissociate from gp41. Hydrophobic heptad repeat regions in the 
gp41 ectodomain coalesce into a coiled-coil structure called the six-helix bundle (88, 89), and it 
is this structure that pulls the viral and host cell membranes together, causing the fusion pore to 
expand. 
 
3.1.2 “Inside-out” regulation: the HIV-1 PR regulates fusogenicity from within the virion 
Comparing the fusogenicity, topology, and stiffness of immature and mature virions has 
revealed that internal processes affect activities that occur on the exterior side of the envelope. 
Mature and immature particles show an approximately 10-fold difference in ability to induce 
syncytia formation (22) or fuse with target cells (23, 24), thus implicating HIV-1 PR activity in 
conferring Env fusion competence. Since the gp41 CT occupies the intravirion space, this 
relationship in theory could result from proteolytic cleavage of the CT. However, though other 
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retroviral CTs are truncated by their virus-associated PR (e.g. (90)), no such cleavage has been 
observed for HIV-1. Instead, a strong, detergent-stable linkage exists between gp120/gp41 and 
uncleaved Gag, and that relationship is lost in mature particles (91). Evidence that maturation 
can directly affect Env behavior recently came from direct imaging of mature and immature 
virus particles by super resolution microscopy. On particles produced in the presence of an 
inactivated PR, the 10-15 Env trimers were found separated at multiple distinct sites on the 
virion surface. In contrast, virus particles that have completed maturation appear to have only a 
single cluster of Env molecules on the surface (92). Interestingly, both Wyma et al. (91) and 
Chojnacki et al. (92) found that preventing cleavage of the MA/CA site was sufficient for 
maintaining the immature phenotype of Env molecules, consequently implicating the HIV-1 PR 
in manipulating Env behavior. 
Other lines of evidence have also shown that inhibiting HIV-1 PR affects Env function. 
When a culture of chronically infected cells was treated with a high concentration of synthetic 
peptide analogue PIs, Meek and colleagues observed a considerable decrease in the formation of 
syncytia (93). More recently, use of the BLAM-Vpr assay showed a dose-dependent decrease in 
virus fusion with primary CD4+ T cells when viruses were produced in the presence of 
Atazanavir, Darunavir (DRV), or Lopinavir (LPV) (25). Moreover, the ability of viruses 
pseudotyped with the Vesicular Stomatitis Virus (VSV) G protein to enter cells was completely 
unaffected by administration of PIs. Collectively, these results demonstrated not just that PIs can 
inhibit fusion, but also that a specific relationship exists between the HIV-1 Env and the HIV-1 
PR, although through an indirect mechanism. Of note, work by Krausslich and colleagues 
utilizing the same BLAM-Vpr assay contradicted these results. Virus produced in the presence of 
2 µM LPV (compared to ~1.2 µM in (25)) did not affect fusion into MT-4 cells (30). However, 
 
 
16 
these authors did report that completely inactivating the PR yielded findings consistent with the 
other results, and suggested that LPV failed to inhibit fusion because even trace amounts of PR 
activity might be sufficient for enabling virus entry. Alternatively, the disparity in results may 
indicate that the ability of HIV-1 PIs to restrict fusion could be a co-receptor-dependent effect 
(24), a cell type-dependent effect, or even a strain-specific effect. Rabi et al. pseudotyped viruses 
with samples derived from patients failing PI-based ART regimens, and found that, even in the 
context of a wild-type PR, Env proteins from 9 of 18 patients were able to confer statistically 
significant resistance to DRV (25). These results support the latter explanation, that the ability of 
PIs to disrupt Env fusogenicity may be Env-dependent. 
 
3.1.3 Proteolytic activation of Env fusion competence results from the release of steric 
restrictions on the gp41 CT 
 Management of Env fusion activity by the HIV-1 PR is indirect, requiring the use of Gag 
as an intermediary. Though the cue that enhances Env’s fusogenic ability comes from cleavage 
of the MA/CA site (91, 92), the interaction that directly manages the change in behavior must be 
between the membrane-associated MA domain of Gag and the CT of gp41. Indeed, ample 
evidence supports the existence of an interaction between MA and gp41. As previously 
mentioned, Env cosediments with immature virus cores following treatment with nonionic 
detergent that should separate membrane proteins from the core (91). Additionally, preferential 
clustering of Env with high-density lipid rafts requires Gag (79, 80, 94). And furthermore, 
deletions (95-98) or single amino acid substitutions in MA (97, 99, 100) are sufficient for 
excluding Env from budding virions. However, no currently published data have pinpointed the 
site of a direct interaction within either the gp41 CT or MA.  
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 An alternative hypothesis that has gained traction suggests that no specific interaction has 
been identified because the interactions between MA and gp41 are actually steric (101). Matrix 
assembles into a hexamer of trimers on membranes enriched in cholesterol and 
phosphatidylinositol-(4,5)-bisphosphate (102). This arrangement forms gaps between the MA 
monomers that assemble into trimers, and larger gaps in the middle of the hexamers built from 
the trimers. Mapping a number of MA mutations that block Env incorporation into virions onto 
the crystallized mature MA trimer (Figure 1.3) reveals that the blocking mutations congregate 
near the potential hexameric gap region (101). The compensatory mutation Q62R, which can 
rescue the Env-incorporation defect exhibited by all four of these mutants, does not map to the 
same location, but instead represents an amino acid found at the trimer interface (101). Freed and 
coworkers note that the disparate location argues against Q62R replacing a lost contact, 
suggesting instead that the compensatory mutation could be adjusting the size and/or spacing of 
the hexameric pore by manipulating the interactions between trimers (101).  In other words, the 
Q62R mutation compensates for the steric clashes by pinching the MA trimer interface closer 
together to create more space in the hole formed by the hexamers.  
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Figure 1.3 A model for the steric restriction and release of Env by Gag and PR. a. Top-
down model of the hexamer of trimers that comprise the MA layer interacting with the CT of 
trimers of HIV-1 Env (purple circles). The mature trimeric form of MA (pdb: 1HIW; (103)) was 
used for the model since the structure of the immature MA lattice has not been determined at 
high resolution. Locations of mutations in MA that obstruct Env incorporation are shown in red. 
The compensatory Q62R mutation is not immediately visible from above. The blue arrow 
identifies its location near the center of the trimer interface. b-d. Model for the activation of Env 
proteins by proteolysis. Env clusters in high concentrations near sites of Gag assembly (color 
code consistent with Figure 1.2). The high concentrations effectively immobilize Env, trapping 
Env in a non-fusogenic conformation. Few Env molecules gain access into the assembly site due 
to their poor mobility and the limitations of the steric interactions. Those that are packaged are 
still in the non-fusogenic state due to the steric limitations provided through interactions with the 
MA layer. After cleavage, the gp41 CT is released, allosterically altering the structure of Env to 
a fusion-competent state, and potentially leading to the congregation of Env trimers to a single 
locus.  
a b
Non-Fusogenic
Env Trimer GagGag-Pro-Pol
c d Fusogenic
Env
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The CT has a variety of functional activities associated with it, including the allosteric 
modulation of gp120 conformation (104-107) and control over fusion peptide mobility (80, 108). 
In theory, by relying on a steric interaction instead of a specific one, the gp41 CT can maintain a 
moderate degree of sequence variability (109), which may be necessary for controlling the 
conformational states of a molecule that must undergo frequent change to escape immune 
pressure. Conceivably, HIV-1 could have evolved this indirect, and non-specific mechanism for 
regulating fusion competence because maintaining a specific amino acid sequence to serve as an 
additional HIV-1 processing site may have limited the conformational flexibility and variability 
in the surface-exposed regions of the Env heterodimer. 
Figure 1.3 presents a model of HIV-1 PR-mediated regulation of Env fusogenicity Gag 
assembly sites manipulate the local membrane composition (9), which creates an environment 
favored by HIV-1 Env. Env clusters around the assemblies in high concentrations (79, 80), but at 
the cost of its mobility (110). The relatively immobilized gp41 CT exerts its allosteric control 
over gp120 (104-107), locking Env in a poorly fusogenic state (80). Owing to its limited 
mobility, lack of a specific interaction for recruitment (101), and the cramped steric interaction 
with MA trimers, Env packaging remains a very inefficient process, which accounts for the 
inclusion of a mere 10-15 Env trimers in the virion (81-83) despite high concentrations of Env 
around the Gag assembly. When trimers of the gp41 CT successfully interact with the MA 
lattice, the steric limitations trap Env in its restricted state. Upon activation of the HIV-1 PR, the 
Env CT is liberated from its trapped state in one of two potential ways: (1) proteolytic cleavage 
of the MA/CA site disconnects MA from the stable immature CA lattice, reducing the rigidity of 
the MA lattice, and consequently imparts surface mobility to Env; or (2), MA/CA cleavage could 
increase the steric clashes between gp41 CT and MA, forcing the Env trimers away from MA-
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rich regions. In either event, the small clusters seem to rearrange into a single cluster on the 
surface of the virion (92). And although clustering might have been inhibitory while associated 
with virion assembly sites (80), the low concentration of Env and conformational freedom 
granted to the liberated gp41 CT provides the flexibility to both gp120 and the gp41 fusion 
peptide necessary for fusion.  
 
3.2  Multiple potential mechanisms by which PIs antagonize reverse transcription 
3.2.1  RT: the heterodimeric polymerase 
 The HIV-1 virion contains two plus-strand RNA copies of the viral genome, which must 
be converted into a single, linear, double-stranded (ds)DNA product for integration into the 
target cell’s genome. The virally encoded enzyme that catalyzes this reaction is RT, a 
heterodimer comprised of the proteins p66 and p51 (reviewed in: (111, 112)). The p66 subunit 
provides the enzymatic functions attributed to RT: an RNA-dependent DNA polymerase, a 
DNA-dependent DNA polymerase, and an RNase H ribonuclease activity. The p51 subunit 
contains the same first 440 amino acids as p66, but is truncated by the HIV-1 PR at position 
F440/Y441 to remove a majority of the RNase H domain. Despite the identical amino acid 
sequence, p51 assumes a distinctly different conformation in which the polymerase active site 
residues are buried within the protein. Instead of a catalytic function, p51 primarily provides 
structural support to the p66 subunit, and also contributes to substrate binding (111, 112). 
 Along with the other viral enzymes, RT originates as a monomer in the Gag-Pro-Pol 
polyprotein. During assembly and budding, activation of the HIV-1 PR results in the liberation of 
the full-length p66 RT molecule. Introducing either an L234A (38) or W401A (113) mutation 
into RT suppresses dimerization and the appearance of p51, suggesting that processing of p66 
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into p51 requires homodimerization of p66. Interestingly, this dimerization event is asymmetric, 
requiring one subunit to undergo considerable structural rearrangement (114). Purportedly, this 
conformational change unravels the RNase H domain, and consequently exposes the RT/RNase 
H (RT/RH) cleavage site. The mature heterodimer is extremely stable (115, 116), and so the 
remaining p66 subunit stays in a conformational state that protects it from cleavage within the 
RNase H domain by the PR (117-119). 
 Reverse transcription takes place within the aptly named reverse transcription complex 
(RTC). Though a functional RTC assembles before cellular entry, very little, if any, reverse 
transcription occurs in the virion, likely due to the absence of nucleotides (120). Until reverse 
transcription begins, the complex is referred to as the pre-RTC. Thus, the pre-RTC constitutes a 
ribonucleoprotein (RNP) core surrounded by a CA shell arranged in a fullerene cone structure 
(121). By electron microscopy (EM), this visualizes as an electron dense nucleoid surrounded by 
a thinner cone-shaped layer of mature CA (122). Aside from RT and its RNA template, the 
electron-dense core contains NC (123, 124), IN (123-126), Vpr (123-125), Vif (126), Nef (123, 
127, 128), and MA (125, 129). Upon entry into the cell, the presumably active RTC interacts 
with the cytoskeleton to facilitate its movement toward the nucleus (129, 130). Viral DNA 
synthesis occurs en route, concomitantly inducing the dissociation of a majority of the CA shell 
(131-133), and a structural remodeling of the core into the pre-integration complex (PIC) (134-
136). 
 
3.2.2 The fragility of reverse transcription to anomalous HIV-1 PR activity 
 Assembly of the pre-RTC occurs during or immediately after the nascent particle buds 
away from the cell as part of the virion maturation process. Accordingly, the activity of the HIV-
 
 
22 
1 PR and the ability of a virus to perform reverse transcription are intricately linked because the 
step-wise proteolytic processing of Gag results in pre-RTC formation. Numerous studies have 
demonstrated the extreme vulnerability of reverse transcription to defects in PR activity by 
measuring the effects of partially inhibiting the HIV-1 PR. Using sub-optimal amounts of PIs 
(26, 28, 30) or phenotypic mixing experiments that partially inhibit select processing sites in Gag 
(29, 30, 51, 137), these groups universally found that minor amounts of certain incompletely 
processed Gag intermediates had disproportionately large dominant negative effects on 
infectivity, and that the inhibitory effects frequently manifest somewhere during reverse 
transcription. For example, introducing a blocking mutation into just 20% of MA/CA cleavage 
sites completely ablated HIV-1 infectivity, and reduced the amount of early reverse transcription 
products by 90% compared to wild type (29). At some sub-optimal PI concentrations, and in all 
the phenotypic mixing experiments, these reverse transcription defects occurred when RT was 
fully functional and fully processed indicating the inhibitory effect lay in RTC formation. 
Even so, the link between PR activity and reverse transcription extends beyond pre-RTC 
assembly. When PR activity is diminished because of PIs (20, 27, 30) or drug resistance 
mutation-associated fitness losses (27, 138, 139), a corresponding decrease in the amount and/or 
functionality of RT in the virion is observed. These differences have been attributed mostly to 
processing defects (26, 27, 30), but reduced RT packaging has also been suggested (139). 
Importantly, the amount of functional RT in the virion closely correlates with infectivity (140, 
141) because viruses with reduced RT functionality are less efficient in completing reverse 
transcription (64, 139, 142). Furthermore, particles with reduced RT content or activity display 
increased sensitivities to NNRTIs (68, 69) and AZT (27, 68), in accordance with the critical 
subset model (66). Thus, a very complex interplay exists between reverse transcription and HIV-
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1 PR activity. Below, we have separated a detailed discussion of several putative mechanisms by 
which PIs disrupt reverse transcription into two parts: decreased RT activity, and improper 
condensation of the RNP core. 
 
3.2.3 Inhibiting PR activity decreases virion-associated RT activity 
 As noted above, nascent viral particles incorporate RT as part of the Gag-Pro-Pol 
polyprotein. In a gel-based activity assay (143) and in virions generated in the absence of a 
functional PR (144), the innate catalytic activity of RT while embedded in Gag-Pro-Pol was 
determined to be 20- to 25-fold less than the fully mature RT heterodimer. This provides one 
avenue for PIs to inhibit reverse transcription: by trapping RT in a precursor form.  
Although some of the first cleavage events in Gag-Pro-Pol are up to 10,000-times more 
resistant to PIs (37, 39, 145, 146), current evidence suggests sequestering RT within Gag-Pro-Pol 
or another incompletely processed intermediate is possible. Two PIs, Saquinavir (SQV) and 
DRV, could effectively inhibit the intramolecular cleavage events in Gag-Pro-Pol in vitro, with 
IC50 values in the range of 1-2 µM (145, 146). Though these values increased to ~7 µM for 
DRV and ~10 µM for SQV in cell culture experiments (146), at least DRV has been detected in 
patient serum at concentrations near 10 µM (147). DRV is the only antiretroviral drug with 
equivalent potency to a three-drug regimen (71), and its prospective ability to inhibit the 
intramolecular Gag-Pro-Pol processing events may contribute to its exceptional potency. 
Furthermore, nM sensitivity to PIs is restored concomitant with the appearance of mature PR 
functionality (39, 145), and both PR/RT (41) and RT/IN (42) are thought to be targets of the 
mature PR (Figure 1.4). In support of this, high molecular weight bands of 113 and 107 
kilodaltons (kDa) are often observed among cleavage products from virions produced in PI-
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treated cells (26, 37, 146). These protein species correspond to the PR/RT/IN intermediate with 
(113 kDa) or without (107 kDa) the abridged TF domain. Since p66 monomers must undergo 
substantial structural rearrangement to dimerize, particularly within the C-terminal domains of 
RT (114), there is a strong possibility that the RT/IN linkage accounts for a majority of the 
restriction on RT function by sterically preventing the structural rearrangements necessary for 
dimerization. Therefore, the intramolecular cleavage events that are highly resistant to currently 
available PIs are nonetheless likely to be insufficient for generating fully functional RT enzymes. 
Unfortunately, the polymerase activities of PR/RT/IN or RT/IN intermediates have not been 
reported to validate this inference.  
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Figure 1.4: Locations of intra- and intermolecular cleavage sites targeted by the HIV-1 PR. 
Diagram of the Gag-Pro-Pol polyprotein, subunits not drawn to scale. Each red arrow identifies a 
processing site cleaved by the intramolecular, embedded HIV-1 PR. Some PIs, such as DRV and 
SQV, may be capable of inhibiting these events. However, on the whole, these sites are much 
less sensitive to PI effects. The green arrows identify target sites for the mature HIV-1 PR. 
Effective inhibition of HIV-1 PR ability to cleave these sites may occur at nM concentrations of 
PIs in cell culture.  
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In addition to p66 excision, cleavage at the RT/RH site also presents an opportunity for 
HIV-1 PR activity to regulate RT functionality. Sluis-Cremer et al. determined that inhibiting 
cleavage at the RT/RTH site required lower concentrations of the PI ritonavir (38). Thus, even if 
PI concentrations are too low to inhibit RT’s removal from Gag-Pro-Pol, RT could conceivably 
be trapped in a p66 homodimer by blocking RT/RTH processing. Both gel-based (148) and in 
vitro (149) activity assays determined that the homodimeric p66 RT molecule was five-fold 
worse than p66/p51 heterodimers at catalyzing DNA synthesis. Slowing or reducing viral DNA 
synthesis could increase exposure of the RTC to cellular restriction factors such as the DNA 
sensor IFI16 (150). Thus, formation of the fully functional RT heterodimer requires multiple 
proteolytic cleavage events, each of which is susceptible to PIs. These data strongly argue that 
PIs can reduce the content or functionality of RT, and therefore the ability to complete reverse 
transcription, through their inhibition of HIV-1 PR processing activity. 
 
3.2.4 Incompletely processed Gag molecules are dominant negative inhibitors to reverse 
transcription  
Sequential proteolytic processing of the Gag polyproteins controls assembly of the pre-
RTC. As briefly described earlier, proteolytic processing of Gag proceeds in a defined order: 
SP1/NC > SP2/p6 ~ MA/CA > NC/SP2 ~ CA/SP1 (Figure 1.2) (44, 45). These cleavage events 
generate specific intermediates, each of which has distinct functional abilities. The temporal 
appearance of each of these intermediates and their associated tasks are critical to the proper 
assembly of the pre-RTC. 
 The initial cleavage event between SP1 and NC yields a membrane-bound MA/CA/SP1 
intermediate and the NC/SP2/p6 intermediate called p15NC. Completing cleavage of the p15NC 
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intermediate is absolutely essential for maturation of the dimeric RNA genome (151). Though 
~10-fold slower than the initial cleavage, the second and third cleavage events occur at 
approximately the same rate, at least in vitro (44). Cleavage of the MA/CA site dissolves the 
immature CA lattice (152), and allows the N terminus of CA to form a salt bridge that is 
essential for the eventual construction of the CA cone (153-155). Most MA remains bound to the 
membrane, however a small amount relocates into the virus core (125, 129). Meanwhile, 
removal of the p6 domain from p15NC yields the 71-amino acid NCp9. This protein has many of 
the same capabilities as the fully mature 55-amino acid NCp7 (reviewed in: (156), but most 
importantly, potently induces nucleic acid aggregation (134, 157). Thus, upon cleavage of 
p15NC to NCp9, the RNP core condenses into the iconic electron dense structure found in 
mature HIV-1 virions. The ultimate fate of p6 remains unknown, as it is not found in the pre-
RTC (123). Given that p6 antagonizes condensation while part of p15NC, its exclusion from the 
pre-RTC is likely necessary.  
 The remaining cleavage events remove spacer peptides from CA and NC. The mature CA 
lattice cannot form without CA/SP1 processing (152), and therefore assembly of the CA cone 
depends upon completion of this step. NC/SP2 processing produces the optimal NC chaperone, 
NCp7. The strand destabilization activity of NCp7 is similar to NCp9, but its aggregative 
abilities are inferior to NCp9 (134, 157, 158a). Additionally, NCp7’s on/off binding kinetics are 
very fast compared to the other NC species (158a, 159b). The faster kinetics ensures that NC 
does not become a physical roadblock that stops RT from sliding along its template (160). For a 
detailed review on the differences between NC species, see (156). 
Partially processed Gag intermediates interfere with proper core assembly. Under ideal 
cell culture conditions and normal PR activity, EM imaging reveals that the pre-RTC correctly 
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assembles up to 90% of the time (28, 29, 51, 161). The remaining virions display a mostly 
immature, but occasionally aberrant morphology. However, retention of minor amounts of 
processing intermediates strongly shifts the distribution toward aberrant and immature 
assemblages (28-30, 51). For instance, at the IC50 for a PI, 40-50% of particles display an 
aberrant or immature phenotype (26, 28, 30). However, less than a 10% reduction in CA/SP1 
processing in cell-free virions was observed when compared with untreated controls (30). These 
results suggested small amounts of processing intermediates could act as strong dominant 
negative inhibitors. 
Our laboratory and others (30, 51) explored the relationship between processing at each 
site in Gag and its dominant negative effect. Progressively interfering with some percentage of 
processing at basically any Gag cleavage site will eventually eliminate infectivity (29, 30, 51, 
137), a phenomenon first reported for Murine Leukemia Virus (162). The sole possible exception 
is NC/SP2 (see below) (29, 30, 137, 161). The two sites most sensitive to interference are the 
MA/CA site (29, 30), and the CA/SP1 site (30, 51), suggesting CA intermediates have the 
strongest dominant negative effect. These results are somewhat surprising since only ~1500 CA 
molecules need to be fully cleaved for assembly of the CA shell (163) – a number that is only 
about 60% of the total estimated amount in the virion (19). Considerably higher sensitivity might 
be expected of NC, since closer to 85% of NCs likely participate in the reverse transcription 
process (164). Nonetheless, both CA/SP1 and MA/CA/SP1 species are observed in virions 
collected after sub-optimal PI treatment (26, 28, 30), suggesting the dominant negative effects 
are valid. 
Visualization of virions partially defective for MA/CA (29) or CA/SP1 (51) cleavage 
found the predominant assembly defects manifested slightly differently for each of these 
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cleavage sites, although the functional block is the same (Figure 1.5). For incomplete MA/CA 
cleavage, an electron dense sphere consistently appeared immediately adjacent to the virion 
envelope, which implies at least one CA molecule still tethered to the membrane via MA was 
included in an assembling cone (29). For incomplete CA/SP1 cleavage, a condensed RNP core 
also formed, although the majority appeared dissociated from the virus envelope (51). The 
authors did not comment on the thickness of the envelope, leaving open the question of whether 
the CA lattice disassembled when various amounts of CA/SP1 cleavage were inhibited. 
However, as we previously noted, immature lattice disassembly has been reported to occur 
following cleavage of the MA/CA site (152), suggesting the defect brought on by the CA/SP1 
mutants is a failure to assemble the mature lattice. This is in contrast to the maturation inhibitor 
Bevirimat, which delays CA/SP1 cleavage, but does so by stabilizing the immature CA array 
(165, 166). 
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Figure 1.5: Schematic representation of the most common effects of CA/SP1 and MA/CA 
on virion morphology. For CA/SP1 (top), the core forms normally, but no CA shell 
encompasses the condensed RNP complex. For MA/CA (bottom), the core forms normally, but 
generally locates immediately adjacent to the membrane. Such placement likely indicates the CA 
shell has incorporated a molecule still attached to the membrane because of failed MA/CA 
cleavage. In both cases, reverse transcription defects are the likely outcome. Gag and Gag-Pro-
Pol color scheme is consistent with Figure 1.2. 
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Both of the dominant negative derivatives of CA prevent the assembly of the fullerene 
cone. The requirement for a nearly complete, conical CA shell during reverse transcription is still 
somewhat obscure. CA does not directly interact with nucleic acid, and no reports exist to 
suggest CA enhances RT activity in vitro. Furthermore, a considerable amount of the CA shell 
may disassemble soon after cellular entry (128, 167). Nonetheless, HIV-1 replication is severely 
attenuated and defective for reverse transcription when cones cannot form (155), dissolve too 
quickly (133, 168-170), or fail to dissociate (170). Several possible reasons for its critical 
importance have been hypothesized (171): for one, though part of the shell is lost, the remnants 
may shield the RTC from nucleases or host restriction factors; it may protect the viral reverse 
transcription products from cytoplasmic innate immune receptors; and potentially, CA may 
recruit host cellular proteins necessary for the completion of reverse transcription. 
 The curious case of NC/SP2. Four publications reported that cleavage of the NC/SP2 site 
is non-essential for infectivity in single round assays (29, 30, 137, 161). Each of these 
conclusions stemmed from versions of the NL4-3 virus isolate defective only in NC/SP2 
processing. Paradoxically, one of these authors reported that partially inhibiting HIV-1 PR 
activity by sub-optimal concentrations of PI was most effective at inhibiting NC/SP2 processing, 
and that the amount of NC/SP2 inhibition closely correlated with the total loss in infectivity (30). 
Furthermore, one group reported that after just four passages, the mutant NC/SP2 cleavage site 
had reverted back to wild type (137). Another had found that, while apparently non-essential, 
inhibiting NC/SP2 did reduce virus fitness (29). And lastly, a fifth report contradicts these results 
with the conclusion that NC/SP2 cleavage does affect viability (172). The principle difference in 
experimental design from that study was the use of the BH10, instead of NL4-3 like the rest, 
though they also used a different cell type to measure infectivity.  
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More indicative of the important role NC/SP2 cleavage plays, mutations in NC/SP2 are 
frequently observed in vivo as compensatory mutations in PI-resistant viruses (173-175). For 
example, in the presence of patient-derived PI-resistant viruses, the NC/SP2 mutations A431V 
and I437V were each individually capable of conferring a fitness advantage to the virus in the 
presence of PIs, and were just as effective as when the entirety of Gag was supplied (175). These 
results suggested that NC/SP2 resistance mutations carry the resistance impact for non-PR 
compensatory mutations, though this conclusion may only be true for particular resistance 
pathways in the HIV-1 PR (176).  
From the available data, we suggest two plausible explanations for these discrepancies: 
(1) NC/SP2 processing is not essential for infectivity, but specifically for the NL4-3 clone; or (2) 
NC/SP2 processing is not essential, however, it makes the virus partially defective. We prefer the 
second option, since if NC/SP2 cleavage was non-essential for NL4-3 only, we would not expect 
to find the reversion to wild type. The differences in the literature are likely explained, at least in 
part, by variances in the amount of cleavage required for replication in the different assay 
conditions. However, the NC/SP2 site overlaps the ribosomal slippery sequence. Thus, it is 
possible that the rapid reversion occurred because of RNA secondary structure requirements. The 
fitness advantage of reducing NCp9 to the NCp7 could derive from the faster on/off binding 
kinetics of NCp7 (158a). NCp9 binds cooperatively, which could interfere with its ability to 
negotiate the strand transfer reactions during reverse transcription that require rapid nucleic acid 
rearrangements (159b). Additionally, the slower dissociation of NCp9 from template strands 
could result in increased pausing and/or dissociation of the RT elongation complex. 
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3.3  Nuclear import and integration: a far reach 
At the completion of reverse transcription, IN molecules bind the LTR regions and 
engage with each other to form a tetramer (reviewed in: (177). IN proceeds to cleave the DNA 
ends, in the first of two enzymatic reactions for which it is responsible, at a specific dinucleotide 
sequence near the end of each long terminal repeat (LTR) region. Generation of the new under-
hanging 3’-OH groups represents the final conversion of the RTC into the PIC, the integration-
competent nucleoprotein complex containing a complete copy of viral DNA. Before IN performs 
its second enzymatic function, in which it utilizes the hydroxyl groups created in the first 
reaction to simultaneously break the phosphodiester bonds in the host DNA and insert the viral 
DNA, the PIC must first enter the nucleus. 
Distinct from other genera of retroviruses, lentiviruses like HIV-1 have evolved 
mechanisms to infect non-dividing cells (3, 4). This necessitates crossing the nuclear envelope 
through nuclear pore complexes (NPCs). Molecules that are approximately 10 nm in diameter or 
more cannot passively diffuse through the NPC (178), and those 40 nm or greater in diameter 
cannot get through at all without disassembling (179). This seemingly poses a considerable 
problem for HIV-1, whose PIC has an estimated diameter of 56 nm (180). Although this is still 
too large to fit through the NPC, it has already shrunk in size from 400 nm in length, and 100 nm 
width during reverse transcription (129). Therefore, further remodeling to transverse the NPC 
likely takes place. Vpr has been identified as potentially mediating this process (136), since it has 
a nucleic-acid binding ability (181, 182) and can bind and fold dsDNA (136). Thus, management 
of Vpr-nucleic acid interactions might organize the genome for nuclear entry. 
Although genetic evidence implicates both CA (183-185) and NC (186, 187) in nuclear 
import and integration, and MA has frequently been found within the PIC (125, 180, 188-190), 
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the likelihood that interrupting HIV-1 PR activity by PI would have an effect on these later steps 
without first affecting the completion of reverse transcription seems low. Even the obvious effect 
of the trapping IN within the Gag-Pro-Pol precursor is more likely to manifest as a reverse 
transcription block. Viruses generated in the absence of IN or with select mutations fail to 
complete reverse transcription (191). IN appears to be essential for encapsidation of the electron-
dense RNP core by the CA cone (192, 193), and also interacts with the host cellular factors 
eEF1A and eEF1G, important components of the elongation complex (194). Nonetheless, Rabi et 
al. mathematically determined that PIs exert some level of inhibition on post-reverse 
transcription steps, independent of their interference of both entry and reverse transcription (25). 
Thus, though such an effect seems unlikely, a relationship between PIs and post-reverse 
transcription functions may occur. 
Delayed condensation of the virion core potentially interferes with nuclear import, and 
not reverse transcription. Nuclear transport of HIV-1 PICs is an active process (3). In quick 
succession, four different genome-wide RNAi screens identified putative host cellular factors 
important for HIV-1 replication (195-197), a list that included a considerable number of nuclear 
transport factors. Several of these putative interacting partners for viral components of the RTC 
and/or PIC have already been confirmed (reviewed in: (198)). As a consequence of this growing 
list, the importance of the HIV-1 CA in nuclear entry has come to the forefront. CA was 
completely absent from early studies identifying the components of the PIC (188-190, 199), 
leading to the conclusion that the CA shell completely dissociated before the RTC/PIC reached 
the nuclear pore. However, later studies demonstrated CA as a critical factor in enabling HIV-1 
to infect non-dividing cells (183, 200). Concomitantly, evidence accumulated that the CA shell 
underwent a biphasic process of disassembly (128, 167), and complete uncoating might not 
 
 
35 
occur until at the NPC (201). Now, CA is known to directly interact with several host proteins 
involved in nuclear entry, including Nup153 (202), Nup358 (203), and Transportin-3 (204). 
With the clear importance of CA as an interacting partner of nucleoporins, one attractive 
mechanism of interference would be causing the misassembly of the fullerene cone. However, 
we have already discussed the dominant negative effects of Gag processing intermediates on 
fullerene cone assembly, and they interfere with reverse transcription. While we cannot rule out 
the possibility that PIs could affect CA assembly in such a way as to allow reverse transcription 
to occur, but then compromise its ability to facilitate nuclear import, this scenario is at present 
without support. Alternative possibilities reside with NC processing intermediates. Mutations of 
the C-terminal domain of Gag that block processing at the SP2/p6 site still allow reverse 
transcription to occur, albeit at a slightly reduced efficiency (137). These mutants were still 
considerably less infectious than wild type, even with detection of late reverse transcripts (137, 
161). Where 2-LTR circles were quantified, the authors found only one-third as many as in wild-
type infections (137). Though there could be alternative explanations, such as decreased stability 
of the 2-LTR circles, these results supported a defect in nuclear entry.  
As for the mechanistic basis of this effect, the p15NC intermediate is incapable of 
condensing the RNP core because of the presence of p6 (134, 157). This does not frequently 
prevent formation of a CA shell, although it no longer takes on the conventional fullerene cone 
shape (161) (Figure 1.6). Instead, maturation of the genomic RNA dimer goes unfinished (151, 
172, 205). Even if the NC/SP2 site is processed to release NCp7, the timing of the reaction could 
ostensibly result in aberrant CA cone formation, or the exclusion of non-structural proteins from 
the RNP core. Furthermore, since no specific RNA structure is required for the initiation of 
reverse transcription (205), and p15NC ably interacts with the tRNALys,3 primer and RT (206), 
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this particular processing intermediate might not interfere with reverse transcription initiation. If 
the mutant core can still facilitate strand transfer reactions, which becomes more likely if NCp7 
is eventually released, then reverse transcription could be completed. However, a defect during 
the conversion of the RTC into the PIC would halt the infection. 
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Figure 1.6: Morphology of SP2/p6 processing defect. Schematic representation of the most 
common morphology found when SP2/p6 cleavage does not occur. Colors consistent with Figure 
1.2. 
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Despite this mechanistic possibility, this block has only been demonstrated when SP2/p6 
processing has been artificially prevented by mutagenesis of the cleavage site. Temporally, 
SP2/p6 is cleaved at approximately the same time as MA/CA cleavage, if not a little ahead  (44). 
Thus, if there is a sufficient concentration of PIs to block SP2/p6 processing, it is highly likely 
that the virus particle would have the added problem of uncleaved MA/CA. However, selective 
errors in SP2/p6 processing might become more likely upon a loss of HIV-1 PR fitness during 
drug resistance selection. In addition to NC/SP2, the SP2/p6 site is one of the most frequently 
observed locations of compensatory mutations (173, 174, 207). Molecular modeling predicts 
SP2/p6 protrudes beyond the substrate envelope, and MA/CA much less so (49). Thus, SP2/p6 
could be preferentially more sensitive than MA/CA to drug resistance mutations in the PR. 
Effectively, the aberrant timing of SP2/p6 cleavage could enable the CA cone to assemble before 
condensation of the core, producing a reverse transcription-competent, but nuclear import-
defective virus. Thus, PIs have the potential to exert at least some influence on steps post-reverse 
transcription, though such an effect may not be immediately apparent. 
 
4. The theoretical potential of PIs that is unique among all inhibitor targets 
Beyond the many pleiotropic effects achieved by inhibiting the PR, targeting the active 
site of the PR itself has an intrinsic advantage in terms of inhibitor binding potential. The theory 
of transition state affinity, simply put, states that, in order to enhance the rate of a reaction, the 
affinity of an enzyme for its substrate must increase while changing from the ground state to the 
transition state by a factor that matches or surpasses the factor by which the enzyme enhances the 
rate of reaction. Later, the enzyme’s grip relaxes as the products are formed and released. In this 
way, the enzyme lowers the free energy of activation for the reaction (208). By extension, the 
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inhibitors that bind most tightly are mimetics of the transition state structure. None of the 
strategies to develop inhibitors of HIV-1 use this most fundamental of inhibitor designs, except 
for the PIs. These inhibitors invariably contain a hydroxyl group that aligns with the two aspartic 
acid residues at the active site. The hydroxyl group displaces a water molecule ordinarily used by 
the aspartic acids to catalyze the hydrolysis of the peptide bond. Thus, the hydroxyl group helps 
the inhibitor mimic the transition state as it would be shaped while adding water to the peptide 
bond. For this reason, HIV-1 PIs stand alone in their potency, reaching Ki values that are actually 
difficult to measure and lie in the low picomolar range (Figure 1.7). 
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Figure 1.7: Comparison of the inhibitory constants for each inhibitor from four of the 
antiretroviral drug classes: Protease Inhibitors (PI), Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTI), Nucleoside Reverse Transcriptase Inhibitors (NRTI), and Integrase Strand 
Transfer Inhibitors (INSTI). All PI values are cited from (209). For NNRTIs, RPV from (210), 
NVP from (211), EFV from (212), and ETR and DLV from Dr. Nicolas Sluis-Cremer (personal 
communication). All NRTI values are cited from (213). All INSTI values are cited from (214). 
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We should not be surprised at the potencies of these PIs, since such high affinities are 
precisely what is predicted by transition state analog theory. This concept of rate enhancement 
by inducing the transition state can be made more clearly by comparing the rates of reactions in 
the presence and absence of enzymes. For this comparison, since reported rate constants for the 
HIV-1 PR vary dramatically based on the substrate and the reaction conditions, we will use an 
average value under conditions where the enzyme is especially active, while acknowledging we 
do not know how this level of catalytic activity compares to the activity of the enzyme during 
virion maturation. A typical reported rate constant (kcat) for peptide cleavage by the HIV-1 PR is 
20 sec-1 (215) whereas the rate constant (knon) for uncatalyzed hydrolysis of a model peptide (the 
glycine-glycine bond of acetylglycylglycine N-methylamide) is 3.6 x 10-11 second-1 (216). Thus, 
the PR enhances the rate of peptide hydrolysis (kcat/knon) by a factor of about 5 x 1011-fold. The 
value of Km for peptide substrates can be as low as 10 µM  (215, 217). Therefore, this enzyme's 
formal affinity for the substrate in the transition state can be described by a dissociation constant 
equal to the substrate’s Km value divided by kcat/knon, or 2 X 10-17 M. This value argues that even 
the best current pM inhibitors (e. g. DRV, Ki 10-12 M) bind 105 fold less tightly than the actual 
substrate in the transition state. Accordingly, PIs still have a considerable amount of room for 
improvement. It is certainly true that there is a big difference between good inhibitors and good 
drugs, and that many good inhibitors never become good drugs. But it is also true that good 
drugs all started as good inhibitors, so that new and/or improved drugs will have to be built on 
new concepts in inhibitor design. 
There is an important corollary in considering the implications of such tight binding 
inhibitors. Chemists have a very large array of structures to query in reaching an optimal 
inhibitor design. In contrast, the virus is limited to the 20 amino acid structures and further 
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limited by the need to maintain binding and function on the normal substrates. Thus, as binding 
of the inhibitor becomes increasingly tight, the impact of one or two amino acid changes (of the 
limited choices available) may not allow enough viral replication to occur for further evolution to 
high levels of resistance. In this case, a very tight binding PI would behave equivalently to highly 
successful combination therapy, where viral suppression is achieved before resistance appears to 
drugs that are otherwise easily circumvented. The possibility for very tight binding to be an 
effective strategy of limiting evolution is most easily proposed for PIs, should they become true 
transition state analogs. 
 
5.  Conclusions and future perspectives 
PIs offer two unique and important features in targeting the PR to block viral replication: 
(i) inhibition of the PR has pleiotropic effects on multiple steps in the viral life cycle, and (ii) PIs 
are based on transition state analog design which has intrinsically high binding potential. 
Executing the proteolytic processing pathway during virion maturation requires multiple PR 
molecules, and thus inhibition has a significant cooperative effect; as the amount of active or 
functional PR decreases, the virus becomes increasingly sensitive to increasing inhibitor 
concentrations. Finally, if increased tight binding to PIs can be achieved, this may limit the 
ability of the virus to evolve biologically significant resistance during the short period when viral 
replication is decreasing to full suppression. This raises the possibility that highly potent PIs may 
become legitimate candidates for single drug therapy. 
 Current PIs/drugs already offer much of this potential. However, rapid metabolism of the 
current inhibitors typically requires a boosting agent to increase drug levels. While drug 
resistance to many of the PIs is well described, no reports of drug resistance to the potent 
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inhibitor DRV have been describe in subjects starting DRV who were previously PI-naïve, 
suggesting generating resistance to DRV de novo is difficult. Furthermore, there has been some 
success using DRV as a single agent in an induction/maintenance strategy of therapy (71, 218). 
Thus, DRV appears to have many of the properties we would anticipate for an optimal PI, which 
also suggests further improvements beyond DRV may take us into truly new territory in HIV-1 
drugs and therapy. 
 
C.  Dissertation Overview 
 The infectivity of a HIV-1 particle strongly depends upon the activities of the viral PR 
during the maturation process. Impaired PR functionality can result in a reduced ability to fuse 
with a target cell (22-25), in a failure to complete reverse transcription (25-30), and, potentially, 
in failure to transverse the nuclear envelope (25). For the heavy reliance placed upon the PR, its 
task is not a simple one. The enzyme must cleave thousands of substrates in a very specific 
sequence, all of which are technically present at the same time. Yet it is highly effective when 
unencumbered by human intervention (28, 29, 51, 161).  
Despite thirty-plus years of study, the mechanisms that govern the HIV-1 PR to ensure it 
accomplishes this prodigious feat remain unknown. The diversity of amino acid sequences 
recognized by the PR as substrate certainly plays a key role (49), yet no one has determined 
exactly how or why one sequence is superior to any other. Complicating matters are the 
existence of contextual determinants (50) and putative cofactors (219-221) that obscure the 
enzyme’s specificity based on sequence alone. HIV-1 PR inhibitors are already the most 
effective treatment for HIV-1 (52, 53, 65, 70, 71), yet even they still have much room for 
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improvement as I have just discussed. Should the mechanisms that control PR function be 
delineated, the design and effectiveness of these interventions would only grow. 
The second chapter of this dissertation discusses the role of RNA as a cofactor for the 
HIV-1 PR. The long-standing hypothesis suggested RNA accelerated the cleavage rate of a 
single substrate, p15NC. The original report observed the phenomenon of RNA-dependent 
enhancement for only this RNA-binding protein and not a secondary substrate also derived from 
Gag. However, when we included p15NC and a second substrate based on the MA and CA 
regions of Gag in a single reaction, the ability of RNA to enhance processing rate was not limited 
to only the RNA-binding protein. This effect, which accelerated processing rate by more than 
100-fold, was maintained even in the absence of p15NC or any other RNA-binding protein. 
These results led to the proposal of a new hypothesis – the interaction responsible for enhanced 
processing occurs between an allosteric binding site on the HIV-1 PR and RNA. The 
acceleration of a peptide assay by the addition of RNA offered convincing evidence in favor of 
this hypothesis, as the peptide was too small to simultaneously interact with the PR and the 
nucleic acid. Gel-shift assays screening for an interaction between the HIV-1 PR and short 
single-stranded DNA (ssDNA) oligonucleotides further confirmed the enzyme’s ability to 
interact with nucleic acid. However, a complementary assay with the HIV-2 PR failed. The HIV-
2 PR also failed to exhibit an improved processing ability in the presence of RNA. The overt 
difference between the HIV-1 and HIV-2 enzymes was their overall net charge; the HIV-1 PR 
was basic, and the HIV-2 PR acidic. This led to the conclusion that the interaction between the 
HIV-1 PR and RNA was non-specific and dependent upon an electrostatic attraction. An analysis 
of the kinetic efficiency of the HIV-1 PR in the presence and absence of RNA demonstrated that, 
mechanistically, both the affinity of the PR for its substrate and its turnover rate increased as a 
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result of the interaction with RNA. While the precise location of the allosteric binding site is yet 
to be determined, I highlight the flap as a high-priority research target owing to its involvement 
in both substrate binding and catalysis. I also suggest that the juxtaposition of the HIV-1 PR and 
virion-packaged RNA could provide an additional regulatory mechanism for PR activity during 
the maturation of virus particles. 
The third chapter sifts through the diversity in HIV-1 processing site amino acid 
sequence with the goal of identifying the underlying substrate preferences of the PR. Prior efforts 
have primarily relied upon small catalogs of short peptide substrates, but the pH and ionic 
strength of those works are not consistent with each other, complicating the interpretation of 
results. The conditions are also far from physiological, calling into question the accuracy and 
relevance of the results. To combat these problems, I generated the largest-to-date dataset of 
globular protein substrates where the cleavage efficiency could be measured under near-
physiological conditions. Multiple natural HIV-1 PR cleavage sites were placed into the same 
context and mutated several times select amino acid positions. The rate of processing for these 
substrates was measured relative to an internal control protein to provide consistent and 
comparable measurements across reactions. I then evaluated the effect of the mutations on a site-
by-site basis, before applying a series of statistical modeling procedures. The first set of models 
sought to identify the underlying similarities among all sites, which I accomplished with the use 
of linear-mixed effects modeling. This procedure accounted for the natural variance in the 
baseline rates among sites, effectively removing the noise in the data. Important physicochemical 
properties and amino acid positions were identified. I also attempted to build models with the 
intention of predicting out-of-sample data. However, these efforts were somewhat unsuccessful 
as the models were largely ineffective. Nonetheless, I identified an inverse relationship between 
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models that could classify fast and slow sites, and those that could classify active and inactive 
PR putative cleavage sites. From this I conclude that the identification of an ideal amino acid 
sequence for the HIV-1 PR will likely require the application of multiple models. More 
specifically, a model to identify non-functional groups is required, and a second model built to 
predict rates would also be needed. 
The fourth chapter will summarize the results presented in chapters two and three, with a 
discussion of future research directions. 
___________________________ 
3Published as “A direct interaction with RNA dramatically enhances the catalytic activity of the HIV-1 Protease in vitro.” Marc 
Potempa, Ellen Nalivaika, Debra Ragland, Sook-Kyung Lee, Celia Schiffer, Ronald Swanstrom in the Journal of Molecular 
Biology, Volume 427, Pages 2360-2378, July 17, 2015. 
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CHAPTER II 
A DIRECT INTERACTION WITH RNA DRAMATICALLY ENHANCES THE CATALYTIC 
ACTIVITY OF THE HIV-1 PROTEASE IN VITRO3 
 
A. Introduction 
 For HIV-1 to spread from cell-to-cell the virus must assemble a particle capable of 
leaving its host cell without re-infecting the same cell. HIV-1 accomplishes this by constructing 
the virion as a rigid (222), non-infectious entity (223), and then later converting the particle into 
a mature, infectious form (20). The timing of this transfiguration is critical for viral infectivity 
since prematurely initiating (224, 225) or slowing the kinetics of maturation by reducing the 
number of active HIV-1 PR molecules (26, 28, 30) both disrupt the production of infectious 
viruses. This, therefore, requires the virus to employ regulatory mechanisms that manage the 
assembly, release, and maturation steps of the virus lifecycle. Many of these mechanisms 
concern the activity of the HIV-1 PR. 
During assembly HIV-1 particles consist of two structural polyproteins, Gag and Gag-
Pro-Pol. Both share the same first four domains – MA, CA, SP1, and NC – but differ in having 
either SP2 and a domain called p6 (in Gag) or a TF domain and monomers of the viral enzymes 
PR, RT, and IN (in Gag-Pro-Pol). The mass assembly of these proteins on the plasma membrane 
triggers the budding process, which is completed with the help of the ESCRT machinery (16). It 
is then, concurrent to or immediately after budding, that the HIV-1 PR activates to begin the 
maturation step of the lifecycle (20).  
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The HIV-1 PR is a dimer of two identical subunits (31-33), necessitating an interaction 
between a pair of Gag-Pro-Pol molecules to create the active site of the enzyme. The low 
stability of this interaction (36, 226) and accompanying poor catalytic activity (34, 36) restrict 
PR activation to budding or budded virions, where a high local concentration of Gag-Pro-Pol 
provides conditions that favor dimerization. The embedded PR overcomes its limited 
functionality through a series of intramolecular cleavage events that free the N termini of the 
monomers (36, 38-40, 227), thereby producing a much more stable enzyme capable of 
completing intermolecular cleavage events (40, 41, 228). The mature enzyme then proceeds to 
cleave the remaining structural polyproteins in a step-wise process that must go to near 
completion (43-45). Even modest under-processing at most sites can result in a non-infectious 
virus particle (26, 28-30, 51, 162).  
Additional regulatory mechanisms exist to control the order and rate of Gag and Gag-
Pro-Pol processing. Principally, the cleavage rate is regulated at the level of the processing site 
amino acid sequence. Each site has a unique sequence, with no obvious pattern connecting them 
(47). Instead, all the sites can occupy a conformation that fits into the conserved shape, i.e. 
substrate envelope, recognized by the HIV-1 PR (48, 49). The ability of each site to fill that 
space therefore defines a key determinant of processing order and rate. For instance, the two 
processing sites that are cleaved last, CA/SP1 and NC/SP2, are the most dynamic sites, 
suggesting they frequently shift in and out of conformations that do not mimic the substrate 
envelope (49). This structural plasticity makes them more difficult to cleave. Secondarily, the 
rate of cleavage for the CA/SP1, SP2/p6, and SP1/NC processing sites also may exhibit some 
dependence on contextual determinants (50, 229, 230). 
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A role for RNA as a cofactor has also been suggested. Maturation generates an 
intermediate called p15NC, which is comprised of the NC, SP2, and p6 domains of Gag. The 
next step of processing requires cleavage at the SP2/p6 site, but this does not readily occur in the 
absence of RNA when examined in vitro (134, 220, 221). In the presence of RNA, (or select 
DNA oligonucleotides), the rate of processing by the HIV-1 PR dramatically increases. In 
contrast, the cleavage rate of a truncated MA/CA substrate remained unaffected after the removal 
of RNA from the reaction system (220). Since p15NC contains the principal viral RNA-binding 
protein, a mechanism was proposed in which an interaction between RNA and p15NC induces a 
conformational change in the protein that exposes a buried cleavage site, and/or stabilizes the 
conformation of the SP2/p6 site to make it a more suitable substrate (220). In agreement with 
this hypothesis, the SP2/p6 site is one of the more dynamic cleavage sites, behind only CA/SP1 
and NC/SP2 (49). Given the close proximity of the SP1/NC site to the RNA-binding domains, 
such a mechanism might also affect SP1/NC processing. Consistent with this, a 30-mer single-
stranded DNA molecule was recently shown to increase the rate of SP1/NC processing within a 
truncated Gag polyprotein (229).  
In an effort to study RNA-dependent processing, we established a two-substrate 
proteolysis system in which cleavage of the p15NC protein by the PR could be measured in 
tandem to the rate of cleavage of an internal control protein that was purportedly unaffected by 
nucleic acid. Contrary to prior results, we found both substrates exhibited an increased 
processing rate in the presence of RNA. Additional single-substrate assays with globular and 
peptide substrates demonstrated that RNA enhances processing in a substrate-independent 
manner. This led us to hypothesize that the critical interaction occurs between RNA and the 
HIV-1 PR, an interaction substantiated with a gel-shift assay. Examination of a panel of HIV-1 
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PRs demonstrated that this enzyme-RNA interaction is conserved across multiple subtypes, as 
well as in patient-derived drug-resistant enzymes. In contrast, the HIV-2 PR does not interact 
with RNA, and does not cleave its substrates more efficiently with RNA present. The interaction 
between the HIV-1 PR and RNA is primarily electrostatic in nature, although sequence and 
structural determinants within the polyanion may also play a role. Use of a tethered dimer of the 
HIV-1 PR revealed RNA-enhanced cleavage does not result from increased dimer stability. 
While the exact mechanism of enhancement has not yet been identified, we did determine that 
RNA affects both the Km and kcat. These findings support the existence of an allosteric binding 
site on the HIV-1 PR, and raise the possibility that PR activity during assembly could be 
regulated in part by the juxtaposition of the PR and virion-packaged RNA. 
 
B. Results 
1.  Multiple substrates of the HIV-1 PR exhibit an enhanced rate of proteolysis in the  
presence of RNA. 
 We first documented a two-substrate protease assay where the rate of p15NC processing 
could be measured relative to an internal control protein. To demonstrate that we could 
independently measure multiple substrates in a single reaction, we performed a time-course 
experiment with two substrates containing the canonical MA/CA cleavage site. One substrate 
consisted of the entirety of the MA and CA domains (MA/CA); the other substrate had a GST-
tag fused to the N terminus of MA and a CA region truncated at amino acid 145 (50) (GMCΔ). 
This truncation occurred between the N- and C-terminal domains of CA, which exist as two 
separate domains (231, 232), ostensibly leaving the conformation of the MA/CA cleavage site 
unaffected. In addition, these N- and C-terminal changes allowed the two forms of MA/CA to 
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migrate to different positions in a polyacrylamide gel in both the uncleaved and the cleaved 
states (Figure 2.1). As we have observed previously (29), both substrates were processed in 
parallel and at nearly identical rates. Thus, the two-substrate system enables the direct 
comparison of relative rates of cleavage by the HIV-1 protease using pairs of protein substrates. 
For this analysis we have relied on coomassie staining of the proteins and the disappearance of 
substrate over time to provide flexibility in the types of proteins that can be analyzed. 
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Figure 2.1: Concomitant processing of multiple substrates by the HIV-1 protease. (a) A 
reaction mixture containing the MA/CA (solid triangle) and GMCΔ (open triangle) substrates in 
equimolar amounts was incubated at 30ºC, pH 6.5 for 1 hour prior to the addition of the HIV-1 
PR. Reactions were run for 10 minutes with the intermittent removal of aliquots that were 
immediately mixed with SDS to halt the reaction. Reaction substrates and products were 
separated by SDS-PAGE and stained by coomassie. MA/CA products are indicated with solid, 
reversed triangles; GMCΔ products with open, reversed triangles. (b) MA/CA (circle) and 
GMCΔ (square) bands were quantified with imaging software and graphed as substrate 
remaining versus time. (c) Reactions containing MA/CA (solid triangle) and p15NC (open 
triangle) in a molar ratio of 1:4 were performed as in Figure 2.1a, +/- 150 nM of a 
heteropolymeric 532-nucleotide RNA derived from the p15NC region of the HIV-1 NL4-3 
genome. (d) Quantification of MA/CA (black circle) and p15NC (grey square) two-substrate 
assays. Dashed lines show reactions without RNA; reactions with RNA are represented with 
solid lines. All errors bars represent the standard deviation resulting from three independent 
experiments. 
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We sought to determine whether we could observe RNA-dependent rate enhancement of 
p15NC cleavage by substituting p15NC into the reaction system for the GMCΔ protein. Due to 
the poor staining profile of p15NC, its final concentration in the reaction was four-fold higher 
than that of the MA/CA substrate. In the absence of RNA (Figure 1c, left panel), cleavage of 
both MA/CA and p15NC was observed. Additional reactions performed with or without nuclease 
pre-treatment were indistinguishable (data not shown), affirming that these reactions were devoid 
of RNA. The percent substrate remaining was quantified by densitometry and plotted as a 
function of time (Figure 1d, dashed lines). Product formation for MA/CA was easily observable, 
however we could not unequivocally identify the products of p15NC cleavage. One stained 
poorly, and the other product ran to the same location on the gel as a contaminant remaining after 
protein purification. To confirm the 25% drop in p15NC band intensity we observed was in fact 
processing of the p15NC substrate by the HIV-1 PR, we performed the reaction in the absence of 
PR and found that there was no observable change in either substrate (data not shown), 
suggesting the decrease in p15NC band intensity was due to PR cleavage. Thus, in this system, 
the MA/CA protein was processed approximately 2.5-fold faster than p15NC in the absence of 
RNA. 
 When we performed the two-substrate reaction in the presence of long, heteropolymeric 
RNA, a 532-base transcript derived from the p15NC region of the HIV-1 genome, we found the 
rate of substrate disappearance accelerated for both substrates (Figure 2.1 c/d). This result 
contradicts previously published work that found MA/CA cleavage unaffected by the presence of 
nucleic acid (220, 229). Nonetheless, we consistently observed a 15-fold increase in the rate of 
p15NC cleavage in concert with an 8-fold increase in the rate of MA/CA processing. Our results 
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argue that substrates that do not contain NC can also exhibit an enhanced rate of cleavage in the 
presence of RNA. 
 
2. RNA-dependent rate enhancement is a substrate-independent phenomenon. 
 In order to confirm that RNA-dependent enhancement of MA/CA cleavage occurs 
independently of p15NC, we performed single-substrate proteolysis assays in the presence and 
absence of RNA. In our single-substrate assays, the MA/CA protein was labeled with the Lumio 
Green Reagent after mutagenesis of the Cyclophilin A loop in CA to create a fluor binding site 
(29). This label binds with high specificity and in a one-to-one molar ratio with the substrate, 
allowing specific and more sensitive detection of the substrate and the CA product compared to 
the coomassie stain (Figure 2.2). As a result, we could reliably determine the percent product 
formed (Intensity of CA band x 100% ÷ total fluorescence intensity of all bands in the lane), 
greatly increasing the accuracy of our data collection. Unfortunately, the label could not be used 
with the p15NC substrate because the zinc-finger domains in p15NC also bind to the Lumio 
Green Reagent. With this assay, we could accurately determine changes in the MA/CA cleavage 
rate of up to 40-fold. However, when comparing the no-RNA to plus-RNA reactions, we 
detected a fold enhancement beyond that value. Therefore, we only estimate the rate of MA/CA 
cleavage as 80- to 90-fold faster in the presence of RNA (Figure 2.2b). The magnitude by which 
MA/CA cleavage was accelerated in single substrate assays was considerably greater than in the 
two-substrate assay. Several explanations likely account for this discrepancy: the increased 
sensitivity of the fluorescence-based assay allowed more precise determination of reaction 
progress while under near steady-state conditions; the potential presence of multiple RNA-
binding proteins in the two-substrate assay meant there was competition for RNA, which limited 
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the effect; and, owing to an inability to purify p15NC to high concentrations, the ionic strength 
of the two-substrate assay was likely higher than anticipated due to a substantially larger 
contribution of protein storage buffer to the reaction mixture. Notably, raising the ionic strength 
of the reaction by increasing the salt concentration drastically reduces the magnitude of the 
RNA-enhancement effect (233), even in single-substrate MA/CA assays (see below). 
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Figure 2.2 RNA accelerates processing independent of the ability of MA/CA to bind nucleic 
acid. (a) MA/CA proteins were tagged with the Lumio Green Reagent via mutation of the 
Cyclophilin A binding loop in CA to include a CCPGCC motif. Single-substrate MA/CA 
proteolysis assays were visualized by coomassie (left) and fluorescence (right). Only CA-
containing reactant and product species are present in the fluorescence stain. (b) Reaction 
progress curves for single-substrate MA/CA (black) and MA/CA-AAA (grey) proteolysis 
reactions performed in the absence (dashed lines) and presence (solid lines) of RNA. (c) and (d) 
Binding reactions containing 100 ng (2 µM) of the single-stranded DNA molecule ODN17 and 
steadily increasing amounts (from 0 µM in lane 1 to 12 µM in lane 9) of MA/CA (c) or MA/CA-
AAA (d) were electrophoresed in a 6% polyacrylamide gel under native conditions. Gels were 
stained with SYBR Gold (left panel) to visualize nucleic acid species. The gels were then washed 
and restained with SYPRO Ruby (central panel) to view protein. The intensity of each nucleic 
acid species relative to the respective band in the no-protein reaction (lane 1) was determined by 
densitometry and plotted as a function of protein:ODN17 concentration (right panel). All errors 
bars represent the standard deviation resulting from three independent experiments. 
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 Since MA/CA also exhibited RNA-dependent enhancement, we considered the 
possibility that this effect resulted from an interaction between MA/CA and RNA. MA contains 
a highly basic region on the globular head of the protein capable of binding nucleic acid (234-
238). Because the RNA species used in prior experiments was a 532-base transcript derived from 
the p15NC region of the HIV-1 genome, it was poorly suited for use in a gel-shift assay. To 
identify a surrogate nucleic acid, we tested the ability of two short ssDNA oligonucleotides, N5 
(21 bases) and ODN17 (17 bases), to accelerate MA/CA processing. Both molecules had 
previously been reported to enhance p15NC processing similarly to RNA, although not as 
potently (134, 221). In agreement with previous reports, both N5 and ODN17 increased the rate 
of processing, but to a much lower degree than RNA (Figure 2.3).  
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Figure 2.3: Short DNA oligonucleotides previously reported to enhance p15NC processing 
also increase MA/CA processing rate. Shown are reaction progress curves for single-substrate 
MA/CA proteolysis assays performed under standard conditions in the absence of nucleic acid 
(squares), in the presence of a 17-mer single-stranded DNA oligonucleotide (ODN17; triangles), 
or in the presence of a 21-mer single-stranded DNA oligonucleotide (N5; circles). Both ODN17 
and N5 were previously reported to enhance p15NC processing. All errors bars represent the 
standard deviation resulting from three independent experiments.  
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Using ODN17, we performed a gel-shift assay to determine the ability of MA/CA to bind 
to nucleic acid. Under native conditions, ODN17 runs as two species (Figure 2.2c, left panel); 
presumably, the lower species corresponds to single-stranded molecules, while the upper band 
may represent a G-quadruplex structure that ODN17 has the potential to form (134, 239). In 
concert with the addition of increasing amounts of MA/CA to the binding reactions, (from 0 µM 
in lane 1 to 12 µM in lane 9), both the upper and lower bands progressively diminished (Figure 
2.2c, right panel), and a new band appeared toward the top of the gel. The new band overlaps 
with where the MA/CA protein runs (Figure 2.2c, center panel), signifying that the MA/CA 
protein interacts with nucleic acid.  
Addressing the question of whether this interaction was required for the enhanced rate of 
MA/CA processing, we replaced the lysines in the K26KQYK30 sequence of MA with alanines to 
generate the mutant protein MA/CA-AAA. In a previous report, mutating these lysines disrupted 
the residual RNA-binding ability of Gag molecules whose NC domain had been deleted (237). 
Consistent with those results, MA/CA-AAA was severely attenuated in its ability to interact with 
ODN17 (Figure 2.2d). If an interaction between MA/CA and nucleic acid was responsible for its 
increased cleavage rate, then we should have found enhanced processing of MA/CA-AAA to be 
considerably reduced or nonexistent. However, RNA-dependent enhancement of MA/CA-AAA 
processing still occurred, and at a nearly identical magnitude (Figure 2.2b, gray lines). These 
results suggest that RNA-dependent enhancement is independent of the substrate. 
In order to confirm the lack of requirement for an interaction between substrate and 
RNA, we performed proteolysis assays utilizing a 12-amino acid peptide as the substrate. The 
HIV Protease Substrate 1 (Sigma) is a fluorogenic substrate too small to interact with RNA and 
simultaneously be cleaved by the HIV-1 PR; conveniently, this peptide also contains the same 
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cleavage site sequence as the MA/CA protein. Adding RNA to the peptide proteolysis reaction 
still accelerated the rate of the reaction, though only by 20-fold (Figure 2.4). Differences in 
reaction conditions for the peptide (i.e. pH), and/or the absence of contextual determinants could 
account for the reduced magnitude of the effect relative to the globular MA/CA substrate. 
Nonetheless, the results of the peptide assay show that the increased reaction rate observed upon 
addition of RNA is independent of the substrate. 
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Figure 2.4: The addition of RNA to a reaction accelerates processing of a peptide substrate. 
A commercially available 12-amino acid peptide substrate was utilized as a substrate for the 
HIV-1 PR. Processing of the peptide substrate was monitored by an increase in fluorescence 
resulting from the separation of a fluorophore from a quencher placed on opposing ends of the 
peptide. Reactions were run at 30ºC, pH 4.8, and performed in the absence (grey) or presence 
(black) of long, heteropolymeric RNA. All errors bars represent the standard deviation resulting 
from three independent experiments. 
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3. The HIV-1 PR can directly interact with nucleic acid. 
 Since an interaction between RNA and substrate is not the mechanism driving RNA-
dependent enhancement, we hypothesized that an interaction was occurring between RNA and 
the HIV-1 PR. We again used ODN17 as a surrogate for RNA-binding, and performed gel-shift 
assays utilizing the HIV-1 PR as the protein in each binding reaction. Similar to the wild-type 
MA/CA protein, adding progressively more PR resulted in the disappearance of the upper 
oligonucleotide band (Figure 2.5, left panel). In this case the fluorescence intensity of the lower 
band remained relatively unchanged regardless of the amount of PR present in the binding 
reaction. Under native conditions, the HIV-1 PR does not enter the gel, likely because of its basic 
profile (HIV-1 PR has an isoelectric point of 9.1), so there is no overt overlapping band in both 
stains. Nonetheless, we infer the presence of a PR-ODN17 complex from the selective loss of the 
upper oligonucleotide band and a low level of fluorescence in the wells of the central lanes of 
both SYBR gold and SYPRO ruby stains. The fluorescence may disappear from the latter wells 
because the addition of more HIV-1 PR increases the net charge of the PR-ODN17 complexes so 
that the complexes flow into the running buffer rather than remain in the well. From this, we 
conclude that the HIV-1 PR can directly interact with nucleic acids. 
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Figure 2.5: The HIV-1 PR can directly interact with nucleic acid. Binding reactions 
containing 100 ng of ODN17 (2 µM) and steadily increasing amounts (from 0 µM in lane 1 to 12 
µM in lane 9) of the HIV-1 PR were electrophoresed in a 6% polyacrylamide gel under native 
conditions. As previously, gels were stained with SYBR Gold (top left) to visualize the nucleic 
acid species followed by SYPRO Ruby (top right) for visualization of protein. The relative 
intensity of each nucleic acid species was determined by densitometry and plotted as a function 
of protein:ODN17 concentration (bottom). The HIV-1 PR does not enter the gel under native 
conditions because of its high isoelectric point (pI = 9.1). Complexes can be inferred from the 
low level fluorescence present in the wells of the central lanes and the selective depletion of the 
upper nucleic acid species. All errors bars represent the standard deviation resulting from three 
independent experiments. 
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4. RNA accelerates processing by HIV-1 PRs from multiple subtypes and from drug  
resistant variants, but not processing by HIV-2 PR. 
 Given that we had only shown a single variant of a subtype B HIV-1 PR was capable of 
interacting with RNA to enhance its activity, we expanded our data set to include HIV-1 PRs of 
subtype C and CRF01_AE, as well as an HIV-2 PR (Table 2.1). We also tested several patient-
derived, drug-resistant subtype B PRs to determine whether the effect is maintained after 
significant changes to the amino acid sequence (19-26 substitutions from the PR of the SF2 
isolate of HIV-1 subtype B used in the prior experiments). All three wild-type HIV-1 PRs 
exhibited a 100-fold or greater increase in the rate they processed the MA/CA protein in the 
presence of RNA relative to their respective no-RNA controls (Figure 2.6). The drug-resistant 
HIV-1 subtype B PRs likewise demonstrated enhanced catalytic activity in the presence of RNA, 
although there was considerably more variability in the magnitude of the effect for these 
enzymes. Despite the variability in magnitude, VSL23, the PR whose activity was least 
accelerated, still cleaved MA/CA 30-fold more quickly. The only enzyme entirely unaffected by 
the presence of RNA was the HIV-2 PR. For this latter assay the cleavage site of MA/CA was 
adapted to reflect the canonical site for HIV-2, allowing the substrate to be efficiently cleaved by 
the enzyme (data not shown). Consistent with these results, we found that the HIV-2 PR did not 
interact with nucleic acid in a gel-shift assay (Figure 2.7; note the HIV-2 PR with its lower 
isoelectric point of 5.3 enters the gel). Both the PR-dependent variability in the magnitude of the 
effect, and the lack of enhancement for the HIV-2 PR further demonstrated that RNA-dependent 
enhancement results from an interaction between RNA and the HIV-1 PR rather than with the 
substrate. 
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Figure 2.6: The rate of processing by multiple HIV-1 PRs, but not the HIV-2 PR, increases 
in the presence of RNA. The rate of MA/CA processing by HIV-1 PRs from three different 
subtypes and an HIV-2 PR were evaluated in the presence and absence of RNA. The MA/CA 
protein substrate for the HIV-2 PR was mutated at the processing site to better reflect the 
canonical HIV-2 MA/CA processing site. Five highly mutated drug-resistant HIV-1 subtype B 
PRs (SLK19, KY26, ATA21, VEG23, and VSL23) were also examined. Reactions were 
performed with the globular MA/CA substrate under standard conditions with the exception of 
PR concentration, which was adjusted on an enzyme-to-enzyme basis to achieve 10% cleavage 
over the course of the reaction in the absence of RNA. SLK19, KY26, and ATA21 required up to 
4-fold higher concentrations; VEG23 and VSL23 were more severely attenuated, and required a 
20-fold higher concentration of enzyme. Results are reported as the magnitude difference in 
acceleration of the RNA-plus reaction relative to each enzyme’s respective no-RNA control. All 
errors bars represent the standard deviation resulting from three independent experiments. 
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Figure 2.7: The HIV-2 PR does not interact with nucleic acid. Binding reactions containing 
100 ng of ODN17 (2 µM) and increasing amounts (from 0 µM in lane 1 to 12 µM in lane 9) of 
the HIV-2 PR were electrophoresed in a 6% polyacrylamide gel under native conditions. Gels 
were stained with SYBR Gold (top left) to visualize the nucleic acid species followed by SYPRO 
Ruby (top right) for visualization of protein. Note the HIV-2 PR with its lower isoelectric point 
(pI = 5.3) enters the gel. The relative intensity of each nucleic acid species was determined by 
densitometry and plotted as a function of protein:ODN17 concentration (bottom). All errors bars 
represent the standard deviation resulting from three independent experiments. 
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5. Long, heteropolymeric RNA is the most effective enhancer of HIV-1 PR activity, but  
small ssDNA molecules and tRNA are still functional enhancers. 
 Whereas MA/CA interacted with both the upper and lower ODN17 bands in the gel-shift 
assay, the HIV-1 PR demonstrated a selective interaction with only the upper ODN17 species. 
Additionally, ODN17 and N5 were considerably less potent enhancers than p15 RNA, requiring 
much higher concentrations to be effective in our earlier assays. These data raised the possibility 
that a specific interaction might occur between enzyme and nucleic acid, which was fulfilled 
much more capably by some component of the p15 RNA transcript used in our assays. To 
determine whether p15 RNA contains some specific feature required for an interaction between 
the HIV-1 PR and nucleic acid, we generated dose-response curves for multiple different RNA 
transcripts, yeast tRNA, and the N5 and ODN17 single-stranded DNA molecules. All long (>400 
bases), heteropolymeric RNAs accelerated the reaction equivalently (Figure 2.8a), including 
transcripts that were not derived from the HIV-1 genome (data not shown). The long RNAs also 
had very similar EC50 values (Table 2.2) that were even closer to identical when adjusted for 
length (EC50/nt). Even though N5 and ODN17 were roughly one-tenth as effective as long 
heteropolymeric RNA in the magnitude of the enhancement effect, both still accelerated MA/CA 
processing by about 10-fold. Though the EC50s of N5 and ODN17 were in the µM range, the 
EC50/nt were reasonably similar to those of long heteropolymeric RNA. Yeast tRNA grouped 
with the single-stranded DNA molecules regarding the magnitude of enhancement, but the EC50 
value was nearer the RNA transcripts. Thus tRNA had the lowest EC50/nt, but this value was still 
only two-fold lower than most other nucleic acids. We conclude that long, heteropolymeric 
RNAs are the most potent enhancers of HIV-1 PR activity, but because all six nucleic acids 
tested had very similar EC50/nt, the amount of nucleic acid, rather than a specific sequence or 
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structure, appears to be the critical determinant. However, this does not yet address why long 
heteropolymeric RNA was 10-fold more potent in the magnitude of enhancing HIV-1 PR activity 
than the other nucleic acids (i.e. 100-fold vs 10-fold enhancement), nor does it explain the 
selective binding of the oligonucleotides observed in the gel-shift assay. 
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Figure 2.8: Multiple nucleic acid species can enhance HIV-1 PR activity, though potencies 
vary. (a) Dose response curves were generated for several long heteropolymeric RNAs, yeast 
tRNA, and the single-stranded DNA oligonucleotides N5 and ODN17. Reactions were 
performed under standard conditions using the MA/CA protein as the substrate. (b) 100 ng of the 
indicated single-stranded DNA oligonucleotides were electrophoresed in a 6% polyacrylamide 
gel under nondenaturing conditions, and then visualized with SYBR gold. The dashed white line 
distinguishes single-stranded species from oligomeric species. (c) Each single-stranded DNA 
oligonucleotide was supplied at a final concentration of 10 µM in MA/CA processing reactions 
and evaluated for its ability to improve HIV-1 PR function. Results are reported as the magnitude 
of acceleration relative to MA/CA processing in the absence of nucleic acid. All errors bars 
represent the standard deviation resulting from three independent experiments. 
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Table 2.2: Length and efficacy of polyanions as enhancers of HIV-1 PR activity. 
 
 Length (nt) 
Max. Fold 
Acceleration 
EC50 
(nM) 
EC50/nt 
(nt x 10^18/L) 
MACA RNA 1248 95 17 13 
p15 RNA 532 92 38 12 
PR RNA 436 82 43 11 
Yeast tRNA 76-90 8.0 108-124 5.7 – 6.7 
N5 21 12 3229 41 
ODN17 17 7.3 1148 12 
Heparin --- 30 175-195 --- 
Poly(dA) 49 < 2 --- --- 
Poly(dC) 49 21 569 17 
Poly(dG) 49 15 506 15 
Poly(dT) 49 18 635 19 
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As a means of further investigating the apparent selectivity of the HIV-1 PR for the larger 
ODN17 species, as well as the discrepancy in the magnitude of the effect between long RNA 
transcripts and single-stranded DNA molecules, we increased our catalogue of oligonucleotides 
and tested each for their ability to enhance PR activity. Figure 2.8b and 2.8c contain the results 
from a selection of these molecules, all of which are between 17 and 21 nucleotides in length 
(Table 2.3). Of the twelve molecules shown, six of them (ODN17, N5, N5cgmut, N10, G6A6C6, 
G6A12) enhanced the rate of the reaction by at least 5-fold; the other six were ineffective even at 
concentrations exceeding 10 µM. Among the single-stranded DNA molecules capable of 
enhancing the reaction, all but the C-rich N10 molecule formed slower migrating species when 
electrophoresed through a 6% polyacrylamide gel. However, we cannot definitively state 
whether N10 did or did not form a secondary species because the SYBR gold stain is much less 
effective at staining C-rich oligonucleotides (e.g. Figure 2.8b, C6A12), and C-rich nucleic acids 
are capable of forming higher order multimeric species (240). With the possible exception of 
N10, these results are in accordance with the gel-shift assay where only the larger nucleic acid 
species interacted with the HIV-1 PR. 
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Table 2.3: List of single-stranded DNA oligonucleotide sequences and lengths. 
 
Oligonucleotide Length (nt) Sequence (5’-3’) 
ODN17 17 TTGGGGGGTACAGTGCA 
N5 21 GCCCTTTTTCCTAGGGGCCCT 
N5cgmut 21 CGCGTTTTTCCTAGGGGCCCT 
N5cgcomp 21 CGCGTTTTTCCTAGCGCGCCT 
N9 21 GGAAGGCCAGATCTTCCCTAA 
N10 21 ATTCCCTGGCCTTCCCTTGTA 
N17 21 ATACAGTTCCTTGTCTATCGG 
G6A6C6 18 GGGGGGAAAAAACCCCCC 
GCaltA6 18 GCGCGCAAAAAAGCGCGC 
G6A12 18 GGGGGGAAAAAAAAAAAA 
C6A12 18 CCCCCCAAAAAAAAAAAA 
GCaltA12 18 GCGCGCAAAAAAAAAAAA 
Poly(dA)49 49 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Poly(dC)49 49 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 
Poly(dG)49 49 GGGGGGAGGGGGGAGGGGGGAGGGGGGAGGGGGGAGGGGGGAGGGGGGA 
Poly(dT)49 49 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 
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We also noticed a direct correlation between the migration distance in the gel, where 
observable, and the magnitude of the enhancer effect (Figure 2.8b and 2.8c). Preheating aliquots 
of the oligonucleotides before use confirmed the importance of these multimeric and/or 
structured species – only those whose slower migrating species remained after heating retained 
their enhancer activity (Figure 2.9) – and also strengthened the correlation between migration 
pattern and effect magnitude. G6A6C6 lost one of its two larger species after heating, with the 
remaining band migrating to a position similar to the species present in the unheated N5 aliquots. 
The magnitude by which the heated G6A6C6 preparation enhanced HIV-1 PR activity resembled 
that of unheated N5, highlighting the proposed relationship. These data suggest that the 
interaction between the HIV-1 PR and nucleic acid is primarily electrostatic in nature, requiring 
a polyanion of some particular size or conformation rather than a specific sequence. Also, the 
potency of an enhancer’s effect may be determined by the size and/or conformation of the 
molecule. 
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Figure 2.9: Heat-induced loss of slower migrating nucleic acid species corresponds with a 
loss in effector potency. (a) Aliquots of each indicated nucleic acid species were either left at 
room temperature or heated at 90ºC for 10 minutes before rapid cooling by centrifugation. Each 
lane contains 100 ng of DNA from the indicated unheated or heated samples. Bands were 
visualized with SYBR gold following electrophoresis in a 6% polyacrylamide gel. (b) Unheated 
(black) and heated (grey) DNA oligonucleotides were provided at a final concentration of 10 µM 
and examined for their ability to enhance HIV-1 PR-mediated processing of MA/CA under 
standard reaction conditions. All errors bars represent the standard deviation resulting from three 
independent experiments. 
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6. The interaction between the HIV-1 PR and nucleic acid is principally electrostatic,  
but additional factors affect the magnitude of enhancement. 
 If the HIV-1 PR-RNA interaction is primarily electrostatic in nature, then a non-nucleic 
acid polyanion should be sufficient to enhance the enzyme’s catalytic activity. To test this, we 
utilized heparin as the polyanion in single-substrate proteolysis assays and generated a dose-
response curve (Figure 2.10a). As expected, heparin enhanced proteolysis, accelerating the rate 
of the reaction by up to 30-fold. This value put heparin squarely between long, heteropolymeric 
RNA and the short single-stranded DNA molecules in effectiveness. With the expected size of 
commercially produced heparin molecules to be 17-19 kDa, an equivalently sized molecule of 
RNA would be approximately 53-60 nucleotides. As this size fits between the HIV-1 RNA 
transcripts and the single-stranded DNA molecules, the magnitude of the effect remains 
consistent with the proposed relationship between size and effectiveness of the polyanion. We 
also tested a polycation spermine (Sigma) in our system, but it had no effect on HIV-1 or HIV-2 
PR activity at all concentrations examined (data not shown). However, we cannot rule out the 
possibility that its ineffectiveness was the result of the small size of individual spermine 
molecules. 
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Figure 2.10: A specific nucleic acid sequence or structure is not required for enhancement. 
Dose-response curves were generated under standard assay conditions for (a) heparin, and (b) 
deoxynucleotide homopolymers. Reactions were performed with the globular MA/CA substrate 
under standard conditions. 
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 If an electrostatic interaction were sufficient, we hypothesized that homopolymers of 
each deoxynucleotide should be equally effective at accelerating the rate of proteolysis. We 
generated dose response curves for 49-mers of poly(dA), poly(dC), and poly(dT), (Figure 2.10b). 
Owing to synthesis constraints, the poly(dG) molecule contained an adenosine every seventh 
base (Table 2.1). We found that only three of the four nucleic acid homopolymers accelerated the 
rate of MA/CA cleavage, with poly(dA) incapable of enhancing the rate of the reaction by any 
significant amount under the conditions tested. The three other oligonucleotides yielded similar 
results in both the magnitude of their effect and their EC50 values (Table 2.2). Furthermore, the 
15-20-fold rate enhancement observed was also consistent with the predicted result based upon 
the size of the molecules. The observation that poly(dA) was ineffective indicates that while a 
polyanion is necessary, it is not sufficient for enhancing proteolysis. 
Additionally, if the PR-RNA interaction is electrostatic in nature, the pH and ionic 
strength of the reaction mixture should influence the enhancer effect. The intracellular ionic 
strength of mammalian cells is approximately 0.15 M, which is similar to the conditions of our 
single-substrate assays. Increasing the ionic strength to 0.2 M by adding NaCl to the reaction 
buffer reduced the effect to only a 10-fold enhancement. RNA had no effect in reactions with an 
ionic strength greater than 0.5 M (Figure 2.11a). Though the pH at the site of virus assembly, 
budding, and maturation has not yet been formally determined, the cytosolic pH of lymphocytes 
is approximately 7.2 (241). When we performed assays at pH 7.2, select shorter nucleic acids, 
including tRNA and G6A6C6, still accelerated MA/CA processing albeit to a limited degree; the 
remaining 17-21 single-stranded DNA molecules became ineffective (data not shown). Long 
heteropolymeric RNA was also still effective, but similarly to raising the ionic strength, the 
magnitude of the effect decreased to approximately eightfold enhancement (Figure 2.11b). 
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Figure 2.11: The ionic strength and pH of the reaction affect the potency of nucleic acid-
dependent enhancement of HIV-1 PR activity. The standard reaction buffer was supplemented 
with (a) sodium chloride to raise the ionic strength or (b) with sodium hydroxide to increase the 
pH to 7.2. The ability of long, heteropolymeric RNA to enhance cleavage of MA/CA by the 
HIV-1 PR was then evaluated. The resulting reaction progress curves are shown. All errors bars 
represent the standard deviation resulting from three independent experiments. 
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7.  RNA-dependent enhancement is not the result of a change in HIV-1 PR monomer- 
dimer equilibrium. 
 We attempted to discern the mechanism by which RNA and other polyanions enhance 
HIV-1 PR catalytic activity. As the HIV-1 PR is a non-tethered dimer, its monomeric and 
dimeric forms exist in a state of equilibrium (242). We hypothesized that RNA may shift the 
equilibrium by stabilizing or promoting the dimeric form of the PR, effectively increasing the 
number of active PR molecules in the reaction. Accordingly, tethering the dimer together should 
abrogate the RNA-enhancement phenotype. We generated an HIV-1 PR dimer where the C 
terminus of one monomer is tethered to the N terminus of the second monomer by a flexible five 
amino acid linker. After controlling for the number of active sites present in the proteolysis 
reactions, we generated a dose-response curve for the tethered dimer with p15 RNA as the 
enhancer (Figure 2.12). Compared to the control, no differences were observed between the 
tethered dimer and wild type PRs. RNA accelerated the rate of both reactions by more than 80-
fold, and with similar EC50 values (36 nM for wild type, 35 nM for the tethered dimer). 
Therefore, RNA-dependent enhancement does not result from promoting dimeric interactions 
between HIV-1 PR monomers. 
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Figure 2.12: RNA acts on the dimeric form of the HIV-1 PR to accelerate MA/CA 
processing. Dose response curves were created to compare the ability of RNA to enhance the 
activity of the monomeric HIV-1 PR (circle) and a tethered dimer of the HIV-1 PR (square). 
Reactions were performed with the globular MA/CA substrate under standard conditions except 
that the concentration of the tethered PR dimer was reduced to reflect its pre-existing dimerized 
state. 
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8. The HIV-1 PR-RNA interaction lowers the Km and increases the Vmax of the  
proteolysis reaction. 
 In order to determine the effect of RNA on the enzymatic parameters of the PR, we used 
the fluorogenic peptide substrate to generate Michaelis-Menten plots and determined the effect 
of RNA on Km and Vmax. In the presence of RNA, Km decreased by almost 4-fold, while Vmax 
increased by 3-fold (Figure 2.13 and Table 2.4). The lower Km indicates that RNA increases the 
affinity of the HIV-1 PR for its substrates, while the higher Vmax demonstrates that RNA also 
increases the rate of the catalysis step. Using Vmax as a surrogate for kcat we calculated the 
relative specificity constant (kcat/Km) for the enzyme with and without RNA present finding that 
RNA increases the relative kcat/Km for the peptide reaction by an order of magnitude (Table 2.4). 
Thus the HIV-1 PR is 10-fold more efficient at cleaving the peptide substrate when interacting 
with RNA. 
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Figure 2.13: Both the affinity of the HIV-1 PR for a peptide substrate and reaction 
turnover number increase in the presence of RNA. Peptide proteolysis reactions were 
prepared where the concentration of peptide was varied from 3 to 40 µM. Reaction progress 
curves were generated for each reaction. The initial velocity of each reaction was determined 
from the reaction progress curves and plotted as a function of peptide concentration in the 
absence (square) or presence (circle) of 400 nM long heteropolymeric RNA. At higher peptide 
concentrations, substrate began outcompeting the HIV-1 PR for binding to the RNA, resulting in 
reduced initial velocity values. These data points (27 µM and above) were excluded from the 
plus-RNA curve in the calculation of Km and Vmax. Each point on the curve was calculated 
twice, with each calculation the result of reactions run in triplicate (i.e. six total reactions per 
point). Error bars represent the difference in the pair of calculated initial velocity measurements. 
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Table 2.4: Enzymatic parameters of the HIV-1 PR for processing of a peptide substrate. 
 Km (µM) Vmax (RLU/min) Relative kcat/Km 
Without RNA 13.6 282,000 1x 
With RNA 3.6 784,000 10.5x 
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There were two other notable features of the plots. First, once the peptide substrate 
concentration reached 25 µM, the initial velocity of the reactions containing RNA began to 
decline, eventually converging with the minus-RNA curve. The peptide concentration where this 
reduction began changed depending upon the amount of RNA present in the reaction (data not 
shown), suggesting that the reduction in effect happened because the substrate was outcompeting 
the PR for binding to the RNA at these high concentrations. These data points were excluded for 
the determination of Km and Vmax in the presence of RNA. Second, despite the HIV-1 PR having 
only a single active site, the Hill coefficient was equal to 1.9 for the minus-RNA plot. The hill 
coefficient for the plus-RNA curve was calculated to be 1.9 as well; however, because of the low 
Km, the rapid loss of steady-state conditions at low starting peptide concentrations, and 
background levels of fluorescence, we did not have enough data points below the Km to show this 
with confidence. We did attempt to gather more data by lowering the PR concentration, and in 
those experiments still found a value for the Hill coefficient to be greater than one (data not 
shown), suggesting the Hill coefficient is greater than one irrespective of whether RNA is 
present. We cannot explain this result, though sigmoidal Michaelis-Menten curves can be 
observed in the absence of cooperativity (243). 
 
C.  Discussion 
Converting a nascent HIV-1 particle into a mature infectious virion requires the viral PR 
to cleave the Gag and Gag-Pro-Pol polyproteins in a precise order (43-45). Given the complexity 
of this process, numerous regulatory mechanisms exist to direct the PR towards specific 
processing sites at various phases of maturation. These determinants of cleavage include 
processing site amino acid sequence (47-49), the local structural context (50, 228-230), and 
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cofactors such as RNA or DNA (134, 220, 221, 229). An effect of RNA or other nucleic acids on 
processing rate has previously been reported only for cleavage sites nearby NC (134, 220, 221, 
229), yet we found RNA accelerated the cleavage of substrates completely independent from 
NC. Moreover, accelerated processing of the MA/CA-AAA and peptide substrates indicated a 
substrate-RNA interaction was not required. We hypothesized that an enzyme-RNA interaction 
could enhance PR activity, and found the HIV-1 PR capable of interacting with nucleic acid in a 
gel-shift assay. The HIV-2 PR lacked this ability, and did not cleave its substrate more efficiently 
in the presence of RNA, providing corollary evidence. Interactions between the HIV-1 PR and 
RNA are primarily electrostatic in nature rather than sequence specific, though some additional 
prerequisites for the polyanion may exist. Mechanistically, RNA both increases the affinity of 
the HIV-1 PR for its substrates, and accelerates reaction turnover. 
 Proteolysis reactions that included RNA progressed more rapidly than those without 
RNA for every substrate tested for cleavage by an HIV-1 PR. This finding is in contrast with the 
original report, which found the rate of only p15NC processing changed in the presence of RNA 
(220). Experimental differences could have contributed to overlooking RNA as a general 
enhancer. In the previous work, most of the assays were limited to the single substrate p15NC, 
and RNA needed to be removed from the reactions rather than added as a supplement. This 
carries the inherent risk that some RNA may have remained in the RNA-free reactions. Very low 
concentrations of long heteropolymeric RNA were sufficient to achieve enhancement (Figure 
2.8), so RNA removal would have needed to be exhaustive. Our two-substrate procedure 
improved upon these limitations by ensuring the reaction conditions were exactly the same for 
both p15NC and MA/CA substrates, and by precisely controlling the amount of RNA added to 
the reaction. We also suspect differences in substrates may have impacted the previous results. 
 
 
87 
Though our MA/CA contained the whole of CA, an unusual truncation of CA within the N-
terminal domain (at amino acid 78) was employed previously. This truncation may have 
contributed by altering the fold of the MA/CA protein in such a way that it affected its ability to 
serve as a substrate. Thus, our results are consistent with most of the experiments that identified 
RNA as an effector of p15NC processing. However, our interpretation of these results is very 
different in that we find the enhancing effect to require an interaction between RNA and the PR 
rather than RNA and the substrate. 
 A more recent publication found the rate of SP1/NC processing increased in the presence 
of a single-stranded DNA molecule (229). The authors attributed this result to an increased 
accessibility of the SP1/NC processing site after NC bound the target nucleic acid molecule. 
Importantly, enhanced SP1/NC processing occurred in the absence of accelerated MA/CA or 
CA/SP1 cleavage. Such a result would argue in favor of RNA selectively enhancing cleavage of 
the sites nearby NC. There are several significant differences between this study and ours. In 
order to prevent aggregation of their substrate, the reactions were performed under high salt 
conditions (300 mM NaCl). We (Figure 2.11) and others (233) have demonstrated that nucleic 
acid-dependent enhancement of PR activity is tempered by increasing the ionic strength of the 
reaction. Also, they used a much higher substrate concentration and a different form of substrate, 
which could also affect cleavage site accessibility. Finally, though we did not directly examine 
the possibility of site-to-site variability in effect, we note that a modest difference in the 
magnitude of RNA-dependent enhancement was observed for p15NC and MA/CA in the two-
substrate assay. While we have shown a robust effect of RNA on HIV-1 PR activity, it is clear 
that understanding, and untangling, the effect of RNA on PR and on substrate requires further 
exploration. 
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The ability of the HIV-1 PR to bind nucleic acid and have this interaction regulate its 
catalytic efficiency is not without precedent. Three other viral proteases have been identified that 
use RNA or DNA as a regulator. The human adenovirus proteinase (AVP) exhibits extremely 
poor functionality on its own, requiring an 11-amino acid peptide and a non-specific interaction 
with DNA or other polyanions to achieve its maximal activity (244-246). Prototype foamy virus 
(PFV) PR utilizes a specific sequence in the PFV genome to facilitate its dimerization and 
activation (247). In addition, the hepatitis C virus nonstructural 3 protein contains a serine 
protease domain (NS3Pro) that can directly bind nucleic acid (248, 249). In contrast to the AVP, 
PFV PR, and HIV-1 PR, this interaction negatively regulates NS3Pro activity (249). Thus, 
enzymes from very different virus families have been identified that can use nucleic acid as an 
interacting partner. 
In addition to our own work, an interaction between HIV-1 PR and RNA has been 
suggested by one other study (233), though this report used extremely low ionic strength and low 
pH conditions. These conditions may have promoted artificial interactions, since they found both 
polyanions and polycations to be capable of accelerating HIV-1 PR activity; in contrast, we 
found polycations to be ineffective (data not shown). One additional difference in our results 
concerns poly(rA), which was reported to enhance PR activity, but we also found ineffective as 
poly(dA). A possible explanation could be that poly(dA) (250) and poly(rA) (251, 252) exist in 
different structural states at acidic versus neutral pH. Regardless, we demonstrate a functional 
interaction between the HIV-1 PR and heteropolymeric RNA can occur in environments with 
ionic strength and pH conditions likely to be encountered in vivo.  
Whether a productive interaction between the HIV-1 PR and RNA actually occurs in vivo 
remains unknown, however. While acknowledging that in vitro experiments cannot recreate the 
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complex environment within an actual virus particle, in our assays with p15NC the NC-to-PR 
dimer ratio was 130:1 and the NC-to-nucleotide ratio was 1:8; the latter ratio is noteworthy 
because the footprint of NC is one molecule per eight nucleotides (253, 254). Thus, in the 
presence of enough NC to entirely coat the available RNA, and in substrate-to-enzyme 
conditions that exceed the ratio of NC-to-PR dimer in virus particles (between 20:1 and 40:1), 
RNA-dependent enhancement was observed. These results would support the possibility that the 
interaction can occur in vivo. On the other hand, the enhancement effect was reduced when the 
reaction pH was raised from 6.5 to 7.2 (Figure 2.11b), implying the effect might be much more 
limited than what we observed in our reactions. Despite this potential reduced significance, an 
important role for the interaction cannot yet be ruled out because the pH at the site of virion 
biogenesis remains undetermined. Of note, the pH optimum for globular substrates appears to be 
slightly below neutral (50). Altogether, the currently available information is insufficient for 
determining whether the interaction between the HIV-1 PR and RNA has a biological role. 
The HIV-2 PR was the sole enzyme examined that failed to process its substrate more 
efficiently in the presence of RNA, and failed to interact with nucleic acid in the gel-shift assay. 
The HIV-1 and HIV-2 PRs have very similar structures (255-257), so the lack of interaction is 
probably not structural. The more likely explanation is that the negative charge of the HIV-2 PR 
(pI = 5.3) prevents electrostatic interactions with RNA. Visualizing the electrostatic potential of 
the HIV-1 PR and the HIV-2 PR reveals that the HIV-2 PR has fewer positively charged regions 
on its surface, especially in the flap regions, which would minimize potential interaction sites for 
polyanions such as RNA (Figure 2.14). Though the HIV-2 PR was the exception among the 
enzymes we examined, it is not the only retroviral PR with a low isoelectric point. Comparing 
the isoelectric points of 31 primate lentiviruses, a majority of the HIV and SIV strains resembled 
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the HIV-1 Group M PRs, but almost half had neutral or acidic PRs (data not shown). 
Orthoretrovirus PRs in general also demonstrate variability in charge, though our limited 
comparison does not rule out the potential for conservation within specific genera (data not 
shown). Regardless, the absence of charge conservation among primate lentiviruses implies a 
functional interaction in vivo is not required in all settings, and adds further weight to the 
argument against a biological role for the interaction between the HIV-1 PR and RNA. That the 
HIV-1 and HIV-2 PRs have similar catalytic properties with peptides in the absence of RNA 
(215, 258, 259) also supports this interpretation. Nonetheless, this information is still insufficient 
for determining whether an interaction between the HIV-1 PR and RNA actually occurs in vivo, 
as RNA could regulate Gag processing in different ways for different retroviruses.  
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Figure 2.14: Electrostatic potential of the HIV-1 and HIV-2 PRs. Positively charged regions 
on the surface of the HIV-1 PR (left, PDB: 1T3R) and HIV-2 PR (right, PDB: 3EBZ) are shown 
in blue; negatively charged regions are shown in red. Both structures were generated in the 
presence of darunavir. The flap region of the HIV-1 PR appears to have a basic profile, while the 
flaps of the HIV-2 PR are of a mixed composition. Highlighted are three amino acid positions 
(41, 43, and 55) involved in binding interactions with putative non-active site inhibitors of the 
HIV-1 PR, which carry a positive charge in the HIV-1 PR but not the HIV-2 PR. 
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All long, heteropolymeric RNAs were equally effective as enhancers, suggesting all the 
RNAs contained a critical sequence and/or structure, or that neither were required. Because no 
small molecule was equally potent to the long RNAs, yet some could still enhance PR activity, a 
sequence requirement is unlikely. Most of the short DNA molecules that improved PR function 
were G-rich, suggesting a G-quadruplex structure could have been necessary. However, the 
successful enhancement of proteolysis by poly(dC), poly(dT), and heparin makes it unlikely a 
specific structure is required. Poly(dC) and poly(dT) also accelerated processing to an equivalent 
extent as poly(dG), implying no nucleotide was preferred either. This leaves electrostatic 
interactions as the primary means of interaction between enzyme and nucleic acid.  
Though an electrostatic attraction appears to be the key requirement, additional 
determinants also exist that modulate the effectiveness of the interaction. Since the magnitude of 
enhancement plateaued at lower levels despite higher concentrations of smaller polyanions, 
simply saturating the binding sites on the HIV-1 PR is not sufficient for achieving a maximum 
magnitude of the effect. Consequently, the size or length of the polyanion must also be 
important. Poly(dA) and yeast tRNA point to one other additional requirement, as they were 
exceptions to this conclusion. Both of these nucleic acids are more rigid than other transcripts: 
tRNA due to base pairing and base modifications (260), and poly(dA) due to strong base-
stacking interactions (261, 262). This suggests that the polyanion must have flexibility to serve 
as an efficient cofactor, in addition to being of sufficient length.  
RNA enhances the catalytic activity of PFV PR by promoting its dimerization (247), so 
we considered this possibility for the mechanism of HIV-1 PR enhancement. Since, the 
concentration of HIV-1 PR was 100 nM in our reactions, which is well above the Kd of 6.8 nM 
determined for similar conditions of pH, ionic strength, and temperature (242), and the estimated 
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half-life of an HIV-1 PR dimer is approximately 30 minutes (242), most of the PR was dimeric 
throughout the assay regardless of the availability of RNA. Therefore, acceleration by RNA was 
likely occurring with already intact PR dimers. The tethered dimer, which does not dissociate 
like the wild-type PR (263), confirms this conclusion because we saw a nearly identical effect of 
RNA on tethered dimer activity. Additionally, for a particle with a diameter of 120 nm and 120-
240 Gag-Pro-Pol molecules, the concentration of the monomeric PR is 220-440 µM, well above 
the dissociation constant of the PR even while embedded in Gag-Pro-Pol (~680 nM) (36). The 
monomer-dimer equilibrium should therefore heavily favor the dimeric species in virus particles. 
Although we have not examined an independent effect on dimerization of the PR, the ability of 
RNA to enhance PR activity appears unlikely to be the related to dimerization. 
RNA increased both the affinity of the HIV-1 PR for a peptide substrate (Km) and its 
molecular activity (kcat), collectively increasing the catalytic efficiency of the HIV-1 PR by an 
order of magnitude for the peptide reaction. Considering RNA affected peptide proteolysis less 
than cleavage of the globular MA/CA protein, the change in the specificity constant for reactions 
with the globular substrates would likely be even more substantial. These data do not, however, 
illuminate the precise mechanistic explanation for RNA-dependent enhancement. As there is a 
direct interaction, and it does not interfere with substrate binding, RNA more likely interacts 
with a secondary binding site(s) on the PR. The consistent inferiority in effectiveness of short 
nucleic acids compared to long heteropolymeric RNA regardless of concentration additionally 
implies that the polyanion must affect the PR in some way beyond simply saturating the binding 
site(s) on the PR. Putative allosteric sites have been identified within the flap/hinge region of the 
PR by means of small molecules (264-266) and existing PR inhibitors (257, 267). As the flaps 
seem to have key roles in both substrate binding and catalysis (268, 269), it is possible to 
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speculate that RNA interacts with the PR flaps to facilitate the many conformational 
rearrangements this highly dynamic region must undergo (270-273). Of note, the flap regions of 
the HIV-1 PR (residues 37-61) contain a trio of basic amino acids (R/K41, K43 (264), and K55 
(264, 267)) that are uncharged in the HIV-2 PR (Figure 2.14), and these same residues were 
identified as a key part of at least some binding interactions.  
In summary, we have found that the HIV-1 PR interacts directly with nucleic acid, and 
this interaction drives the accelerated rate of processing observed for p15NC and other 
substrates. No specific RNA sequence or structure is necessary for it to serve as an enhancer, but 
larger and more flexible polyanions are more effective. Though the exact mechanism by which 
RNA improves the catalytic efficiency of the HIV-1 PR remains undetermined, the net effect on 
the enzyme is both an increase in substrate-binding affinity and an increase in turnover rate. 
These data suggest an allosteric binding site may exist on the HIV-1 PR, and argue in favor of 
viral genomic RNA being an additional regulator of HIV-1 PR activity during virion maturation. 
 
D. Materials and Methods 
1. Constructs 
 The MA/CA and p15NC regions were amplified by PCR from the pBARK plasmid, 
which contains the entirety of the gag and pro genes from NL4-3. Primers were designed to add 
a 6xHis tag to the N terminus of each protein, a termination codon at the C terminus, and 
flanking NdeI sites. Following digestion with NdeI, the PCR products were cloned into pET-30b 
(Novagen) to create pET-p15 and pET-MA/CAxTC. The pET-MA/CAxTC plasmid underwent 
an additional round of mutagenesis to introduce a tetracysteine motif (CCPGCC) in the 
Cyclophilin A binding loop (His87-Ala92) of CA and create pET-MA/CA. Two additional 
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plasmids coding for the alternative MA/CA substrates, MA/CA-AAA and HIV-2 MA/CA, are 
derived from pET-MA/CA. For pET-MA/CAaaa, the nucleic acid sequence was altered to 
change MA amino acids K26KQYK30 to A26AQYA30. In the pET-MA/CA-HIV2 construct, the 
coding sequence for the cleavage site was altered from SQNY/PIVQ to the canonical HIV-2 
MA/CA sequence of GGNY/PVQQ. The pET-GMCΔ construct was created as previously 
described (50). The PR region was also amplified out of pBARK and cloned into pET-30b, but 
without the addition of the 6x-His tag and termination codon, creating pET-PR. 
 
2. Nucleic Acids 
 All long heteropolymeric RNAs were generated by in vitro transcription. The pET-
MA/CA, pET-p15NC, and pET-PR plasmids were linearized with EcoRV, and purified with the 
Qiagen PCR purification kit. The MEGAscript T7 high yield transcription kit (Ambion) was 
utilized to generate RNA from the linearized DNA according to manufacturer’s instructions. 
RNA was purified from the reactions with the Qiagen RNeasy kit and stored short-term in 
nuclease-free water at -20ºC. All short single-stranded DNA molecules were ordered from 
Sigma-Aldrich, and resuspended in nuclease-free water. Nucleic acid concentrations were 
determined with a NanoDrop spectrophotometer (Thermo Scientific).  
 
3. Expression and Purification of Globular HIV-1 PR Substrates 
 Escherichia coli BL21 DE3 lysogens (Novagen) were transformed with plasmids coding 
for the p15NC, MA/CA, MA/CA-AAA, HIV-2 MA/CA, or GMCΔ proteins. Starter cultures 
were grown overnight in 2xYT media, and then used to inoculate MagicMedia (Invitrogen) for 
protein production. Expression cultures were grown for 8 hours at 37ºC and 225 rpm, before 
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pelleting by centrifugation and freezing overnight at -80ºC. Pellets were resuspended in lysis 
buffer (TBS pH 7.5, 1% Triton X-100, 2 mM beta-mercaptoethanol) and lysed by sonication. 
Cellular debris was collected by centrifugation, and the resulting supernatant was applied to Ni-
NTA Superflow columns (Qiagen) for purification of the His-tagged proteins by affinity 
chromatography. Purified proteins were concentrated using Vivaspin Concentrators (GE 
Healthcare), and underwent buffer exchange into storage buffer (20 mM sodium acetate, 140 
mM sodium chloride, 2 mM beta-mercaptoethanol, 10% glycerol, pH 6.5). Sample pH was 
confirmed using a micro-pH electrode (Thermo Scientific). Purified protein samples were tested 
for residual nucleic acid with a NanoDrop spectrophotometer (Thermo Scientific), and the levels 
were found to be negligible.   
 
4. HIV-1 Proteases 
 Purified HIV-1 proteases were produced as described previously (50, 274).  
Oligonucleotides for the heavily mutated variants were designed and purchased. Briefly, HIV-1 
protease variants were expressed from a pXC35 Escherichia coli plasmid vector. The cell pellets 
were lysed and the protease was retrieved from inclusion bodies with 100% glacial acetic acid. 
The protease was separated from higher molecular weight proteins by size-exclusion 
chromatography on a Sephadex G-75 column. The purified protein was refolded by rapid 
dilution into a 10-fold volume of 0.05 M sodium acetate buffer at pH 5.5, containing 10% 
glycerol, 5% ethylene glycol, and 5 mM dithiothreitol (refolding buffer). The tethered dimer 
gene construct coded for two copies of the HIV-1 monomer linked by the nucleotide sequence 
that codes for Gly-Gly-Ser-Ser-Gly with unique nucleotide sequences for each monomer (275, 
276). The HIV-2 PR (258) was a generous gift from Dr. John M. Louis (NIH). The theoretical 
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isoelectric points of the viral proteases were calculated using the online ExPASy pI/MW tool. 
 
5. Two-substrate Proteolysis Reactions 
 Two-substrate proteolysis reactions were run in proteolysis buffer (50 mM sodium 
acetate, 50 mM NaMES, 100 mM Tris, 2 mM beta-mercaptoethanol, pH 6.5). Reactions were 
150 µl in volume and pre-incubated at 30ºC for 1 hour before addition of the enzyme. The pre-
incubation step was included for consistency, although the its primary role was to allow fluor 
binding in reactions that included the Lumio Green Reagent (Invitrogen). In the MA/CA and 
GMCΔ reactions, both substrates began the reaction at concentrations of 2.5 µM. In the MA/CA 
and p15NC reactions, the initial concentration of MA/CA was 2.5 µM, while the concentration 
of p15NC was raised to 10 µM due to its poor staining profile in the subsequent analysis. The 
HIV-1 PR was used at a concentration of 150 nM in the two-substrate assays. RNA was also 150 
nM when present. Reaction pH was confirmed as 6.5 using a micro-pH electrode (Thermo 
Scientific) after the final time point had been collected, and was unaffected by the presence of 
RNA. To collect time points, 12 µl aliquots were removed from the reactions at the indicated 
times and added directly to SDS to quench the reaction. The zero minute time point was removed 
immediately prior to the addition of enzyme. Where applicable, RNA was pre-mixed into the 
reaction 5 minutes prior to the removal of the zero minute time point. The quenched aliquots 
were loaded directly into a precast 16% Tris-Glycine gel (Invitrogen), and the substrates and 
products were then separated by SDS-PAGE at 100V for 2.5 hours before staining with 
SimplyBlue Safestain (Invitrogen). Band intensities were quantified with molecular imaging 
software (Carestream), and results were reported as the percent substrate remaining. 
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6. Single-substrate Proteolysis Reactions 
 All presented single-substrate proteolysis reactions with globular proteins were run in the 
proteolysis buffer. For the indicated reactions, the ionic strength was raised to 0.2 M and 0.5 M 
by the addition of sodium chloride to a final concentration of 50 mM and 350 mM, respectively. 
Select reactions for data not shown were performed in intracellular buffer (76.6 mM 
monopotassium phosphate, 60 mM potassium hydroxide, 12 mM sodium bicarbonate, 2.4 mM 
potassium chloride, 0.8 mM magnesium chloride, pH 7.2). Reaction pH was confirmed after 
collection of the final time point by a micropH electrode (Thermo Scientific). The final 
concentrations of MA/CA, MA/CA-AAA, and HIV-2 MA/CA were 2 µM. Reaction mixtures 
additionally included the Lumio Green Reagent (Invitrogen) to a final concentration of 2.5 µM, 
and were pre-incubated at 30ºC for one hour prior to initiating proteolysis. The concentration of 
RNA, where not directly stated, was 150 nM. Heparin and spermine were acquired from Sigma. 
The HIV-1 and HIV-2 PRs were used at a concentration of 100 nM in the single-substrate 
assays. The tethered dimer of the HIV-1 PR was used at a concentration of 45 nM, an amount 
with activity equivalent to the monomeric PR in the absence of RNA. The concentrations of the 
remaining enzymes were adjusted so that approximately 10% of MA/CA was processed in the 
absence of RNA after ten minutes. Most of the other enzymes were used at concentrations 
similar to the HIV-1 PR (75-400 nM); VEG23 and VSL23 required concentrations of 2 µM, 
however. Time points were collected, quenched, and electrophoresed as for the two-substrate 
assays. The fluorescently labeled proteins were imaged with a Typhoon 9000 (GE 
Healthcare/Amersham Biosciences), and quantified by ImageQuant TL (GE Healthcare) 
software. Results were reported as the percent product formed. The initial rate of the reaction 
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was determined using only the data points collected where the reaction was ≤10% complete, or 
was estimated based on the first non-zero data point collected. 
 
7. Peptide Proteolysis Reactions 
 Peptide proteolysis reactions were run in the peptide buffer (100 mM sodium chloride, 30 
mM sodium acetate, pH 4.8). The peptide utilized was HIV Protease Substrate 1 (Sigma), a 12-
amino acid long peptide containing the canonical HIV-1 MA/CA cleavage site. Substrate master 
mixes and the PR master mix were aliquoted into separate wells of a 96-well half-area plate 
(Costar) and pre-incubated in the 30ºC reaction chamber for five minutes, during which time the 
background level of fluorescence was determined. A multi-channel pipet was used to 
simultaneously mix the HIV-1 PR into the substrate mixtures to a final concentration of 100 nM. 
Reactions were followed in real-time on an Envision MultiLabel Reader (PerkinElmer) for 10 
minutes with time points collected every 20 seconds. When included in the reaction, the 
concentration of RNA was 400 nM. Reaction rates were calculated using the data points from 
only the first 10% of cleavage for each substrate concentration. To determine when 10% 
cleavage had occurred for each reaction, a standard curve was generated from 50 µM reactions 
that had been run to completion and diluted to various concentrations. The values were linear 
from background to the upper limit of detection, a range of 0.25 µM to 7 µM. All values 
necessary to follow the first 10% of each reaction fell within this range (0.3 µM – 4 µM). 
 
8. Electrophoretic Mobility Shift Assays and Native DNA gels 
 Binding reactions were 10 µl in size and contained 100 ng of ODN17 (final concentration 
of ~2 µM). Protein was added to a set of reactions incrementally such that their concentration 
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increased from 0 µM to 12 µM. Where the mixture of nucleic acid and protein was insufficient to 
reach full volume, storage buffer was used. The pH of the binding reactions was confirmed to be 
6.5 by a micropH electrode. After five minutes at room temperature, 1 µl of High-Density TBE 
Sample Buffer (Novex) was added. Samples were then loaded into a precast 6% DNA 
retardation gel (Invitrogen), and electrophoresed at 100V for 35 minutes. Gels were stained with 
SYBR gold (Invitrogen) according to manufacturer’s instructions, and viewed with molecular 
imaging software (Carestream). After three five-minute washes with deionized water, the gels 
were stained for protein with Sypro Ruby (Invitrogen), also according to manufacturer’s 
instructions. Results were reported as percent band intensity. 
Native DNA gels were prepared similarly to the gel-shift assays, but nuclease free water 
was used in place of storage buffer. Additionally, no protein was present in any sample, and gels 
were only stained with SYBR gold. Where applicable, aliquots of the stock solutions were heated 
to 90ºC for 10 minutes, then cooled rapidly by centrifugation prior to dilution. Diluting the 
samples before heating results in a lower retention of the higher molecular weight species.
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CHAPTER III 
 
DISSECTING THE SEQUENCE DIVERSITY OF HIV-1 PROTEASE PROCESSING SITES 
 
 
A. Introduction 
 The production of infectious HIV-1 particles requires the virally-encoded PR to cleave 
the structural polyproteins Gag and Gag-Pro-Pol within a nascent virion. These polyproteins 
have the same first four N-terminal domains, MA, CA, SP1, and NC, but differ in their 
remainder. Whereas Gag, which makes up 90-95% of the structural proteins in an immature 
HIV-1 particle (7), includes a 16-amino acid SP2 region and the late domain p6, Gag-Pro-Pol 
contains a TF region, and the individual domains of the PR, RT, and IN enzymes. Complete 
cleavage of the structural proteins by itself does not guarantee the virus particle will be 
infectious. The order and dynamics with which the PR cleaves Gag and Gag-Pro-Pol also 
strongly affect the ability of a virus particle to infect a new cell (44, 161, 277, 278). 
Given the importance of HIV-1 PR activity in the formation of mature virus particles, it 
serves as an exceptionally important target for antiretroviral drugs (52, 53, 65, 70, 71). Though a 
series of very potent PIs are currently in use, the error-prone polymerase activity of HIV-1 RT 
means drug-resistance is an ever-present danger (279). Thorough understanding of the specificity 
of the HIV-1 PR would aid in the development of increasingly potent PIs to help combat this 
problem. However, despite substantial effort, the determinants of HIV-1 PR specificity remain 
obscure. The principal deterrent is the absence of a consensus amino acid sequence for the HIV-1
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PR. Instead, the PR recognizes a conserved molecular shape called the substrate envelope (48, 
49). An extremely diverse set of sequences is capable of occupying this conformation (280), 
providing the major obstacle to delineating enzyme specificity. Beyond sequence recognition, 
additional factors also complicate understanding. Contextual determinants alter the order of 
processing from what it may be if it were based on sequence alone (50, 229, 230), and whether a 
putative interaction between the HIV-1 PR and nucleic acid affects specificity also remains 
unknown (219). 
Aside from a handful of studies employing globular proteins (35, 46, 47, 50, 230) and a 
few others that attempted molecular modeling (281, 282), the studies investigating HIV-1 PR 
specificity have followed one of two approaches. In the first approach, the kinetic efficiencies of 
reactions with short, 6-12 amino acid-long peptides derived from retroviral cleavage sites are 
determined (215, 283-298). These efficiencies are compared in the attempt to identify the ideal 
amino acid within any given subsite. Aside from the relative ease of their synthesis, peptides 
have the advantage of removing most contextual determinants, theoretically making the rate of 
processing a direct reflection of the enzyme’s preferences. However, a few factors confound 
interpretation of these results: pH and ionic strength conditions vary across studies, none of 
which recapitulate physiological conditions, and the inherent bias resulting from the use of a 
limited number of template sequences (often only one) potentially restricts generalizability. 
The second approach utilizes bioinformatics. The common practice is to partition a 
dataset of amino acid sequences into two groups: sequences successfully cleaved by the HIV-1 
PR, and sequences that are not cleaved. Following separation, a variety of statistical and machine 
learning algorithms are used to build a set of rules with the intention of predicting the category to 
which any given amino acid sequence belongs (299-313). While several of these approaches 
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have been fairly successful in their task (reviewed in: (309)), simply categorizing sites on the 
basis of cleavability does not necessarily mean the models can discern between well- and poorly-
cleaved substrates. To our knowledge, no such analysis has been published to date. Furthermore, 
the datasets used to derive the cleavage rules are often compilations of the peptide studies, 
subjecting the bioinformatics analyses to the limitations of those reports as well. A few of the 
latest attempts have addressed at least this issue (299, 305, 310-312) by expanding their datasets 
to include a recently published, proteome-derived peptide dataset (280). Proteolysis assays from 
this study still used low pH conditions, however. 
In this report, we attempted to bridge the gap between these methodologies, while 
simultaneously addressing some of the limitations of the peptide assays. Rather than focus on a 
single template sequence, we mutagenized six of the HIV-1 Gag and Gag-Pro-Pol processing 
sites (MA/CA, CA/SP1, SP1/NC, SP2/p6, TF/PR, and RTH/IN. These sites and their derivatives 
were all housed in the same globular protein background to reduce the impact of varied context. 
We additionally reduced the contextual effects imposed by the globular protein construct through 
the introduction of glycine triplets on each side of the cleavage site. This set-up was engineered 
to judge specificity based as much as possible on processing site amino acid sequence alone, 
while still housing the cleavage site within a globular substrate. Use of a globular protein enabled 
the observation of efficient processing by the HIV-1 PR under near-physiological pH and ionic 
strength conditions (50). The use of an internal control protein as a reference point also allowed 
us to achieve tremendous consistency in our measurements across all of our reactions. The final 
dataset consisted of 81 observations (66 cleaved, 15 non-cleaved). We evaluated the effect of the 
mutations incurred within each site, and also use a series of statistical analyses to identify 
properties shared across all cleavage sites. In addition, we developed 1570 predictive models 
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with statistical model-building software, and then evaluated them on out-of-sample datasets. We 
define a number of potentially important relationships between amino acids in each of the six 
cleavage sites examined, and suggest that predictive models capable of distinguishing between 
fast and slow sites cannot also distinguish between functional and non-functional cleavage sites. 
 
B. Results  
1. A two-substrate system enables the accurate measurement of the relative rates of  
cleavage for HIV-1 processing sites. 
 The HIV-1 PR recognizes a conserved structure rather than a particular amino acid 
sequence (48, 49), enabling the HIV-1 PR to cleave a highly diverse set of amino-acid 
combinations (280). To determine which sequences the HIV-1 PR preferentially cleaves, we 
transferred five other eight-amino acid HIV-1 processing sites derived from the NL4-3 or HXB2 
strains into the linker region between the MA and CA domains of a globular protein construct. A 
length of eight amino acids was chosen since this amount conventionally defines a HIV-1 
cleavage site (18, 48). The protein construct consisted of an N-terminal GST-tag, the full MA 
domain, and the N-terminal domain of CA (GMCΔ) (50, 219). In agreement with previously 
published results, the relative processing rate of the wild-type GMCΔ protein was approximately 
the same as a protein comprised of full MA and CA domains, when measured in a two-substrate 
assay (Figure 3.1, black bars). The relative processing rate for each of the alternative cleavage 
sites revealed which sites the HIV-1 PR preferred. This order was SP1/NC > MA/CA ~ RTH/IN 
~ CA/SP1 > TF/PR ~ SP2/p6. Most sites exhibit a relative rate consistent with those determined 
for when each site is in its natural context (42, 44, 45). However, two of the sites, CA/SP1 and 
SP2/p6, are out of order relative to that seen previously, with their relative positions switched. 
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Figure 3.1: The order and relative rates of processing are mostly unaffected by the addition 
of glycine linkers. Each listed processing site was inserted into the linker region of the GMCΔ 
substrate. The cleavage rate for each substrate was measured relative to a wild-type version of 
the MACA substrate included within the reaction as an internal control (black). Glycine triplets 
were added to all substrates, including the internal control, and the relative rates were re-
determined (gray). All reactions were performed at 30ºC in 50 mM NaMES, 50 mM sodium 
acetate, 100 mM Tris, pH 6.5.  
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We made additional modifications to the GMCΔ substrates to include glycine triplets on 
each side of the processing site. The glycines disrupted any local contextual determinants that 
might be affecting processing, leaving the efficiency of the reaction almost entirely dependent on 
site sequence. All substrates exhibited a decrease in processing rate due to the introduction of the 
glycines, though the magnitude of that effect varied depending upon the cleavage site (data not 
shown). The general decrease in processing rate suggests that for most of the sites the immediate 
context of the MA/CA site does not affect the rate of cleavage, with the glycines likely providing 
more mobility and then requiring a greater decrease in entropy when binding to the PR. Since the 
lack of glycines in the internal control made it a better substrate than nearly all of the processing 
sites, we switched to a new internal control that also included glycine insertions. When all 
samples were compared to this internal control, the new order of cleavage was SP1/NC > 
RTH/IN > MA/CA ~ CA/SP1 > TF/PR ~ SP2/p6 (Figure 3.1, gray bars). The only substrate 
whose position changed in the order determined when the glycines were absent was that of 
RTH/IN, which was now cleaved more efficiently relative to the other sites. The increase in the 
relative rate of cleavage of the RTH/IN indicates that there is a feature of the MA/CA site that is 
inhibitory to the cleavage of the RTH/IN sequence when placed in that context. 
 
2. The relative rates of processing for mutant substrates differed by as much as  
3000-fold. 
The number of substrates was expanded to 81 with the addition of 75 mutant sites. Each 
of the mutants differed from one of the six natural cleavage sites by one or two amino acid 
substitutions (Table 3.1). We chose these substitutions based on the following criteria: 
appearance in published HIV-1 subtype B sequences (http://www.hiv.lanl.gov/), ease of 
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generation (i.e. single nucleotide changes), and/or appearance in other HIV-1 processing sites 
(i.e. partial site exchange). We also had a general interest in choosing mutations that might 
improve processing rate. Eighteen of the 20 amino acids were included in the dataset, the two 
exceptions being tryptophan and cysteine. The introduced substitutions were not distributed 
equally between the P4, P3, P2, P1, P1’, P2’, P3’, and P4’ positions, (Schechter and Berger 
nomenclature (55) – the scissile bond connects amino acids P1 and P1’, the new C- and N-
terminus, respectively; the integers increase in concert with added distance from the scissile 
bond), but all eight sites were represented.  
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Table 1: Cleavage sites and their rates. 
Amino Acid 
Sequence Relative Rate log(Relative Rate) 
SQVL/FLDG 15.630 1.19 
ATIM/FQRG 13.894 1.14 
ATIM/MQRG* 10.447 1.02 
TTIM/MQRG 9.789 0.99 
ATIM/LQRG 7.729 0.89 
AAIM/MQRG 6.817 0.83 
ATIF/MQRG 6.806 0.83 
ATIM/IQRG 6.318 0.80 
RQVL/FIDG 6.009 0.78 
ATVM/MQRG 5.906 0.77 
NTIM/MQRG 4.630 0.67 
RQVL/FLDG 4.383 0.64 
ARVF/LEAM 4.238 0.63 
ARVL/FEAM 3.438 0.54 
ATIL/MQRG 2.694 0.43 
RKVL/FLDG* 2.325 0.37 
ATIM/MQKG 2.166 0.34 
RKVL/YLDG 1.930 0.29 
SFNF/PQFT 1.924 0.28 
SQNF/LIVQ 1.857 0.27 
SQNY/LIVQ 1.696 0.23 
REVL/FLDG 1.281 0.11 
AQVL/AEAM 0.996 0.00 
SQNF/PIVQ 0.987 -0.01 
SQNY/PIVQ* 0.943 -0.03 
SQNY/PIVE 0.926 -0.03 
KKVL/FLDG 0.888 -0.05 
ATVL/AEAM 0.796 -0.10 
RKVL/FLDA 0.796 -0.10 
PGNF/FQSR 0.760 -0.12 
ARVL/AEAM* 0.743 -0.13 
RGVL/FLDG 0.668 -0.18 
RKVL/FLNG 0.535 -0.27 
ATIM/IQKG 0.520 -0.28 
ARIL/AEAM 0.435 -0.36 
SFNF/PQIT 0.430 -0.37 
ATIM/MIRG 0.384 -0.42 
SRNY/PIVQ 0.380 -0.42 
SENY/PIVQ 0.375 -0.43 
SFSF/PQFT 0.347 -0.46 
AKVL/AEAM 0.314 -0.50 
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Table 1: (cont) 
Amino Acid 
Sequence Relative Rate log(Relative Rate) 
RKVL/FLEG 0.310 -0.51 
ATTM/MQRG 0.273 -0.56 
RKVL/FLHG 0.229 -0.64 
SHNY/PIVQ 0.225 -0.65 
SQNF/LQSR 0.219 -0.66 
RKVF/LLDG 0.153 -0.81 
ATIM/MLRG 0.149 -0.83 
PGNF/FQNR 0.140 -0.85 
SQNY/AIVQ 0.112 -0.95 
SGNF/LQSR 0.098 -1.01 
RKVL/FLDR 0.097 -1.01 
PGNF/LQSR* 0.065 -1.19 
SFVF/PQIT 0.058 -1.24 
PGNF/LQNR 0.053 -1.28 
AGNF/LQSR 0.049 -1.31 
SFSF/PQIT* 0.047 -1.33 
RGNF/LQSR 0.029 -1.54 
SLSF/PQIT 0.028 -1.56 
SQSF/PQIT 0.019 -1.72 
SFSF/PQVT 0.019 -1.72 
PANF/LQSR 0.018 -1.74 
PGNF/PQSR 0.016 -1.80 
PGNY/LQSR 0.011 -1.95 
SFGF/PQIT 0.006 -2.24 
SKVF/PQIT 0.005 -2.30 
SFSL/PQIT 0.000 NA 
ARVL/PEAM 0.000 NA 
ARVL/AQAM 0.000 NA 
ARVL/AKAM 0.000 NA 
RKNF/LQSR 0.000 NA 
PQNF/LQSR 0.000 NA 
PRNF/LQSR 0.000 NA 
SKSF/PQIT 0.000 NA 
RKVF/PLDG 0.000 NA 
SQNI/PIVQ 0.000 NA 
ARVI/AEAM 0.000 NA 
ATII/MQRG 0.000 NA 
PGNI/LQSR 0.000 NA 
SFSI/PQIT 0.000 NA 
RKVI/FLDG 0.000 NA 
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Most reactions were 15 minutes in length, approximately the length of time required for 
50% of the internal control to be processed by the HIV-1 PR. If a substrate failed to break the 
limit of detection (2%), it was retested in an extended 2-hour assay. If the reaction failed to 
register above this detection limit in the extended assay, it was labeled as inactive. Of the 75 
mutant cleavage sites, 60 exhibited detectable cleavage by the PR. Rates were calculated using 
only the data points where ≤10% processing had occurred, or were estimated from the first 
collected time-point. The difference between the fastest and slowest site was approximately 
3000-fold (Figure 3.2). In order to improve interpretability, we present the data after log-
transformation. 
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Figure 3.2: The best site was cleaved 3000-times faster than the worst functional site. The 
rate of each cleavage site is reported relative to the MA/CA internal control, after all values have 
been log-transformed. The sites are ordered from high-to-low, and are colored according to the 
natural HIV-1 processing site from which they were derived. Starred bars identify wild-type 
processing sites. The double starred bar marks the alternative TF/PR reference site. Reaction 
conditions were the same as figure 3.1: 30ºC in 50 mM NaMES, 50 mM sodium acetate, 100 
mM Tris, pH 6.5. The x-axis labels were omitted because of a lack of readability. Site sequences 
are alternatively shown in Figure 3.3. 
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3.  The MA/CA cleavage site (SQNY/PIVQ) was relatively tolerant to mutations.  
 The MA/CA site is the natural cleavage site of the GMCΔ construct. Its distinguishing 
feature is a proline in the P1’ position, which takes part in a critical structural interaction 
following cleavage of the site (153-155). Proline is presumably selected at this site because it is 
required for this interaction, and would otherwise be a sub-optimal amino acid (although it is the 
P1' amino acid in other cleavage sites). We wondered if mutating the proline to the other amino 
acids found in the P1’ position of HIV-1 processing sites might improve MA/CA processing. 
There were mixed effects, with the larger of those being negative. A substitution to leucine, a 
slightly larger and more hydrophobic amino acid, increased the rate of processing by 
approximately two-fold (Figure 3.2 top left). Meanwhile, replacing the proline with an alanine 
was highly detrimental. With the exception of one inactive mutant site, this alanine-containing 
site was the worst MA/CA site we examined. Its slowed cleavage by 10-fold. Alanine does seem 
to be a suitable P1’ amino acid – it appears in the CA/SP1 site, which, independent of context, 
was cleaved almost equivalently to MA/CA (Figure 3.1) – suggesting that a proline in the 
MA/CA site actually provides an adequate, if not good, substrate for the HIV-1 PR. However, 
we have yet to test the effect of the larger P1’ amino acids (phenylalanine and methionine) on 
MA/CA processing. 
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Figure 3.3: Few amino acid substitutions improved substrate processing over the natural 
site by more than two-fold. Each wild-type HIV-1 processing site was mutated in one or two 
locations and retested in the two-substrate assay. The cleavage sites are separated as indicated, 
MA/CA (top left), CA/SP1 (top middle), SP1/NC (top right), SP2/p6 (bottom left), TF/PR 
(bottom middle), RTH/IN (bottom right). ND = “not detected”. Starred bars identify wild-type 
processing sites. The double starred bar marks the alternative TF/PR reference site. Reaction 
conditions were the same as figure 3.1: 30ºC in 50 mM NaMES, 50 mM sodium acetate, 100 
mM Tris, pH 6.5. 
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Since charged amino acids occasionally appear in the P3 position (and the primed 
counterpart P3’), we wondered whether a charged amino acid in the P3 position would improve 
processing of the MA/CA site. To examine this, we replaced the wild-type glutamine with 
glutamic acid, arginine, and histidine. Each reduced the rate of cleavage. Both glutamic acid and 
arginine caused an approximately 2.5-fold decrease in rate, while the histidine-containing site 
was further reduced (5-fold loss in relative rate). Since the two-fold change in rate is not much 
different from the variability observed when simply repeating an assay (for the full dataset, the 
average was 1.25-fold, range 0- to 2-fold), it would be hard to argue either the glutamic acid or 
arginine substitution had a significant effect. Thus, our results agree with earlier published data 
(287-289, 314), which argues that the P3 position is relatively tolerant to substitutions.  
 We also examined the effect of a conservative substitution (phenylalanine) for the P1 
tyrosine. No difference in the rate of cleavage was observed either when paired with the wild 
type P1' proline or with a P1' leucine substitution. This argues against an important role for the 
hydroxyl group on the tyrosine. 
 Only one of the tested amino acid substitutions produced an inactive MA/CA cleavage 
site. This change was in the P1 position, but it was a substitution to a beta-branched amino acid, 
a P1 substitution already known to block PR cleavage (29, 46, 47, 286). 
 Altogether, only two of the eight non-inactivating mutations we introduced had a greater 
than 2.5-fold effect on the rate of MA/CA site processing. We conclude from this that, despite 
the presence of a proline within the site, the MA/CA site is relatively tolerant to amino acid 
substitutions.  
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4. The rate of processing of the CA/SP1 site (ARVL/AEAM) is very sensitive to  
substitutions. 
 The CA/SP1 site is very poorly cleaved in its native context (44), but cleaved almost as 
efficiently as the MA/CA site in the GMCΔ substrate (Figure 3.1). This is despite having the 
smallest pair of amino acids occupying the two scissile bond positions (leucine/alanine). We 
asked whether this amino acid pairing was detrimental to the rate of processing by changing the 
L/A sequence to either L/F or F/L to mimic more conventional P1/P1’ couplets (Figure 3.3, top 
middle). In both cases, we found the mutations increased the rate of processing by 5- to 6-fold. 
We also attempted to place a proline in the P1’ position, but this cleavage site sequence was 
inactive. Therefore, the pairing of small amino acids in the P1/P1’ positions is in fact limiting for 
processing. The key amino acid is almost certainly the P1' alanine, since changing that amino 
acid to a phenylalanine was sufficient to increase the rate of cleavage by 5-fold. 
 Since the P3 position of MA/CA tolerated amino acid substitutions, we investigated 
whether this was a feature of additional cleavage sites. Two of the substitutions we made in the 
CA/SP1 P3 position, arginine to glutamine or threonine, had practically no effect. These data 
agree with the conclusion that there is some tolerance for different amino acids in the P3 position 
of this cleavage site as well. However, there was one noteworthy exception. A conservative 
substitution of an arginine to a lysine caused the most significant change among the P3 
substitutions in this cleavage site, more than a 3-fold decrease in processing rate. Based on the 
results of the RTH/IN (see below), we suspect this effect may be specific to the way a P3 lysine 
impacts how the cleavage site interacts with the PR. 
 We tested a total of 10 variant CA/SP1 cleavage sites, four of which were inactive for 
cleavage. One of these was the aforementioned P1’ mutation to proline, and another was a P1 
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substitution to the beta-branched isoleucine. Introduction of a lysine into the P2’ position created 
an inactive site, consistent with the absence of lysine in any of the central four positions (P2, P1, 
P1’, or P2’) and with previous analyses (47, 289, 297, 302, 308, 310, 313). The most unexpected 
result was the change of the glutamic acid in the P2’ position to glutamine; this conservative 
substitution produced a dramatic negative effect even though glutamine occurs in P2' of other 
HIV-1 cleavage sites (SP1/NC, SP2/p6, and TF/PR). This reveals that cleavage of the CA/SP1 
site is highly dependent upon the interaction of the HIV-1 PR with the negative charge of the P2' 
glutamic acid residue. We suggest that it may be critical for the cleavage of the suboptimal 
leucine/alanine P1/P1’ combination. Mutation of P2’ to glutamine in the presence of the better 
leucine/phenylalanine P1/P1’ pairing would provide an important test of this hypothesis. 
 In summary, the CA/SP1 site exhibited a considerable degree of diversity in response to 
amino acid substitutions, including several conservative substitutions. For example, the P3 
position was relatively tolerant to a variety of substitutions, while P2’ was incredibly sensitive to 
even highly conservative changes. The volatility in this position may result from having a 
suboptimal amino acid composition at the P1/P1' site of proteolytic cleavage. Testing the same 
mutations in leucine/alanine and leucine/phenylalanine P1/P1’ sites would be advantageous in 
confirming this conclusion.  
 
5. The wild-type SP1/NC site (ATIM/MQRG) is difficult to improve. 
 The processing site between the SP1 and NC domains is the most efficiently cleaved site 
in either Gag or Gag-Pro-Pol. Despite testing a number of substitutions, we found only a single 
substitution improved the rate of processing (Figure 3.3, top right). However, the increase in rate 
resulting from a change in the P1’ position from a methionine to a phenylalanine was a modest 
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1.3-fold. Combined with the results of the CA/SP1 cleavage site, this modest improvement does 
point to a slight preference of the HIV-1 PR for an aromatic amino acid in the P1’ position. A 
pair of alternative substitutions to the P1’ amino acid, one to leucine and one to isoleucine, were 
both detrimental to processing rate. Still, the effects of these mutations were only modest 
reductions of 1.4- and 1.7-fold, respectively. While the current repertoire of substitutions 
suggests the P1’ position of the SP1/NC site does not have a strong influence over the site’s 
processing rate, we note that all mutations so far examined in this position are reasonably 
similar; each is a large hydrophobic amino acid. Additional tests with the smaller P1’ occupants, 
i.e. proline and alanine, are warranted.  
 The three substitutions that had a significantly negative, though not inactivating, effect on 
cleavage all occurred in either the P2 or the P2’ position. Each caused at least a 25-fold decrease 
in processing rate. Two of these substitutions (P2’ glutamine to isoleucine and to leucine) were 
to fairly dissimilar amino acids. Isoleucine does appear in the P2' position of other cleavage 
sites, so the unsuitability is in some way impacted by other amino acids in the SP1/NC cleavage 
site. One possibility is that, since the P2 position naturally contains an isoleucine, both the P2 
and P2’ sites cannot contain a beta-branched amino acid. Alternatively, since leucine was also 
harmful and is not beta-branched, it may be advantageous to have at least one of these amino 
acid positions be able to form a hydrogen bond with the PR. The third mutation with a negative 
effect on the rate of cleavage (40-fold) was a substitution of threonine for the P2 isoleucine. A 
change of P2 isoleucine to valine resulted in only a modest 2-fold rate reduction, suggesting the 
extremely harmful effect of threonine could be the hydroxyl group in its side chain. If this is true, 
then in conjunction with the P2’ mutations, the results argue that combinations of like-and-like 
in P2 and P2’ of SP1/NC are disfavored. The optimal layout alternatively pairs a hydrophobic 
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amino acid and a polar amino acid. Switching a polar amino acid into P2 in conjunction with a 
hydrophobic amino acid in P2’ will need to be tested to determine the accuracy of this 
conclusion. Lastly, just as for the MA/CA site, the only inactive site was the one in which the P1 
amino acid had been altered to isoleucine.  
 To recap, the SP1/NC site had only a single mutation improve its rate of processing with 
even a modest effect. All others resulted in a modest to severe loss in rate. The most notable 
substitutions were those introduced at the P2 and P2’ positions. These mutations suggested 
dissimilar pairs of amino acids in the P2 and P2’ positions produce the most efficiently processed 
sites. Switching a polar amino acid into the SP1/NC P2 position in conjunction with a 
hydrophobic amino acid in P2’ will need to be tested to determine the accuracy of this 
conclusion. Additionally, interchanging the SP1/NC amino acids into alternative sites will be an 
interesting test of whether the SP1/NC sequence houses optimal amino acids, or whether its 
impressive rate of processing results from the sum effect across the cleavage site. 
  
6. The SP2/p6 site (PGNF/LQSR): selection against optimization? 
 Cleavage at the SP2/p6 processing site must occur prior to the assembly of the CA shell 
around the viral RNP core (137, 161). This means the SP2/p6 site should be processed ahead of 
the CA/SP1 site. However, these two processing sites show the opposite pattern (i.e. CA/SP1 > 
SP2/p6) when cleaved on the basis of sequence alone (Figure 3.1). Thus, there must be 
contextual determinants, including assembly itself, that impact the rates to make CA/SP1 one of 
the slowest sites. The role context must play in generating these rates during assembly can be 
seen by the substitution of leucine to phenylalanine in the P1’ position, which allowed the 
SP2/p6 site to be cleaved 12-fold faster (Figure 3.3, bottom left), more in keeping with the 
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observed relative rates of cleavage of these sites in the Gag protein. This is a very infrequent 
mutation – only 9 of 2254 SP2/p6 cleavage sites from an alignment of Gag/Gag-Pro-Pol 
contained phenylalanine in the P1’ position (data not shown). After leucine, proline was the most 
common P1' amino acid, and that substitution in our data made the SP2/p6 processing site 4-fold 
worse. These results suggest the SP2/p6 site is under selection against optimization. 
 The otherwise most notable feature of the SP2/p6 site is the presence of an unusual P4/P3 
pairing, a proline and glycine respectively. This doublet is one of two cleavage sites to form an 
unusual conformation in which the P4 amino acid actually occupies the position in the HIV-1 PR 
binding site that normally belongs to the P3 amino acid (48). Given the only two other 
occurrences of a proline in a cleavage site are both associated with a critical structural role (153-
155, 228) the presence of this proline may be similarly important. Its extremely high level of 
conservation further supports this conclusion (2247/2254 sequences contained a proline in the P4 
position). Additional evidence that this proline has some other as-yet-unexplained role comes 
from our mutation data, since mutating only the proline did not have a severe effect on 
processing rate. Mutating the proline to an alanine or arginine was not problematic, with the 
worst effect between these two being a 2-fold decrease in cleavage rate. Mutation to a serine 
actually improved the processing rate by 1.5-fold. Changing only the glycine, on the other hand, 
induced a considerably larger effect. While alanine could substitute for glycine, albeit 
ineffectively, both glutamine and arginine exchanges were not tolerated. It is likely that this lack 
of tolerance reflects the incompatibility of the P4 proline with almost any other amino acid in the 
P3 position, since mutation of both the P4 and P3 amino acids to the MA/CA-derived serine-
glutamine doublet was favorable, increasing the rate of cleavage by 3.5-fold. 
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 There were four inactive SP2/p6 sites among the mutant cleavage sites we tested. As with 
all other sites, an isoleucine in the P1 position prevented cleavage. The other inactive sites were 
prefaced above, and resulted from a substitution of the glycine at the P3 position while the 
proline was still present at P4. The final inactive site replaced the P4/P3 sequence with an 
arginine/lysine pair. While this does replace both the proline and glycine, the arginine/lysine 
pairing appears to require a beta-branched in the P2 position (see RTH/IN below). Therefore, the 
defect in the arginine/lysine site is more likely due to the presence of an asparagine in the P2 
position than the loss of the glycine. This, of course, requires additional testing to confirm. 
 In conclusion, the SP2/p6 site appears to be under selection against the optimal amino 
acid sequence, most dramatically at the P1' position. Additionally, the proline in the P4 position 
likely has a critical, as-yet-unexplained purpose in the virus lifecycle given its high level of 
conservation and lack of general importance to SP2/p6 processing rate. The glycine, meanwhile, 
compensates for the presence of the proline to enable processing by the HIV-1 PR. 
 
7. The TF/PR site (SFSF/PQIT): a site with potential. 
 While we have observed the TF/PR as an intermolecular cleavage event, in the virus it is 
actually one of three cleavage events that must occur intramolecularly with an immature enzyme 
at least some of the time (36-39). This cleavage event is essential for releasing HIV-1 PR from 
the Gag-Pro-Pol precursor to achieve full enzymatic activity (35, 36, 40). To avoid premature 
activation of the enzyme, which can interfere with particle production (224, 225), this site might 
be expected to remain under some negative regulation. There is some evidence for this, though 
not necessarily as compelling as the evidence in the SP2/p6 site.  
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Two single amino acid changes allowed a 7- and 9-fold increase in rate (Figure 3.3, 
bottom middle). One of these was an isoleucine to phenylalanine change in the P3’ position. 
Though this substitution did not occur a single time in the alignment (data not shown), its 
absence is almost certainly for a structural reason. The P1’-P4’ amino acids are all part of the 
PR. After processing, these amino acids participate in a beta-sheet with the C-terminal amino 
acids of the PR, and it is the formation of this beta-sheet that gives the HIV-1 PR the 
conformational stability necessary for robust enzyme activity (40). It is possible that a 
phenylalanine in this position is not tolerated because it fails to adequately assemble this beta-
sheet.  
The other substitution to bring about a significant increase in processing rate is the serine 
to asparagine change in the P2 position. While the serine is more frequent in the alignment 
(1232/2254), P2 asparagine also occurs a substantial amount of the time (779/2254). Thus, there 
does not appear to be much of a restriction on this substitution from occurring. Considering the 
embedded HIV-1 PR only occupies the wild-type conformation an estimated 3-5% of the time 
(34), it’s possible the immature PR active site might have a slightly different sequence 
preference than the mature version. Therefore, the 9-fold difference in rate we observe when 
cleaved in trans may not exist when TF/PR is cleaved intramolecularly. Alternatively, this 
sequence does overlap with the p6 domain, which could be where the selective pressure is being 
applied. 
Among the mutated TF/PR sites tested, three resulted in an inactive site – two if we 
exclude the isoleucine substitution in the P1 position. One of these substitutions was a lysine in 
the P3 position, providing yet another example of the damaging effect of this mutation. We do 
note that accompanying the lysine with a valine in the P2 position rescued the site to a very low 
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level of cleavage, pointing toward a requirement for a beta-branched P2 amino acid with a P3 
lysine. However, we note that this site just barely broke the limit of detection in the two-hour 
assay. The remaining site with an undetectable amount of processing altered the P1 amino acid 
from phenylalanine to leucine. This paired a proline in the P1’ position with a leucine in the P1 
position. The only other occurrence of the L/P doublet in our dataset was in the CA/SP1 site, and 
it too was defective.  
 In summary, the strongest conclusion that can be drawn from this data is that a serine in 
the P2 position is not an optimal amino acid in the substrate for the mature HIV-1 PR. The larger 
asparagine provides a more favorable substrate, though whether this remains true for the 
embedded, immature PR is unknown. The effect of this mutation on p6 function must also be 
considered.  
 
8. The RTH/IN site (RKVL/FLDG) has a suboptimal amino acid in the P3 position. 
 The RTH/IN site takes on an unusual conformation when bound to the PR. Like the 
SP2/p6 site, the P4 amino acid occupies the position within the PR that is normally occupied by 
the P3 amino acid (48). For this particular site though, the P4 amino acid is arginine, and the P3 
amino acid is lysine. The presence of a basic amino acid in the P3 position does not necessarily 
cause this unusual conformation, as the CA/SP1 site includes an arginine in the P3 position but 
takes on the conventional processing site layout when bound to the PR. We suspect this effect 
results specifically from an odd, non-optimal interaction between the HIV-1 PR and the P3 
lysine. In support of this concept, all of the mutant RTH/IN sites that were better substrates for 
the PR did not have the lysine in them (Figure 3.3, bottom right). Additionally, the four instances 
in which we placed a lysine into the P3 position all had harmful effects. Two of these 
 
 
123 
(SKSF/PQIT and RKNF/PQSR) were completely inactive; one of them (SKVF/PQIT) was 
barely detectable even after extending the length of the cleavage assay, having been rescued by 
the inclusion of a beta-branched amino acid in the P2 position; and the last was a conservative 
substitution in the CA/SP1 site (arginine to lysine) that still caused a 2.5-fold reduction in 
processing rate. Altogether, these results point toward lysine in the P3 position as a sub-optimal 
amino acid.  
 Continuing to look at sites containing a lysine in the P3 position, there was a definite 
pattern present in order to optimize a site with that amino acid. Prefaced in the last paragraph, 
lysine must be paired with a beta-branched amino acid to avoid inactivity. While it can be paired 
with an aromatic amino acid in the P1, these sites were poorer substrates than when the P1 
amino acid was leucine. For instance, flipping the RTH/IN P1/P1’ amino acids so that a 
phenylalanine is in the P1 position and a leucine is in the P1’ position resulted in a 15-fold 
decrease in processing rate. We conclude that when lysine is in the P3 position, the optimal 
amino acid arrangement in a site has a beta-branched amino acid at the P2 position, and a non-
aromatic residue at P1.  
 The mutated RTH/IN sites had only one inactive site among those tested, aside from the 
P1 isoleucine. This site contained a phenylalanine in the P1 position and a proline at P1’. The 
failure of this site likely results from the conflicting requirements of the proline and lysine. 
Lysine’s preferences have just been documented. Proline prefers large aromatic amino acids in 
the P1 position, and is compromised by a beta-branched amino acid at P2 (288). Therefore, the 
central amino acids and external amino acids require opposite features, which makes the site 
uncleavable. 
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 In summary, the P3 lysine appears to be a problematic. We hypothesize that it is the key 
amino acid in creating the unusual conformation the RTH/IN site takes on in order to be 
recognized by the HIV-1 PR as substrate. For the optimal site including a P3 lysine, a beta-
branched amino acid in P2 may be an absolute requirement, while a non-aromatic amino acid in 
the P1 site is preferred. 
 
9. Mixed-effects modeling enabled the identification of patterns and important 
predictors common to all cleavage sites. 
 While simple substitution allowed us to identify important patterns within individual 
cleavage sites, we sought also to identify patterns that permeated throughout all sites. Because 
each of the original sites was not cleaved at the same rate, the rate for each cleavage site tended 
to group with other sites derived from the same natural HIV-1 processing site (Figure 3.2). In 
order to account for these baseline differences in rate when considering the effect of a mutation, 
we used linear-mixed effects modeling. In this modeling procedure, observations are not 
considered independent, but are grouped categorically by original cleavage site. We confirmed 
that this was an important distinction by comparing the null standard ordinary least squares 
model with the null linear mixed-effects model (different only in the inclusion of the categorical 
separation of observations). A likelihood ratio test to compare the effectiveness of the two 
models at describing the data found the mixed-effects model was significantly better at doing so 
(χ2(1) = 32.95, p < 0.0001).  
Our next step was to define each cleavage site by a specific set of criteria. Eight 
physicochemical properties were chosen (Table 3.2). The first model we developed considered 
each site as a single unit and did not concern itself with where any mutation was made. When all 
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variables were included in this model, the residual distribution did not meet the requirements of 
the normality assumption (Figure 3.4A). This was indicative of a missing term from the model, 
likely that of an interaction. 
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Figure 3.4: Mixed-effects modeling accounts for different baseline conditions to build a 
superior model than ordinary least squares analysis. (A) Quantile-quantile plots for the three 
stages of building a multiple-property mixed-effects model. The residuals for the full model 
without the interaction are plotted in the left panel, those for the full model with the interaction 
term in the central panel, and the final reduced model in the right panel. The solid red line 
represents the theoretical normal distribution of residuals. The dashed red lines define the 95% 
confidence envelope. (B) The theoretical relationship between the net hydrophobicity of a 
cleavage site and relative rate of cleavage when cleavage sites contain different amounts of polar 
accessible surface area. (C) A plot of the relative processing rates predicted by the reduced 
mixed-effects model versus the actual observed values. 
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After examining each possible two-way interaction among terms, one model was found 
to be significantly superior. The interaction included in this model suggested the total 
hydrophobicity of a site had varying effects on reaction rate when different amounts of polar 
surface area were present in the site (Figure 3.4b). In short, sites that were more hydrophobic but 
contained a higher total quantity of polar surface area produced faster sites. However, when sites 
were more hydrophilic, the amount of polar surface area did not matter.  
We desired the model of maximum parsimony, and to obtain that model we performed a 
series of likelihood ratio tests to identify and remove non-significant terms. The final reduced 
model contained only five terms (Table 3.3). Its effectiveness at describing our dataset was not 
significantly different from this original model (χ2(3) = 2.18, p = 0.5358), but was still 
considerably superior to the null model (χ2(5) = 46.41, p < 0.0001). The root mean square error 
(RMSE) was 0.39 logs, meaning this model predicted most of the source data to within 2.5-fold 
of its observed value.  
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Table 3.3: Properties of the reduced full-site model. 
 Coefficient Chi Square (Df) Significance 
Intercept -8.586 ± 2.029 18.01 (4) p = 0.0012 
Net Hydrophobicity 0.671 ± 0.285 7.40 (4) p = 0.1161 
Polar ASA 0.007 ± 0.002 15.00 (4) p = 0.0047 
Polarizability 0.010 ± 0.003 12.53 (4) p = 0.0138 
Net Charge -0.738 ± 0.109 36.05 (4) p < 0.0001 
Hydrophobicity*Polar 
ASA -0.004 ± 0.001 15.79 (4) p = 0.0033 
Coefficients are non-standardized. 
ASA: Accessible Surface Area 
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10.  Individual predictor models identified potential relationships between amino acid  
positions within cleavage sites. 
Though effective, evaluating processing sites as a singular whole fails to identify key 
characteristics of specific positions or interactions between positions. Unfortunately, including 
all of the positional and interaction terms was not feasible. Such models would suffer from both 
over-fitting (where a model describes the noise in the data rather than the key relationships) and 
multicollinearity (where predictor variables are too highly correlated to separate their effects). 
Moreover, the categorical separation of cleavage sites further reduced the effective sample size, 
making the number of variables we could use before falling victim to over-fitting even smaller. 
Thus, to evaluate the prospective importance of variables on a position-by-position basis, we 
considered each of our eight physicochemical properties independently of the others.  
Seven of eight criteria described the data significantly better than the null model, the lone 
exception being amino acid charge. Judging by RMSE, none of the individual models were as 
effective as the model built using all the criteria. Among the individual models, two interaction 
terms were identified. One reflected an interaction between P2 and P4’ in the hydrophobicity 
model (χ2(1) = 7.40, p = 0.0065). Processing sites with slightly hydrophilic P2 amino acids were 
cleaved more efficiently when P4’ was hydrophobic, though a variety of different amino acids 
could be accommodated in P4’ when P2 was hydrophobic (Figure 3.5A). The other interaction 
was between P2 and P2’ in the polarizability model (χ2(1) = 12.2, p = 0.0005). Here, sites 
containing P2 amino acids with lower polarizability faired better when P2’ was slightly higher in 
polarizability (Figure 3.5B). The sensitivity of this interaction to the change in polarizability in 
the P2’ position was impressive. On a scale with a range of 113 atomic units (a.u.), a difference 
of only 5 a.u. in the P2’ site could cause as much as a 100-fold effect. 
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Figure 3.5: The theoretical relationships for the interactions identified within individual 
mixed-effects models. (A) A plot of the relationship between hydrophobicity of the P2 amino 
acid and processing rate when different amino acids occupy the P4’ position. (B) A plot of the 
relationship between the polarizability of the P2 amino acid and processing rate when different 
amino acids are found in the P2’ position. 
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The models were simplified by removing variables that were non-significant in likelihood 
ratio tests, and some patterns stood out in the variables that remained (Table 3.4). Three positions 
were removed from nearly all of the models: P3, P1, and P3’. The P3 and P3’ results are 
consistent with our earlier observations, with the exception of the P3 lysine. The P1 result, on 
the other hand, was not. We suspect P1 was on this list not because of its lack of importance, but 
because only cleavage sites containing four very effective P1 amino acids were included in our 
dataset. The positions on which rate was most dependent, according to these models, were P2, 
P1’, P2’, and P4’. The P4 amino acid was important under only select circumstances, whereas 
these other four positions were present in nearly all models. 
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11. Building models for prediction. 
 
 Mixed-modeling procedures are effective tools for building a descriptive model. 
However, if we desire a model that may be applied to the prediction of out-of-sample cleavage 
sites, the categorical distinction between cleavage sites must be discarded and ordinary least 
squares methodologies applied. This is because all possible cleavage sites (n = 208) cannot be 
grouped into one of the six categories within our dataset. We explored a variety of model 
selection techniques, including best subsets and stepwise regression, ridge, elastic net, and lasso 
regression, and partial least squares regression. (Short descriptions of each are in the methods.) 
We continued to evaluate the processing sites on the basis of the eight criteria used in during the 
mixed-effects modeling procedures. A ninth criterion of total side chain surface area was also 
evaluated. We developed models where all eight amino acids were treated as one unit, and where 
each amino acid was considered individually. For the latter, we built models that included 
measurements from one, two, or three of the nine criteria (i.e. one, two, or three pieces of 
information for each of the eight amino acids). Models were built where interactions were 
excluded, and where they were included. In total, 1570 models were generated. 
Approximately one-fifth (308/1570) had a better RMSE than that of the principal mixed 
effects model, though the first mixed-effects model was considerably more parsimonious (and 
therefore statistically preferred). All 15 of the top models used three criteria to evaluate the sites, 
included interaction terms, and made use of the stepwise selection procedure (Table 3.5). One 
concern for these models was the number of variables. We allowed up to 25 in the selection 
process; 11 of 15 made full use of that allotment, and all 15 of them contained more than 20. 
This points toward the models overfitting the data. The lack of consistency between the variables 
found in the mixed-effects models and the models built for prediction was also suggestive of a 
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problematic fit. The positions deemed unimportant when the different sites were analyzed as part 
of groups (P3 and P3’) were the very same positions that appeared frequently in the prediction 
models. For example, the P3/P3’ interaction term was the most common element within these 
models (Figure 3.6).  
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Table 3.5: Characteristics of the top fifteen models for describing the source data, and for 
predicting out-of-sample rates. 
Rank Criteria INT Procedure RMSE RMSEoos 
1 Hydrophobicity Nonpolar ASA Side Chain Length Y Stepwise 0.10 9.57 
2 Molecular Weight Nonpolar ASA Side Chain Length Y Stepwise 0.12 3.25 
3 Hydrophobicity Molecular Weight Nonpolar ASA Y Stepwise 0.12 2.92 
4 Hydrophobicity Polarizability Nonpolar ASA Y Stepwise 0.12 2.45 
5 Polar ASA Total ASA Side Chain Length Y Stepwise 0.12 11.2 
6 Nonpolar ASA Total ASA Side Chain Length Y Stepwise 0.12 2.61 
7 Hydrophobicity Polar ASA Side Chain Length Y Stepwise 0.12 2.91 
8 Hydrophobicity Nonpolar ASA Polar ASA Y Stepwise 0.12 13.4 
9 Hydrophobicity Molecular Weight Polar ASA Y Stepwise 0.13 9.26 
10 Hydrophobicity Nonpolar ASA Total ASA Y Stepwise 0.13 1.82 
11 Molecular Weight Nonpolar ASA Polar ASA Y Stepwise 0.13 3.18 
12 Nonpolar ASA Side Chain Length van der Waals Volume Y Stepwise 0.13 4.29 
13 Polarizability Polar ASA Total ASA Y Stepwise 0.13 6.28 
14 Polarizability Polar ASA Side Chain Length Y Stepwise 0.13 3.31 
15 Nonpolar ASA Polar ASA Side Chain Length Y Stepwise 0.13 3.73 
1354 Polarizability --- --- N Ridge.o 0.57 0.96 
1367 Polarizability --- --- N Elastic Net.o 0.58 0.96 
1564 Full Site --- --- N OLS 0.94 0.98 
1568 Full Site --- --- N Best Subset 0.96 1.00 
1337 Polarizability --- --- N Lasso.m 0.56 1.00 
1310 Polarizability --- --- N Ridge.m 0.56 1.00 
673 Charge Polarizability van der Waals Volume N Ridge.m 0.47 1.02 
1300 Polarizability --- --- N Elastic Net.m 0.56 1.03 
1496 Polarizability --- --- Y Lasso.o 0.62 1.04 
1338 Polarizability van der Waals Volume --- N Lasso.o 0.56 1.04 
1298 Polarizability --- --- N OLS 0.56 1.06 
1301 Polarizability --- --- N PLSR 0.56 1.07 
1491 Polarizability van der Waals Volume --- Y Lasso.o 0.62 1.07 
890 Polar ASA --- --- Y Ridge.o 0.50 1.07 
1489 Charge van der Waals Volume --- Y Ridge.o 0.62 1.07 
Abbreviations: INT – Interactions; OLS – Ordinary Least Squares; PLSR – Partial Least Squares 
Other notations: __ .m/o reflects whether the lambda used in the penalty term of the methodology listed was the minimum 
lambda (_.m), or the value of lambda that was one standard error away from the minimum (_.o). 
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Figure 3.6: The distribution of variables within the top 15 models developed for prediction. 
All 15 models were the result of step-wise selection to reduce three-property models that 
included two-way interaction terms. An upper limit on the number of variables that could be 
included in each model was supplied, but no guidance on which variables to include was 
supplied. Labels that duplicate the same position imply an interaction between two properties at 
that position.
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12.  No correlation exists with rates determined by peptide analysis at low pH. 
 
We compiled a small dataset from published results that had reported cleavage rates for 
substrates relative to a wild-type MA/CA sample (Table 3.6). We wished to apply our models to 
this dataset to judge their ability to predict processing rates. Within this dataset, 14 observations 
of 10 cleavage sites overlapped with our own. These were removed and directly compared to our 
results (Figure 3.7). The dashed line represents a perfect 1:1 correlation between rates. Only one 
sample falls very near this line (PQNF/LQSR), but that sample was inactive in our assay and 
barely detectable elsewhere (215). Boxed data points are results for the same site (the pair of 
boxed black points differed in context). The Pearson product-moment correlation was trending 
towards significance, but ultimately was not (r = 0.470, CI = -0.081 to 0.801, p = 0.0899), 
implying no relationship exists between our results and the previously published results. This 
suggested our models would not likely be a good predictor of the out-of-sample data. Our results 
confirmed that they were not. Using RMSE as a comparator, all of the best models at describing 
our data were quite terrible at predicting the out-of-sample data. The lowest RMSE among these 
top 15 models was 1.82 logs, which meant the predicted rates were off by 66-fold of the 
published value on average. Three of the predictive models had RMSEs below one (Table 3.5), 
but not by much (lowest RMSE = 0.96). Furthermore, two of the top four models were among 
the worst models at describing the source data. In summary, none of the 1570 models could 
predict of the precise rates for the out-of-sample dataset with a high accuracy. 
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Table 3.6: Out of Sample Rate Data 
Source pH Ionic Sequence log(Rate) 
Tözser 97 5.6 2.25 M SDTY/YIVQ -0.39 
Tözser 97 5.6 2.25 M SQTY/YIDQ -0.43 
Tözser 97 5.6 2.25 M SDAY/YTDS -0.53 
Tözser 97 5.6 2.25 M SDAY/YADS -0.54 
Tözser 97 5.6 2.25 M SDIY/YTDS -0.65 
Tözser 97 5.6 2.25 M SDTY/YLDS -0.68 
Tözser 97 5.6 2.25 M SQNY/YTVQ -0.82 
Tözser 97 5.6 2.25 M SDTY/YADS -0.97 
Tözser 97 5.6 2.25 M SQNY/YNQS -1.07 
Tözser 97 5.6 2.25 M SQNY/PTVQ -1.27 
Tözser 97 5.6 2.25 M SQTY/YTVQ -1.28 
Tözser 97 5.6 2.25 M SQTY/PIVQ -1.43 
Tözser 97 5.6 2.25 M SDTY/YTDS -1.45 
Tözser 97 5.6 2.25 M SFTY/YTDS -1.47 
Tözser 97 5.6 2.25 M SDNY/PIVQ -1.49 
Tözser 97 5.6 2.25 M SQNY/YTDQ -1.66 
Tözser 97 5.6 2.25 M SDLY/YTDS -1.68 
Tözser 97 5.6 2.25 M SDTY/YTFS -1.69 
Tözser 97 5.6 2.25 M SGTY/YTDS -1.69 
Tözser 97 5.6 2.25 M SDTY/YTGS -1.74 
Tözser 97 5.6 2.25 M SDEY/YTDS -1.78 
Tözser 97 5.6 2.25 M SQTY/YTDS -1.82 
Tözser 97 5.6 2.25 M SDTY/YTQS -1.89 
Tözser 97 5.6 2.25 M SQTY/YTDQ -1.89 
Tözser 97 5.6 2.25 M SQTY/YIVQ -1.9 
Tözser 97 5.6 2.25 M SQNY/YIVQ -1.96 
Tözser 97 5.6 2.25 M SQNY/PIDQ -2 
Tözser 97 5.6 2.25 M ATAM/MATA -2.04 
Tözser 97 5.6 2.25 M SDTY/YEDS -2.1 
Tözser 97 5.6 2.25 M SQTY/YTQS -2.22 
Tözser 97 5.6 2.25 M SGTY/YTGS -2.31 
Tözser 97 5.6 2.25 M SDTY/YTLS -2.43 
Tözser 97 5.6 2.25 M SDTY/YTDQ -2.45 
Tözser 97 5.6 2.25 M SDEY/YEDS -2.48 
Tözser 97 5.6 2.25 M SDTY/YGDS -2.96 
Tözser 97 5.6 2.25 M SDGY/YTDS -3.05 
Tözser 97 5.6 2.25 M SLTY/YTDS -3.05 
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Table 3.6: (cont) 
Source pH Ionic Sequence log(Rate) 
Tözser 91A 5.6 2.25 M PQNYPIVQ -0.3 
Tözser 91A 5.6 2.25 M GQNYPIVQ -0.42 
Tözser 91A 5.6 2.25 M NQNYPIVQ -0.75 
Tözser 91A 5.6 2.25 M DQNYPIVQ -0.84 
Tözser 91A 5.6 2.25 M AQNYPIVQ -1.01 
Tözser 91A 5.6 2.25 M RQNYPIVQ -1.33 
Tözser 91A 5.6 2.25 M TQNYPIVQ -1.36 
Tözser 91A 5.6 2.25 M MQNYPIVQ -1.66 
Tözser 91A 5.6 2.25 M KQNYPIVQ -1.7 
Tözser 91B 5.6 2.25 M RKILFLDG 0.65 
Tözser 91B 5.6 2.25 M SLNLPVAK 0.39 
Tözser 91B 5.6 2.25 M RQVLFLEK 0.11 
Tözser 91B 5.6 2.25 M TLNFPISP -0.27 
Tözser 91B 5.6 2.25 M GLAAPQFS -0.49 
Tözser 91B 5.6 2.25 M AETFYVDG -0.66 
Tözser 91B 5.6 2.25 M GGNYPVQH -1.05 
Tözser 91B 5.6 2.25 M ARLMAEAL -1.29 
Tözser 91B 5.6 2.25 M PFAAAQQR -1.61 
Tözser 91B 5.6 2.25 M PRNFPVAQ -1.88 
Bagossi 98 5.6 2.25 M SQLYPIVQ -1.09 
Bagossi 98 5.6 2.25 M LQNYPIVQ -2.29 
Bagossi 05 5.6 2.25 M SQAYPIVQ -0.3 
Bagossi 05 5.6 2.25 M SQVYPIVQ -0.7 
Bagossi 05 5.6 2.25 M SQGYPIVQ -1 
Bagossi 05 5.6 2.25 M SQIYPIVQ -1 
Bagossi 05 5.6 2.25 M SQFYPIVQ -1.52 
Margolin 90 6.0 0.025M SQNYPAVQ -1.43 
Pettit 02 7.0 2.25 M SQNMPIVQ -0.6 
Pettit 02 7.0 2.25 M SQNLPIVQ -1 
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Figure 3.7: No correlation exists between processing rate in the two-substrate assay and 
those reported by prior publications. Rates are reported as relative to the MA/CA cleavage site 
on a linear scale. The dashed line denotes a perfect 1:1 correlation. The boxes group data points 
with identical cleavage sites. Data is referenced from: 214, 229, 284, 294, 295. 
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13. The predictive models were more effective as classifiers of fast and slow sites. 
In lieu of being able to predict precise rate values, we ascertained whether the models 
could simply make a distinction between sites cleaved faster or slower than a reference value. 
Though the ideal choice would have been the rate of cleavage of our internal control protein, 
only 3/66 samples from the out-of-sample data set had rates faster than MA/CA. We did proceed 
with this analysis, in which we generated receiver operating characteristic (ROC) curves and 
calculated the area under the curve (AUC) as a measurement of accuracy. With these guidelines, 
several of our models were able to separate both our own data and the out-of-sample data very 
successfully (Figure 3.8A). Two models scored above 95% with both datasets. However, we felt 
choosing a value that introduced more parity would better evaluate the models. So, a rate of one-
quarter that of MA/CA (-0.6 logs) became the classification point. One dozen models perfectly 
partitioned the source data, and almost 300 models succeeded at a better than 95% success rate 
(Figure 3.8B). Unfortunately, separation of the out-of-sample data was far less effective. Only 24 
models sorted the sites with better than 70% accuracy, a milestone of adequacy, not success. 
There were three models that scored better than 95% on the source data and better than 70% with 
the out-of-sample data. While they did correspond to some of the models with the lowest RMSE 
when evaluating the source data, they were all on the bottom half of the models when predicting 
the out-of-sample data. Thus, even though these models were reasonable classifiers, they were 
still some of the poorer predictors of precise rates. 
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Figure 3.8: Few prediction models can separate out-of-sample data into fast and slow sites 
with good accuracy. ROC curves were generated for each prediction model to distinguish 
between well and poorly cleaved processing sites. The reference point chosen was either (A) the 
rate of MA/CA processing or (B) one-quarter the rate of MA/CA processing. The second 
grouping was chosen to increase the parity in the out-of-sample data. Gray lines denote 95% 
accuracy (x-axis) and (A) 95% or (B) 70% percentile (y-axis). Red points denote the top fifteen 
of the prediction models at describing the source dataset according to the minimization of 
RMSE. 
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14. Models built to predict processing rates could not distinguish between active and  
inactive sites. 
Most studies attempting to determine HIV-1 PR cleavage site specificity focus on the 
difference between functional and inactive sites (299-313). These studies operate under the 
premise that developing a set of cleavability rules will define cleavage site preferences. 
However, we questioned whether models that could discern between active and inactive sites 
were also models that capable of distinguishing between fast and slow sites.  
In order to examine this question, we assembled three more datasets. The first dataset, 
which we labeled the DEAD set, contained all 81 samples tested in the two-substrate proteolysis 
system (66 live, 15 dead). The second dataset was a derivative of the combined Schilling (280) 
and Impens (311) datasets that had been cleaned and made available by Rögnvaldsson, You, and 
Garwicz (311). In this dataset, all cysteine- and tryptophan-containing cleavage sites were 
removed since our own results lacked these amino acids. We labeled this data the NOCW set, 
and it contained 491 active and 3143 inactive sites. There were no duplicates with our own data, 
and only two sequences with as many as five amino acids in the same position. The third dataset 
was a subset of NOCW, consisting of only the sequences with leucine, methionine, 
phenylalanine, or tyrosine in the P1 position (FLMY). The FLMY set had 684 sequences, of 
which 271 marked as cleaved.  
Examining first the ability of our models to separate the functional and non-functional 
sites of our own data, we found limited success. The best model at partitioning the DEAD set 
achieved an accuracy of 84%, but this was one of only six to exceed 80% accuracy (Figure 
3.9A). However, its AUC with the FLMY data was only 54%. Essentially, this model was no 
better at predicting whether a site in the FLMY data was active or inactive than if it had guessed 
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randomly. Allowing the models the chance to separate the NOCW data, they performed about as 
well as they did on the FLMY dataset (data not shown). The average difference in AUC for each 
model was only 3.51 ± 2.78%. Thus, the added diversity in the P1 position did not make a 
difference in prediction ability.  
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Figure 3.9: Models built for rate prediction were ineffective at distinguishing between 
active and inactive sites. (A) A comparison of the accuracy of the prediction models at 
separating active and inactive sites from the source and FLMY dataset. Red points denote the top 
fifteen prediction models at describing the source data according to the minimization of RMSE. 
(B) A comparison of the ability of each model to classify cleavage sites as faster or slower than 
one-quarter the rate of MA/CA (y-axis) and the ability to classify functional and non-functional 
sites (x-axis). The trend line and significance of the correlation is shown. (C) ROC curves for the 
best and worst fast/slow classifiers compared for their accuracy as separators of fast and slow 
sites (top left panel) and active and inactive sites (top right panel). Similarly, the best and worst 
models at partitioning live and dead sites were compared on the basis of their ability to separate 
fast and slow sites (bottom left panel) and active and inactive sites (bottom right panel). 
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When we compared the ability of our collection of models to separate out-of-sample data 
on the basis of both rate and activity, we found a significant negative correlation Figure 3.9B. As 
a more targeted illustration of this relationship, we performed a statistical test to compare ROC 
curves. Two pairs of ROC curves were drawn from the data. The first pair represented the best 
and the worst model at predicting whether a cleavage site was faster or slower. The second pair 
was the best and worst model at separating active from inactive sites (FLMY dataset). While 
there was a significant difference between the model pairs in accomplishing the task for which 
they were chosen, when asked to do the other task, the models were not statistically different 
(Figure 3.9C). Thus, our models, which were based off the physicochemical properties of the 
cleavage sites, could not discern between active and inactive sites as well as between fast and 
slow sites. This suggests that simply defining the requirements for processing will not also define 
the content of optimal HIV-1 PR processing sites. 
 
 
C. Discussion 
 The successful maturation of HIV-1 particles into infectious virions depends upon the 
order and dynamics with which the PR cleaves Gag and Gag-Pro-Pol. Though context and 
putative cofactors also affect HIV-1 PR specificity (50, 219-221, 228-230), the primary 
determinant of where and when the PR functions is the eight-amino acid processing site 
sequence. In this chapter, we generated the largest-to-date dataset of mutant HIV-1 processing 
sites assayed in the context of a globular protein. Six different wild-type HIV-1 processing sites 
were mutated with various substitutions, and from these mutants we were able to identify a 
number of important relationships among amino acids across the eight positions that represent 
the processing site. We also applied statistical model-building programs to identify patterns 
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common to all sites and to build a series of predictive models. While there was good correlation 
between the patterns found in the site-by-site analysis and the descriptive mixed-effects models, 
the predictive models were dissimilar in what they highlighted. We tested these models on an 
out-of-sample dataset, and found the results to be disappointing. Utilizing the models as 
classifiers was slightly more effective, although performance was still at best only adequate. 
Very few models could separate both fast from slow sites and active from inactive sites to even a 
low level of success.  
 Six HIV-1 processing sites were placed into the MA/CA linker region of a globular 
protein substrate, and their rates of processing were measured relative to the wild-type MA/CA 
site. We found the order of cleavage to be SP1/NC > MA/CA ~ RTH/IN ~ CA/SP1 > TF/PR ~ 
SP2/p6. This order agrees with the previously published results for this assay with the exception 
of the SP1/NC site. We previously reported the SP1/NC site to have a relative rate of 
approximately half that of the MA/CA site (50), whereas we now report a rate of ~10-fold 
greater than MA/CA. The difference stems from our use of the HXB2 version of the MA/CA 
cleavage site (ATIM/MQRG) rather than the version found in the NL4-3 clone of HIV-1 
(ATIM/IQKG). The relative rate of the Met-Met site to the internal control was more consistent 
with the findings of Tritch et al. (230), and represents a rate much closer to that observed by 
Pettit et al. when the site was in its natural context (44). In addition, the expected rates of the 
CA/SP1 and SP2/p6 sites differed from those observed when in their natural context. Both of 
these sites are believed to be under the influence of contextual determinants, which would 
account for their different rates. 
 The addition of glycine triplets to the natural HIV-1 substrates caused a global reduction 
in processing rate, but had only one effect on the order in which the cleavage sites were 
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processed.  In the presence of glycines, the RTH/IN site was processed more efficiently relative 
to the other cleavage sites than when the glycines were absent. The observation of this change in 
order implies there is a feature of the MA/CA context that negatively regulates the RTH/IN site. 
One other report has suggested a restrictive effect of the MA/CA linker region on a non-native 
cleavage site, though that was the SP1/NC site (230). That restriction was similarly enforced on 
the upstream portion of the cleavage site; alteration of the P5 amino acid was necessary for the 
SP1/NC site to exhibit its characteristic processing rate. We did observe an increase in the 
relative processing rate of SP1/NC when placed in the context of the glycine linkers,, though it 
was not as noteworthy a change as that previously published. Thus, despite the lack of apparent 
structure in the MA/CA linker region (315), the MA-adjacent portion has some influence over 
the cleavage site structure. This effect could influence orienting the normal MA/CA processing 
site, which necessarily contains a proline in the P1’ position. Substrates must form a beta-strand 
like structure (48), and more rigidity in the linker region could mitigate the typical disruptive 
effect of proline on secondary structure.  
 In the analysis of each cleavage site, the MA/CA (with a P1' proline being fixed) and 
SP1/NC cleavage sites distinguished themselves as lacking significantly suboptimal amino acids. 
Neither of them could be significantly improved with a single amino acid substitution, nor did 
any of the collective 22 substitutions introduced result in an inactive site (excluding the expected 
P1 isoleucines). We conclude that these two processing sites are already largely optimized. This 
inability to improve the SP1/NC and MA/CA sites could reflect the importance the virus places 
in controlling the timing of their cleavage. Proteolytic processing begins at the membrane before 
particle release (20), and excessive or early PR activity interferes with virus particle production 
(224). Any increase in processing rate of the initial target site of the HIV-1 PR (SP1/NC) could 
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ostensibly lead to excessive processing and a destabilization of the virus particle before release 
can be achieved. As for MA/CA, cleavage at its junction releases steric constraints on the HIV-1 
envelope protein to improve its fusogenicity (22-25). Earlier processing of MA/CA could cause 
virus particles to gain the ability to fuse with target cells while still in the immediate vicinity of 
its cell of origin, increasing the risk of superinfecting the original cell. Thus, the virus protects 
itself from potential breakdowns in the lifecycle by using cleavage sites that cannot be improved 
any further. They are still somewhat sensitive to negative alterations, though this may be less of a 
concern. 
 Each of the other four sites could be improved with single amino acid substitutions. For 
CA/SP1, the absence of this change to an improved rate of cleavage can likely be related to 
secondary structure. While in the immature CA lattice, the CA/SP1 site assembles into an alpha-
helical bundle (316-321). Though phenylalanine is not a disfavored amino acid in alpha-helices, 
alanine (at P1') has a higher helical propensity (322). An additional concern is whether the P1’ 
alanine is part of the interaction face between Gag molecules, as the phenylalanine could be 
disruptive to the formation of the helical bundle. In the absence of a high-resolution structure of 
this interaction, this possibility remains unknown. Alternatively, if the phenylalanine does 
accelerate processing of the CA/SP1 site to such an extent that the CA shell begins to form 
before condensation of the RNP core completes, an improperly formed reverse transcription 
complex might be more susceptible to interference by host antiviral proteins, could fail to 
complete reverse transcription, or even may exhibit defects in nuclear entry (Chapter 1). 
 We have already given some discussion to the structural reason that might otherwise 
deter the TF/PR site from making the P3’ isoleucine to P3’ phenylalanine change that potently 
improved TF/PR processing. However, to reiterate, the P1’-P4’ amino acids are all apart of a 
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critical beta-sheet formed following cleavage at the TF/PR site. This beta-sheet imparts stability 
to the HIV-1 PR that is absolutely essential for processing cleavage sites in trans. The structure 
of the HIV-1 PR (323) shows the P3’ amino acid points toward the interior of the HIV-1 PR. The 
orientation of this side chain is consistent with the idea that the phenylalanine, a larger and 
longer amino acid than isoleucine, might sterically conflict with other amino acids. This would 
either disrupt the interior of the HIV-1 PR and/or the stability of the beta sheet. Thus, the 
isoleucine to phenylalanine change does not occur.  
As for the higher prevalence of serine in the TF/PR P2 position despite asparagine’s clear 
superiority as a substrate, overlap between Gag and Gag-Pro-Pol reading frames may provide the 
explanation. The coding region for the ALIX binding motif in the p6 domain (LYPxnLxxL) 
(324) entirely overlaps the TF/PR processing site. The difference between a serine and 
asparagine in the TF/PR site corresponds to a difference of alanine or threonine in the x2 position 
of the binding motif, respectively. That P2’ overlaps with a non-conserved position presumably 
allows its diversity, but that same lack of conservation in the x2 amino acid does not necessarily 
mean that the x2 amino acid’s identity does not affect ALIX binding. If an alanine in this position 
does help virus particle release efficiency, or if a threonine hurts it, it could explain serine’s 
predominance. 
 Similar to the CA/SP1 and TF/PR sites, both SP2/p6 and RTH/IN allowed substitutions 
that improved the processing rate. However, we are unaware of any potential structural 
explanation for selection against these substitutions. For the SP2/p6 site, a leucine to 
phenylalanine substitution in the P1’ position improved rate by 12-fold. The relative scarcity of 
this mutation in our cleavage site alignment (9/2254) becomes even more glaring when 
recognizing that this substitution is a frequent compensatory mutation within Gag after drug 
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resistance mutations have developed in the HIV-1 PR (173). One simple explanation is that the 
cleavage site would simply become too good. The SP2/p6 site was cleaved roughly 1.5-fold 
faster than the MA/CA site in an in vitro assay with full-length Gag (44). If this 12-fold effect is 
projected on to that 1.5-fold increase, then cleavage of the SP2/p6 site would occur with 
approximately the same efficiency as cleavage of the SP1/NC site, if not faster. Thus, should 
viruses produce SP2/p6 sites with a phenylalanine/phenylalanine pairing in the P1/P1’ positions, 
the order of processing may be disrupted and the pre-reverse transcription complex would not 
assemble correctly. 
 The improved processing rate of the RTH/IN site by the P3 lysine to glutamine mutation 
was not as beneficial as that of the SP2/p6 P1' substitution. Though IN is important to the 
encapsulation of the RNP core within the reassembling CA protein during virion maturation 
(192, 193), the importance of the timing of its release by cleavage at the RTH/IN site is 
unknown. IN can be included in viable viruses solely via a Vpr-IN fusion protein (325), implying 
IN facilitates the inclusion of the RNP within the CA shell after cleavage at the RTH/IN. 
However, whether this is actually necessary remains untested. Furthermore, why a mutation that 
would accelerate the release of IN from RT might interfere with such a role is unclear. Looking 
at a crystal structure of the HIV-1 heterodimeric RT (326), the RTH/IN cleavage site would 
occur immediately after the end of an alpha helix. One could speculate that if the lysine is in fact 
the causative agent for the unusual conformation the RTH/IN site adopts, it does not mutate 
because this shape is necessary to ensure the helix break and/or to stably position the site away 
from the body of the heterodimer.  
 Regardless of whether the lysine causes the P4 amino acid to assume the conformation of 
the RTH/IN site, there was a definite pattern in the makeup of the site. Lysine required a beta-
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branched amino acid at the P2 position and strongly preferred a non-aromatic amino acid in the 
P1 site. It was not absolutely prohibitive to a proline in the P1’ site, though cleavage of the site 
by the HIV-1 PR was exceptionally poor. Since proline has the exact opposite preferences, the 
near total incompatibility is not altogether surprising. These results support the concept of 
“blueprint” amino acids. In short, these blueprint amino acids are the amino acids around which 
the site is built. According to this concept, they are chosen because of an external requirement, 
i.e. for a function unrelated to their role as a substrate. For the P1’ proline sites, these are the 
stabilization of CA monomers (MA/CA) (153-155) and the regulation of intramolecular cleavage 
order (TF/PR) (228). For lysine, this is the ensured termination of the C-terminal alpha helix of 
the RNase H domain and/or the stable positioning of the cleavage site coming out of the helix. 
This blueprint concept is key to unraveling processing site composition. 
 The second half of understanding the makeup of each cleavage site comes from the 
identification of interdependent amino acid positions. Recall that the mixed-effects models we 
generated included several interactions. Two of these interactions concerned specific positions 
within the cleavage sites, namely the P2 and P4’ positions, and the P2 and P2’ positions. 
Importantly, the overlap between these interactions links all three amino acids together. This 
increases the likelihood that if we know one of these positions, we can predict the optimal amino 
acids for both of the other sites. Here, we immediately return to our current catalog of blueprint 
amino acids for a simple example. Both proline and lysine influenced the composition of a pair 
of other amino acids in the cleavage site, and one of these is the P2 amino acid. As stated above, 
because we know one of the three amino acids in this interdependent group, we can limit the 
potential amino acids that can occupy the other two sites. Effectively, we are proposing that 
processing sites are built by a cascading selection process. Depending on the location of the 
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blueprint amino acid, it will limit the potential content of certain other positions in the cleavage 
site. At least one of these positions will overlap with a different set of linked amino acids, and 
therefore will limit the repertoire of amino acids that can fill those positions. This continues until 
all sites are filled.  
In addition to our descriptive models, we built 1570 predictive models. Unfortunately, 
they were extremely poor predictors of out-of-sample data. There are multiple possible 
explanations for this deficiency. First, the models were likely overfit to the data. We allowed a 
certain number of variables in each of the models, and all of the models were very near that limit. 
Another potential problem is that our dataset did not represent a true random sample. There are 
25.6 billion (208) possible eight amino acid combinations, yet our dataset comprised a limited set 
of highly related sequences. The results are therefore very biased to these particular groupings of 
amino acids. Furthermore, because the null mixed-effects model was significantly better than the 
null standard linear regression model meant there was a significant amount of noise in our data 
due to the differences in baseline cleavage rates. By viewing each data point as an independent 
sample during the model creation process, the models were trained on that noise. As a result, the 
wrong variables were likely included. For example, the P3/P3’ interaction was the most frequent 
term found in the top 15 prediction models. However, the P3 position was highly amenable to 
substitution in both the MA/CA and CA/SP1 sites, with the sole possible exception of lysine. In 
addition to our own work, a considerable amount of experimental (47, 287-289, 314) and 
bioinformatics evidence (308, 313) sharing that conclusion has been generated. Thus, the 
limitations of our dataset could be the major reason the predictive models failed to perform as 
well as hoped. 
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Some fault also likely lies with the out-of-sample data. First, not all of the reactions were 
performed under the same pH and ionic strength conditions (215, 283-298). This is a 
complication among HIV-1 PR cleavage studies that confounds the interpretation of results 
across studies. Both substrate binding (Km) and turnover rate (kcat) are affected by pH and ionic 
strength (294), making the comparison of HIV-1 PR specificity across reactions difficult. The 
specificity constant for the MA/CA peptide across these studies is sourced from the same initial 
experiment (215, 284, 295, 296), yet when this peptide was retested (283), the specificity 
constant was nearly twice as large as in the original publication (45.3 mM-1s-1 versus 82.44 mM-
1s-1). Thus, the relative rates of processing we derived from these studies potentially have 
additional complications. Fortunately, our own results do not suffer from this concern because all 
reactions included a reference site. Altogether, the limited ability of our prediction models to 
identify the rates of processing for out-of-sample data does not necessarily mean the models are 
wrong. However, this initial modeling attempt is not encouraging, and more data should be 
gathered before a firm conclusion is made.  
In addition to the prediction of precise rates, we examined the models as simple 
classifiers of fast and slow sites. Here, at least, we achieved a modicum of success. Because our 
out-of-sample dataset contained primarily rates that were much slower than the MA/CA site, we 
chose to evaluate our samples relative to a processing rate of one-quarter that of MA/CA. Our 
predictive models were successful at separating our source data, but were again considerably less 
effective utilizing the out-of-sample data. However, not all models were failures. Two-dozen 
models could partition the out-of-sample results to an acceptable level (>70% accuracy), and 
each of these models was at least 88% effective with the source data. As far as we are aware, we 
 
 
156 
are the first to attempt a classification between fast and slow sites. Therefore, there is no 
benchmark to which we can compare our results. 
In contrast, many have built cleavage rules to distinguish between active and inactive 
sites. These algorithms perform very well (85% or better) on data sets much larger than our own 
(309, 311), making our best active/inactive predictor model (75%) non-competitive. As a result 
of this analysis, we noticed an inverse correlation between the ability of a model to separate fast 
and slow cleavage sites and its ability to predict which cleavage sites are active versus inactive. 
This is not particularly surprising. Take, for example, the defective sites that were identical to the 
wild-type substrates save for an isoleucine in the P1 position. The value of isoleucine on each of 
the physicochemical scales we used are nearly identical to that of leucine. While leucine is a very 
capable amino acid in the P1 position – it was actually the P1 amino acid of the fastest site we 
measured – isoleucine is guaranteed to block cleavage. Thus, our models likely did not separate 
these samples successfully because they would appear to be nearly identical numerically. It is 
possible that separation could be achieved with the addition of a categorical variable to 
distinguish beta-branched amino acids from non-beta-branched amino acids, however the lack of 
variation in the data will complicate the application of the statistical procedures we employed. 
We alternatively suggest that models wishing to identify ideal amino acid combinations ought to 
select those combinations in two phases. In one phase, the precise rates of processing are 
predicted; in the other, the sites that violate a cleavability rule are removed from contention.  
In this report, we measured the cleavage rate of more than 80 substrates of the HIV-1 PR 
relative to the cleavage rate of the MA/CA processing site. To our knowledge, these results 
represent the largest-to-date dataset of globular substrates for the HIV-1 PR cleaved under near-
physiological pH and ionic strength conditions. We discussed the amino acid preferences for six 
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of the HIV-1 cleavage sites found in Gag and Gag-Pro-Pol. For the MA/CA and SP1/NC 
cleavage sites, we were unable to provide a significant improvement over their wild-type 
sequences with only one or two amino acid substitutions. The other four cleavage sites were all 
much more amenable to cleavage rate increases with amino acid changes. In addition, we 
identified lysine in the P3 position as a very influential amino acid to its surrounding context, 
and suggest it join P1’ proline with the distinction of being a “blueprint” amino acid. These 
blueprint positions help dissect processing site sequences by limiting the content of other amino 
acid positions, that in turn link to still more parts of a cleavage site. Lastly, we applied a large 
number of predictive models to out-of-sample data with the hope of predicting their cleavage 
rates. However, we were largely unsuccessful. A few of the models were at least adequate as 
classifiers, though no model could classify both active and inactive, and fast and slow sites with 
good accuracy. This leads us to conclude that the identification of an ideal cleavage site sequence 
must satisfy the terms of two models: one that predicts rate, and one that predicts viability.  
 
D. Materials and Methods 
1.  Constructs 
 The MA/CA protein was generated as in Chapter Two. Briefly, MA/CA was amplified 
from the pBARK plasmid, which contains the entirety of the gag and pro genes from NL4-3. A 
6xHis tag was added to the N terminus, a termination codon at the C terminus, and flanking NdeI 
sites were introduced to enable cloning into the pET-30b (Novagen) vector. An additional round 
of mutagenesis introduced a tetracysteine motif (CCPGCC) in the Cyclophilin A binding loop 
(His87-Ala92) of CA.  
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The original pET-GMCΔ construct was created in a similar manner, where the GST-tag 
was added to the N-terminus of MA by overlapping PCR. The full procedure is published in 
(50). Each alternative cleavage site was introduced by a two-step procedure: first generation of 
the insert by overlapping PCR centered on the cleavage site, followed by subcloning into the 
pET-GMCΔ vector utilizing the NdeI cleavage sites that had been previously introduced. The 
glycine insertion mutants for each of the natural HIV-1 cleavage sites were also generated by this 
procedure. All other mutations made within each processing site were introduced by site-directed 
mutagenesis. The decision for which mutations to be made were dependent upon the presence of 
mutations within the HIV sequence compendium (http://www.hiv.lanl.gov/), their presence in 
alternative cleavage sites, and/or due to their ability to be made with a single nucleotide 
substitution. Primers were obtained through Sigma-Aldrich. 
 
2. Expression and purification of the HIV-1 PR and globular HIV-1 PR substrates 
 Growth and expression of globular substrates proceeded as described in Chapter Two. 
Briefly, E. coli BL21 DE3 lysogens (Novagen) were transformed with pET-MA/CA or pET-
GMCΔ. Following growth overnight in 2xYT media, starter cultures were used to inoculate 
MagicMedia (Invitrogen) for protein production. Expression cultures were grown for 8 hours at 
37ºC and 225 rpm, pelleted by centrifugation and frozen overnight at -80ºC. Lysis was 
performed by sonication in TBS pH 7.5, 1% Triton X-100, 2 mM beta-mercaptoethanol. Cellular 
debris was collected by centrifugation, and the protein collected by affinity chromatography 
using the Ni-NTA Superflow columns (Qiagen). Purified proteins were concentrated using 
Vivaspin Concentrators (GE Healthcare), and underwent buffer exchange into storage buffer (20 
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mM sodium acetate, 140 mM sodium chloride, 2 mM beta-mercaptoethanol, 10% glycerol, pH 
6.5). The pH was confirmed to within 0.2 units with a micro-pH electrode (Thermo Scientific).  
 Purified HIV-1 proteases were produced as described in Chapter Two. 
 
3. Two-substrate proteolysis reactions 
 Two-substrate proteolysis reactions were run in proteolysis buffer (50 mM sodium 
acetate, 50 mM NaMES, 100 mM Tris, 2 mM beta-mercaptoethanol, pH 6.5). Reactions were 
150 µl in volume and pre-incubated at 30ºC for 1 hour before addition of the enzyme to allow the 
Lumio Green Reagent (Invitrogen) to bind the CCPGCC motif in the CA region of each protein. 
Both substrates were included at an initial concentration of 1.2 µM. The HIV-1 PR was used at a 
concentration of 150 nM in the two-substrate assays where the substrates lack the glycine 
insertions, and 400 nM when the glycines were present to make up for the minor drop in 
processing rate. Aliquots were collected at specific time points throughout the course of the 
reaction and added directly to SDS to halt the reaction. The zero minute time point was removed 
immediately prior to the addition of enzyme. Most reactions were limited to 15 minutes, the 
timeframe required for the internal control to reach ~50% processing, though only data points 
generated within the first 10% of processing were used to generate relative rates. Sites exhibiting 
<10% cleavage after 15 minutes were retested in extended, 120-minute assays. If cleavage was 
not still observed after 120 minutes, the site was deemed defective. After the final time point was 
collected, reaction pH was confirmed as 6.5 using a micro-pH electrode (Thermo Scientific). 
Substrates and products were separated by SDS-PAGE using precast 16% Tris-Glycine gels 
(Invitrogen). The fluorescently labeled proteins were then imaged with a Typhoon 9000 (GE 
Healthcare/Amersham Biosciences), and quantified by ImageQuant TL (GE Healthcare) 
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software. Results were reported as the percent product formed. The initial reaction rate for each 
substrate was determined using only the data points collected where the reaction was ≤10% 
complete, or was estimated based on the first non-zero data point collected. To determine the 
relative rate of processing, the ratio of initial velocities was compared using the internal control 
as the denominator, and the value recorded. The relative rate for each mutant was determined in 
at least two separate reactions. The average variance in estimated rate between the two reactions 
was 1.25-fold, with a range of 0 to 2-fold. Overall, these values differed by over 3000-fold, and 
were log-transformed for ease of interpretation. 
 
4. Statistical modeling procedures 
 All statistical procedures were performed using “R” software, version 3.2.0 (327), and the 
RStudio version 0.99.447 interface. The physicochemical properties used to analyze the data 
include hydrophobicity (328), nonpolar, polar, and total side-chain accessible surface area (ASA) 
(329), total amino acid polarizability – a volumetric measurement of an amino acid’s response to 
an external electric field (330), total amino acid van der Waals volume (331), total amino acid 
molecular weight, side-chain length, and amino acid charge. The side-chain length was 
determined using PyMol. The distance between the alpha-carbon and furthest atom was 
determined with the “Distance” function provided within the standard PyMol software. To this 
value was added one van der Waals radius (332) according to the identity of the atom used in 
distance calculation. Unless required by the statistical procedure, the data was not standardized. 
Predictions for the out of sample data were generated using the predict function that 
accompanied each statistical procedure. 
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Out of sample data: Three out of sample datasets were generated. The first dataset was 
generated from a series of previously published studies where comparisons of the observed rates 
were made to a wild-type version of the MA/CA processing site (46, 215, 283, 284, 290, 295, 
296). Most samples (63/66) were recovered from reactions performed in similar pH and ionic 
strength conditions, though they were spread across five publications and the reference value for 
the MA/CA processing site appears to have only been determined once. The second dataset 
(NOCW) is a compilation of the Schilling (280) and Impens (311) datasets, after all cleavage 
sites containing cysteine and tryptophan were removed because they did not appear in our 
reactions. Rognvaldsson et al. (311)  originally organized this data for use and posted it online 
for others to access. No rates are given, only the classification of whether the processing site was 
cleaved or not. There are 3634 samples in this dataset, of which 491 are cleaved. The third 
dataset (FLMY) is a smaller version of the NOCW set where only the processing sites containing 
one of the four common amino acids at the P1 position were included. This contained 684 sites, 
271 cleaved. 
Linear mixed-effects modeling: The linear mixed-effects models were generated with the 
lmer function from the “lme4” package (333). Each processing site was grouped according to 
their relationship with one of the cleavage sites found within the Gag or Gag-Pro-Pol 
polyproteins, and this grouping was used as the random effects term of a random-intercept 
mixed-effects model. Likelihood ratio tests were performed using the anova function from the 
standard “stats” package (327). To enable valid comparisons between models, full maximum 
likelihood estimation was utilized instead of restricted/residual maximum likelihood. Selection 
of the most parsimonious model was accomplished by step-wise elimination of the least 
significant (i.e. highest p value) term as determined by the likelihood ratio test. One variable was 
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removed at each step until further removal resulted in a significant change to the model’s 
effectiveness. 
Ordinary least squares (OLS) modeling: All ordinary least squares regression analyses 
were performed using the included lm function in the basic R package. The analyses were 
performed in only the absence of interactions. Given that no selection was performed with these 
standard models, and the upper limit of variables was set at 25 (roughly 1/3rd the number of 
observations), interaction terms could not be included without violating this limit. Any 
singularities (i.e. multicollinearity among variables) were automatically removed from the 
modeling procedure by the R software. Combinations of one, two, and three physicochemical 
properties were considered when individual amino acids were used as the model criteria. 
Best subset and step-wise selection: Best subset selection compares all possible 
combinations of variables at every possible level. Step-wise selection begins with a base model, 
and then attempts to add or remove a variable at every step of selection. All variables are tested 
at each step for their affect on model significance. Both best subset selection and step-wise 
selection were performed using the regsubsets function of the “leaps” package (334). The 
exhaustive search is the default, and may be used when the total number of possible variables is 
less than 40. It was applied to any model lacking interactions, and also the one-property model 
with interactions. The two- and three-property models with interactions were generated with the 
step-wise selection procedure. The maximum number of variables allowed in each model was 25 
– one for each predictor variable in a three-property OLS model without interactions plus one 
more for the intercept. After the selection process, the model with the lowest Bayesian 
information criterion (BIC) was picked for use in OLS analysis. 
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Ridge, elastic net, and lasso regression: These ‘shrinkage’ methodologies are useful 
when the number of potential variables is larger than the total amount of observations. These 
methods are similar to OLS analysis, but a penalty term/shrinkage factor (lambda) is introduced. 
In ridge regression, no variables are removed but the coefficients of insignificant variables are 
reduced closer and closer to zero. Lasso regression uses a slightly different penalty term that 
results in the removal of insignificant variables. Elastic net regression compromises between 
ridge and lasso, behaving more like one or the other depending upon the value chosen for a so-
called tuning parameter. All three methodologies were performed using the glmnet function of 
the “glmnet’ package (335). For ridge regression, the tuning factor (alpha) was set to zero; for 
lasso regression, alpha was set to one; and for elastic net regression the alpha was calculated with 
the train function of the “caret” package by repeated cross-validation (336). All variables for all 
shrinkage methodologies were necessarily standardized to avoid improperly weighting of the 
regression coefficients. The programs do return unstandardized coefficients, however. Lambdas 
were chosen by cross-validation after the value for alpha had been chosen using the cross 
validation function cv.glmnet provided by the “glmnet” package. Both the minimum lambda and 
the lambda one standard error away from the minimum were used to generate models. The 
minimum lambda is often not sufficiently parsimonious, which is why a second lambda that was 
not significantly different from the minimum lambda was also used. 
Partial least squares regression (PLSR): Combinatory methods like principal component 
analysis and partial least squares regression take a multi-dimensional model and reduce the 
dimensionality into a smaller number of new components (i.e. combinations of the original 
variables). These new variables may then be used in standard OLS regression. PLSR differs from 
principal component analysis by considering the variance in the response variable in addition to 
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the variance among the predictor variables. This makes PLSR much more advantageous for 
constructing predictive models as compared to principal component analysis. “caret” (336) and 
“pls” (337) packages were required for completing PLSR. The number of components for each 
model was chosen with the train function from the “caret” package making use of repeated cross 
validation. Variables were again standardized, and as in the best-subset selection methodologies, 
the maximum number of components allowed was 25. The actual PLSR fit was performed with 
the plsr function of the “pls” package, relying upon cross-validation as to choose the models. 
Receiver operator characteristic (ROC) curves: ROC curves measure the performance of 
a classifier at distinguishing between one of two categories. The curve is a reflection of the 
sensitivity (true positive/(true positive + false negative)) and specificity (true negative/(true 
negative + false positive)). Accuracy is reflected in the area under the curve (AUC). Above 90% 
is excellent, above 80% is good, 70% is adequate, 60% is poor, and below 60% indicates the 
model is useless as a classifier. All ROC curves and AUC determinations were made with the 
roc function in the “pROC” package (338). The statistical tests to compare ROC curves, i.e. the 
DeLong test, were also within the “pROC”.
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CHAPTER IV 
CONCLUSION 
 
 A two-substrate enzymatic assay provides an elegant solution to overcome the potential 
inconsistencies between reactions that might otherwise result when observations are made 
separately. From the use of a two-substrate system, I discovered that the enhanced rate of 
processing exhibited by the HIV-1 PR in the presence of RNA was a general phenomenon rather 
than one specific to the p15NC substrate. This result contradicted the prevailing hypothesis that a 
substrate-RNA interaction was necessary (220, 221). After the initial discovery, I utilized a 
globular substrate with a severely compromised ability to interact with nucleic acid, as well as a 
peptide substrate too small to simultaneously interact with RNA and the HIV-1 PR to 
resoundingly disprove the long-standing hypothesis. Both of these reactions continued to exhibit 
RNA-dependent rate enhancement, leading to the conclusion that the substrate’s ability to bind 
nucleic acid was irrelevant or at the very least optional. 
As an alternative hypothesis, I suggested RNA-mediated enhancement resulted from a 
direct interaction between the RNA and an allosteric binding site on the HIV-1 PR. The reactions 
where I used the peptide substrate already supported this conclusion, but to directly demonstrate 
the interaction I performed a series of gel-shift assays. The progressive addition of a higher 
concentration of the HIV-1 PR to a constant amount of nucleic acid – in this case short ssDNA 
molecules also capable of enhancing PR activity – resulted in the selective disappearance of high 
molecular weight nucleic acid species when observed in a gel. Unfortunately, the prototypical
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“shift” was not observed in these assays. Though the unbound species could no longer be 
detected, the overall basic charge of the HIV-1 PR meant it was incapable of migrating into the 
gel under native conditions and no new band appeared near the top of the gel. Nevertheless, the 
selective disappearance of a nucleic acid species was a strong indicator of a direct interaction. 
Additional support for the hypothesis stemmed from work with the HIV-2 PR. This alternative 
enzyme was completely unaffected by the addition of RNA to its processing reactions, and also 
failed to interact with nucleic acid in the gel-shift assays. The lack of effect given that the 
substrate (save the cleavage site) was the same strongly demonstrated the effect was enzyme-
dependent. 
The selective interaction of the HIV-1 PR with high molecular weight nucleic acid 
species and the HIV-2 PR’s lack of interaction suggested specific requirements must be satisfied 
for the interaction to occur. The HIV-2 PR had a net negative charge, in contrast to the net 
positive charge of the HIV-1 PR, immediately pointing to an electrostatic determinant. The 
failure of the positively charged polymer spermine, and the success of the negatively charged 
polymer heparin at mimicking the effect of RNA in proteolysis assays supported this hypothesis. 
Additionally, the similarity in the magnitude of the enhancement effect caused by equal-length 
cytosine, thymine, and guanine homopolymers additionally suggested that the size of the 
polyanion was critical, whereas the structure or sequence was not. Larger sized polyanions will 
have a larger net-negative charge, and this will improve the strength of the interaction between 
enzyme and enhancer. Work with the adenosine homopolymer and tRNA actually intimated a 
rigid structure in the polyanion was unfavorable. 
Also of interest was the mechanistic explanation for how RNA improved the efficiency 
of the HIV-1 PR. To gauge whether RNA altered the binding affinity of the enzyme for its 
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substrate, the rate of product formation post-substrate binding, or potentially both, I performed a 
series of peptide cleavage assays to determine the values for kcat and Km in the presence and 
absence of RNA. The results found the kcat increased and the Km decreased, collectively 
demonstrating that both substrate binding and reaction turnover improved as a result of the 
interaction between RNA and PR. 
The discovery that the enhanced reaction rate in the presence of RNA results from the 
interaction between the enzyme and RNA opens up an abundance of future research 
opportunities. Foremost among them is the investigation of the phenomenon’s relevance in vivo. 
All assays I conducted were in vitro, and, despite a strong similarity to physiological conditions, 
the reactions can never perfectly recapture the environment within a lymphocyte. The most 
straightforward option to address in vivo relevance would be to identify the precise binding 
site(s) on the HIV-1 PR, mutagenize them to block the interaction, and then determine the fitness 
of the virus relative to the wild-type version. There are, of course, potential complications to this 
strategy, as the mutations that disrupt the interaction might additionally damage the functionality 
of the PR even in the absence of RNA. But because RNA is a required structural element of virus 
particles (14), any antagonism from that direction is likely out of the question. One alternative 
strategy would be to create a hybrid HIV-1/HIV-2 strain that contains the HIV-2 PR and its 
preferred cleavage site sequences in Gag and Gag-Pro-Pol. Provided such a virus is viable, 
growth competition assays with the wild-type virus would be recommended. If the virus were not 
viable, a number of tests to determine the defect would be the correct course of action; a BLAM-
Vpr fusion assay or PCR screen for early and late reverse transcription products for example. 
Direct imaging of virus particles by electron microscopy and the identification of processing 
intermediates by western blot would also likely be worthwhile.  
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The most likely location on the HIV-1 PR for the interaction with RNA is the flap. The 
flap region is key to both substrate binding and hydrolysis of the scissile bond (268-273), which 
satisfies both of the criteria established by the enzyme kinetics assays. This region of the HIV-1 
PR also contains a large number of basic amino acids while its counterpart in the HIV-2 PR does 
not. The HIV-1 and HIV-2 PRs have very similar tertiary structures (255-257), so simply 
replacing the corresponding amino acids from the HIV-2 PR into the HIV-1 enzyme might be 
sufficient to disrupt the interaction with RNA while also minimizing the effect on enzyme 
functionality. Certain positions with the HIV-1 PR have been mutated before without a major 
effect on enzyme activity (339) and this may be a good place to start, albeit the reactions that 
identified these locations were almost certainly RNA-rich. 
Other possible research goals concern antiretroviral inhibitors. If we presume the effect is 
significant in vivo, then the important question becomes ‘how does the interaction with RNA 
affect drug resistance?’ We know from Chapter Two that several highly drug-resistant HIV-1 
enzymes all retained the ability to interact with RNA in vitro. In most cases, the effect of this 
interaction was substantial enough that these extremely inefficient versions of the enzyme 
became comparably functional to the wild-type PR. Furthermore, we know the virus requires 
multiple copies of the HIV-1 PR to complete maturation (25); one enzyme simply does not have 
sufficient functionality to complete the process. Since RNA dramatically increases the catalytic 
ability of the HIV-1 PR, this could mean that a smaller number of enzymes is required to 
complete maturation. Thus, RNA-mediated enhancement could mean that higher drug 
concentrations are required to effectively inhibit the virus. Once an HIV-1 enzyme unresponsive 
to RNA has been identified, a study that compares the inhibitory concentrations of PIs between 
the mutant and wild-type version would be valuable. 
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Regardless of whether the PR-RNA interaction has a prominent role in vivo, the fact 
remains that an allosteric binding site exists on the enzyme. Thus, another inhibitor-oriented 
research proposal would be to identify small-molecule binding partners for the interaction site. 
Several have already identified putative flap-binding molecules (257, 264-267), giving some 
credence to the proposal. One of the more difficult tasks would be designing a system in which 
flap-binding inhibitors could be differentiated from substrate mimetics. That RNA binding 
affected Km implies RNA interacts with the unbound version of the PR. Thus, inhibitors would 
likely need to interact with a PR that is not engaging a substrate. A fluorescence anisotropy-
based competition assay between putative inhibitors and labeled polyanionic species might 
provide one solution. However, the physiological, low-salt conditions in which one would want 
to run the assay might cause aggregation of the polyanion, in turn interfering with detection. 
Structure-based drug design following the identification of the binding site could be a more 
lucrative strategy. 
With regard to the study of HIV-1 PR sequence specificity, it has suffered from a litany 
of problems. There are, of course, the inherent difficulties: the existence of a wide variety of 
amino acid sequences capable of occupying the substrate envelope (280); the different contextual 
effects in place around each of the natural cleavage sites (50); and, as determined in Chapter 
Two of this dissertation, the existence of cofactors that affect substrate binding and reaction 
turnover. There are also issues resulting from a lack of coordination among researchers; 
specifically, an inconsistency in the reaction conditions utilized in different publications. 
Additionally, few, if any, have explored specificity in an environment where the pH and ionic 
strength is remotely similar to that encountered by the PR in vivo. Unfortunately, this latter issue 
was often necessary because peptides were used as substrates. However, unlike peptides, the 
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HIV-1 PR can efficiently process globular substrates under more normal pH conditions in vitro 
(50). In Chapter Three, I discussed the results of assays run using a series of globular proteins as 
substrates under near-physiological conditions. Each of these proteins contained a different 
cleavage site sequence, but all cleavage sites were placed within the same protein construct. I 
again employed the two-substrate system to take advantage of the internal control protein. This 
secondary substrate offered a reference point from which I could compare the relative rates of 
processing for each cleavage site with an exceptional level of accuracy and consistency. 
Six cleavage sites were drawn from different locations throughout Gag and Gag-Pro-Pol. 
When examined in the two-substrate system, a relative order of processing was determined that 
differed from the order determined by in vitro assays where each site was in its natural context 
(42, 44). This was not unexpected as a previous publication found a very similar relationship 
among the sites (50). I ensured the present context was not responsible for this alteration in order 
by introducing a triplet of glycine residues on either side of the cleavage sites. The flexibility of 
these glycine segments disrupted any residual contextual cues. When re-examining the glycine 
versions, there was a minor, though noticeable effect on one particular site, RTH/IN. This result 
indicated there was some feature in the protein construct that negatively regulated the RTH/IN 
site. Since the natural site in this context obligatorily contains a proline, which is disruptive to 
the beta-strand conformation the enzyme requires for substrate recognition, the minor degree of 
influence this context imparts on the cleavage site might be essential to properly position the 
amino acids. 
The existence of proline in this site is not a unique event. Three of the natural HIV-1 
processing sites I examined contain a proline, though only two of them in the P1’ position. This 
particular amino acid arrangement has been used to differentiate processing sites into two groups 
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– P1’ proline and non-P1’ proline sites. Other work has already concluded that the P1’ proline 
sites prefer large, aromatic residues in the P1 position (46, 47, 287, 295, 298), and non-beta-
branched amino acids in the P2 position (288). From my dataset of 81 substrates, I confirmed 
these results, and further suggest a second site-defining amino acid to be a lysine in the P3 
position. Lysine was associated with a number of inactive or poorly cleaved sites. I suspect this 
was because it attempts to force the processing site into an unconventional structural 
arrangement where the P4 amino acid occupies the position normally expected of the P3 amino 
acid, an arrangement that is particular to only a pair of sites (48). I also noticed a pattern in the 
composition of efficiently cleaved sites containing a lysine in the P3 position. These sites 
required a beta-branched amino acid in the P2 position, and strongly preferred a non-aromatic 
amino acid in the P1 site. Notably, these preferences conflicted with those of sites with a P1’ 
proline. Because the presence of a lysine in the P3 position could be used to predict the optimal 
layout of a site, I labeled it as a site-defining amino acid.  
Although several patterns could be identified by eye, a more detailed examination of the 
dataset was gained by the application of statistical modeling procedures. In order to compare 
each site, I applied nine different physicochemical properties to each amino acid. Having utilized 
multiple HIV-1 processing sites as a starting point, the effect of each amino acid substitution was 
partially hidden by the baseline rate of the cleavage site from which it was derived. As a means 
of overcoming this obstacle, I used linear mixed-effects modeling. This procedure grouped the 
data according to whichever cleavage site was used as its reference site. In doing this, more than 
50% of the variability was removed from the data, all of which was effectively noise. 
The first analysis considered each site as a whole entity – in other words, the location of 
any differences had no bearing on the result. This model was actually the most effective 
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descriptive analysis among all the models that I built, at least when the principal of maximum 
parsimony is also considered. The most important physicochemical properties included 
hydrophobicity, net charge, total polarizability (a volumetric measurement of an object’s 
response to an external electric field, i.e. the acquisition of a dipole moment), and the amount of 
polar surface area available. I also found an interaction existed between the hydrophobicity and 
amount of polar surface area. Substrates that were more hydrophilic than hydrophobic did not 
vary much in rate, but those that were hydrophobic tended to be preferred cleavage sites if they 
had more polar surface area. Thus, better sites were comprised of strongly hydrophobic amino 
acids intermixed with polar amino acids. 
Additional mixed-effects modeling analyses looking at individual amino acid residues 
within the sites were more complicated to perform. While the dataset was large compared to 
similar studies previously published, it was still only of modest size. This limited the number of 
variables a model could contain before causing an error in the statistical procedures. Grouping 
the data further limited this number. The solution I decided upon was to look at each property 
individually. From these analyses, the P2, P1’, P2’, and P4’ positions were strongly implicated 
as important to the determination of processing rate. Furthermore, a relationship existed between 
the hydrophobicity of the P2 and P4’ amino acids, and the polarizability of the P2 and P2’ amino 
acids. The overlap of these two interactions suggests we may think of these three amino acids as 
a unit, and that a limited number of optimal or functional combinations may exist. These units 
are not necessarily site-defining amino acids, as both the P1’ proline and P3 lysine were the 
amino acids that imposed restrictions on the P2 amino acid (and by extension the P2’ and P4’ 
prime amino acid), rather than the reverse.  Nevertheless, their interrelatedness simplifies 
otherwise pattern-deficient HIV-1 cleavage sites. 
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The positional interactions were not only on opposite sides of the scissile bond, but were 
also trans-interactions. This implied that the interaction of an amino acid with one monomer of 
the HIV-1 PR might actually affect the relationship of the other PR monomer with an amino acid 
in the cleavage site. These results highlighted not just the interdependence of amino acids within 
a cleavage site, but also the interplay between monomers of the HIV-1 PR. This give-and-take 
between halves of the enzyme would ostensibly impart the asymmetry the homodimeric PR 
requires to recognize an amino acid sequence (49, 274).  
While a descriptive analysis was useful, ultimately I sought to build predictive models 
that could be utilized to identify an idealized amino acid sequence. For this, each observation 
was treated independently and non-mixed-effects modeling techniques were employed. Given 
there exist 25.6 billion (208) possible amino acid combinations as potential substrates for the 
HIV-1 PR, I could not use mixed-effects techniques because only a very small percentage of the 
total catalog of substrates could be grouped with any of the current set of cleavage sites. The 
resulting models suffered accordingly, as it is more likely they modeled the noise in the data than 
the actual patterns. Analyzing the distribution patterns in the top 15 (of 1570) predictive models 
revealed that most of the terms in the models included positions deemed relatively unimportant 
by the mixed-effects modeling procedure (e.g. P4, P3, P3’). As a result, the ability to predict out-
of-sample data, albeit data derived from multiple sources and obtained under low pH/high salt 
conditions, was extremely poor. The models were slightly more effective as classifiers of fast 
and slow sites, however.  
Many others have applied statistical and machine learning algorithms to the task of 
separating active and inactive cleavage sites. As one final analysis, I employed my set of 
statistical models to this alternative classification test as well. While none of the models were 
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competitive with any of the previously published results, I did note an inverse correlation 
between the ability of my models to be a rate-classifier and their ability to be an active/inactive 
classifier. Since all of the naturally occurring cleavage sites only require one amino acid 
substitution to become inactive (P1 isoleucine), this result is not altogether surprising. At least on 
a physicochemical basis, the ability of a model to distinguish between a functional site with eight 
non-ideal amino acids and a non-functional site with seven ideal amino acids and one damaging 
amino acid could be limited. Thus, the identification of an ideal amino acid sequence by 
physicochemical descriptors will require a two-step procedure: one step in which all cleavage 
sites violating a set of cleavability rules are removed, and one in which the rate of each site is 
predicted. 
The results presented in Chapter Three were the product of my first attempt at building 
descriptive and predictive models. The immediate future directions for this research entail the 
revision and reapplication of the methods. All of the predictive models were generated 
independently of the mixed-effect modeling results, and they were inferior to those models 
according to most statistical criteria. It is possible to force the models to include the terms 
identified by the mixed-effects modeling procedures, and that is an avenue worth exploring given 
the failure of the current set of predictive models. An expansion of the dataset is also warranted. 
I made a number of site-specific mutations, so expanding the dataset with sites based on these 
predictions would also provide a more worthwhile out-of-sample dataset, especially since the 
results would be generated under the same conditions as the data used to create the models. 
Additionally, the new information will help refine and improve the models when they are 
eventually refit to the entire set that is collected. I also identified several potential patterns within 
characteristic of cleavage sites in general (i.e. the ability to predict site composition by knowing 
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the P1’, P3, or even one of the P2-P2’-P4’ amino acids), and a more targeted set of mutations to 
test those patterns would help in confirming those results.  
Once the predictive modeling procedures produce a functional model, use of this model 
in an algorithm that cycles through each of the 25.6 billion permutations of eight amino acids 
will identify candidate combinations for the ideal cleavage site sequence. When this sequence 
has been identified, it will naturally be tested. Following that, the long-term goal of this research 
is its application to drug design. With an idealized sequence, small molecule substrate mimetics 
could be designed and tested for their inhibitory abilities. Additional refinements to already-
existent HIV-1 PIs could also be an application for the results. 
A series of outstanding questions about the basic virology of HIV-1 could also be 
addressed using the information gathered in this dataset. While the order of processing was 
defined long ago (44, 45), the actual length of time available to complete each step remains 
unknown. This could be monitored by the adjustment of the relative rates of processing. 
Additionally, special conditions could be present during the assembly and budding process that 
promote ordered processing. A test of whether or not slowing the kinetics of processing is 
detrimental to infectivity – even if the relative order is maintained – is another interesting 
research question. Furthermore, do the enzymes have a structural role in generating the mature 
virus architecture, or does the timing of cleavage at the RTH/IN site, for example, have no 
bearing on infectivity? IN has been implicated in encapsulation of the RNP core by the CA shell 
(192, 193), suggesting the timing of release for IN may be important for virus infectivity. 
In Chapter One, I discussed the key role the HIV-1 PR plays in the virus lifecycle. This 
enzyme completes a highly complicated series of cleavage events within a newly created virus 
particle to prepare it for infection of a new cell. The two chapters thereafter detailed a pair of 
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studies where I uncovered potential mechanisms controlling HIV-1 PR activity throughout this 
process. The second chapter identified RNA as a prospective binding partner for the HIV-1 PR, 
an interaction that greatly enhances the catalytic efficiency of the enzyme in vitro. In the third 
chapter, I explored the sequence specificity of the HIV-1 PR. The physicochemical factors 
affecting processing rate were defined under conditions more similar to those encountered by the 
PR in the cell, providing a necessary upgrade to the specificity studies of previously published 
work. Lastly, in this fourth chapter, I reviewed my results and presented a selection of possible 
applications of the results to future research. In conclusion, I have addressed several unresolved 
questions about the complex interplay between the HIV-1 PR and its substrate, and I have 
additionally developed a number of exciting new research directions worthy of future 
investigation. 
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